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Abstract 
Identification of mechanisms of gemcitabine resistance using a whole genome shRNA 
screen in a novel in vitro coculture model of pancreatic cancer. 
Graham David Mills 
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult to treat major 
cancers, with a 5-year survival of less than 5%, and little to no improvement in prognosis 
over the previous fifty years. The complexity and heterogeneity of the pancreatic tumour 
and its highly desmoplastic stromal microenvironment present major physical and 
biochemical barriers to the delivery and efficacy of therapeutics. Improving the success rate 
of therapeutic interventions for this cancer requires both a detailed understanding of 
stromal dynamics and drug resistance within the tumour, as well validated in vitro and in 
vivo models through which novel therapeutic targets can be identified and investigated. 
Within this project I focused initially on further developing, validating, and evaluating 
mechanistically a coculture model of gemcitabine resistance, established previously.  I 
demonstrated that the gemcitabine resistance observed in coculture was a product of cell-
cell contact, transient in nature, and related to cell density-mediated signalling processes. I 
discovered that the mesenchymal-like cell lines thought to drive the resistance effect within 
the model were epithelial cancer cells in origin, rather than a cancer associated fibroblast 
(CAF) line, verified through genotype and protein signature experiments.  
This finding was expanded through demonstration that true pancreatic CAFs did not induce 
gemcitabine resistance in the coculture model and hence demonstrated the real challenge 
in isolating true pancreatic CAFs from genetically engineered mouse PDAC tumour tissue 
using canonical techniques. Nevertheless, the in vitro coculture model data was congruent 
with in vivo and clinical gemcitabine efficacy data, suggesting it may have utility as a lower 
cost model for evaluating efficacy of novel drug combinations with the aim of subsequent 
translation into the clinic. 
The coculture model was used as the foundation of a genome-wide shRNA depletion screen 
to identify sensitizers of gemcitabine resistance in PDAC in vitro culture.  The primary screen 
and subsequent validation screen identified 19 high confidence genes with potential 
3 
 
translational value, of which knockdown sensitised to gemcitabine within this model.  This is 
alongside an expanded list of 444 genes significantly contributing to the resistance 
phenotype, representing pathways such as MTORC signalling and DNA damage response. 
This dataset serves as the first shRNA-mediated coculture screen for gemcitabine resistance 
in PDAC. 
My findings lay credence to the value of this model of gemcitabine resistance for preclinical 
use and provides a robust and voluminous shRNA dataset supporting target identification 
for the ablation of gemcitabine chemoresistance in PDAC.   
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1. Introduction 
 
1.1 Introduction to PDAC 
1.1.1 Biology of the pancreas 
The pancreas is the primary glandular organ in the human body, forming a key component 
of both the endocrine and digestive systems. The endocrine system is responsible for 
production of key hormones such as insulin and glucagon, required to modulate circulating 
glucose levels, while the digestive system produces enzymes such as lipase and amylase, 
required for breakdown of food and absorption of nutrients in the stomach and small 
intestine.  
Corresponding to the two functions, the cellular composition of the pancreas is divided 
between cells driving endocrine functions and those driving digestive functions.  
Pancreatic islets are the primary hormone-producing cells, constituting 1-2% of the pancreas 
volume. The primary component by volume of the pancreas are acini – clusters of acinar 
cells producing digestive enzymes, or zymogens, required for intestinal absorption. These 
enzymes are secreted from acini into the interlobular and then main pancreatic duct, 
leading directly to the duodenum. Abrogated function, characterised by decreased to zero 
production of the key digestive enzymes, drives diseases such as Exocrine Pancreatic 
Insufficiency (EPI) (Wilschanski and Novak, 2013). 
Investigation into human pancreas form and function as a step within the drug development 
process relies often on the use of murine models, and therefore corresponding cell types 
and functions. This similarity is of importance as candidate therapeutics are de-risked 
(efficacy and toxicity) with pre-clinical murine data on pharmacodynamic and 
pharmacokinetic effects before human testing. This therefore requires a degree of 
anatomical and functional parallels between both species. Similarities and differences in 
both have been reviewed previously, with functional roles of endocrine and exocrine 
cellular compartments maintained, despite moderately divergent anatomical structures of 
secretory ducts (Dolenšek, Rupnik, and Stožer, 2015). Coupling biological correlations with a 
long history of use in research into the pancreas, the mouse is an invaluable tool in 
pancreatic cancer research. 
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1.1.2 Pathology of disease 
Abrogated endocrine or exocrine functions within the pancreas can lead to onset and 
development of diseases such as diabetes and EPI, respectively. Pancreatic neoplasia 
encompass several different diseases. Each is classified based primarily on the cell type of 
neoplastic origin.   
The principal endocrine form of neoplastic disease is pancreatic neuroendocrine tumours 
(PNETs), making up 1-2% of the total number of clinically significant pancreatic cancers 
(Zhang et al., 2016). Developing from islet cells, PNETs are largely benign, further sub-
divided based on the type of islet cell affected, and whether normal hormone function is 
abrogated. 
Most pancreatic cancers though are carcinomas, arising from the exocrine compartment of 
the pancreas. Whilst several rare forms of exocrine cancers exist, such as acinar cell 
carcinoma and pancreatoblastoma, over 95% of exocrine cancers are pancreatic ductal 
adenocarcinoma (PDAC) (Warshaw and Castillo, 1992). PDAC neoplasms typically but not 
exclusively arise from epithelial cells lining the secretory exocrine ducts, most typically 
initiating in the head of the pancreas (Hezel, Kimmelman, Stanger, Bardeesy, and Depinho, 
2006).There also exists a rare subset of mucin-related PDAC tumours called mucinous cystic 
neoplasm (MCNs) which arise in the tail and body of the pancreas separate to the ductal 
branch (Fernández-del Castillo, 2008). 
PDAC evolves initially through progressive growth of non-invasive precursor lesions, most 
commonly pancreatic intraepithelial neoplasms (PanINs). Through clonally selected 
proteomic and genetic modifications PanINs progress rapidly, later stages characterised by 
increasing levels of nuclear atypia and dysregulated growth (Hruban, Goggins, Parsons, and 
Kern, 2000) (Fig 1.1).  
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Figure 1.1 Growth stages of pancreatic intraepithelial neoplasms. Adapted from (Hruban et 
al., 2000). 
Both PDAC and PanINs are further characterised histologically by a dense desmoplastic 
reaction within the developing tumour. This is a product of both a high density of non-
tumour microenvironment cells such as fibroblasts, endothelial cells, and immune cells, as 
well as a highly elevated production rate of extracellular matrix (ECM) proteins such as 
fibronectin and collagen I and III (Erkan et al., 2008; Maitra and Hruban, 2008). This activity 
will be addressed in further detail later as a causative factor related to disease prognosis 
and treatment strategy.   
A primary prognostic challenge of PDAC is the asymptomatic nature of early disease. 
Surgery is the only curative option for patients, but less than 20% of PDAC patients present 
early enough for surgical resection to be a consideration (Sohn et al., 2000). In the other 
80% the disease may have invaded locally or spread to distal sites within the body, 
rendering local resection ineffective for total removal of tumour tissue.  
Typical symptoms include malaise, nausea, back pain, weight loss, and often anorexia. All 
are highly nonspecific, and often attributable to other less morbid maladies. Diagnostic tests 
rely on endoscopic ultrasound, MRI, CT and PET scans, and can also include serum markers 
such as CA19-9.  These may also provide information on prognosis (Pancreatic Cancer UK, 
2016; Vincent, Herman, Schulick, Hruban, and Goggins, 2011).  
As of 2011, only 4% of patients presenting with PDAC will be alive within 5 years post-
presentation – the highest mortality rate amongst the major cancers (Cancer Research UK, 
2014b) . Whilst pancreatic cancer is only the 11th highest cancer in terms of UK incidence 
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(Cancer Research UK, 2015), it is the 5th leading cause of cancer-related death (Cancer 
Research UK, 2016; Siegel, Ma, Zou, and Jemal, 2014), reflecting the clinical challenge the 
disease presents . Of all major cancers, PDAC has had both the lowest gross and relative 
improvements in survival in the last 50 years (Cancer Research UK, 2011). Reasons for such 
poor survival include late diagnosis and resistance to most available therapy, at least in part 
due to the highly desmoplastic nature of the tumours, as will be described later. 
Age is one of the predominant risk factors for PDAC development, with the majority of 
patients in the UK >75 years of age upon presentation (Cancer Research UK, 2014b). Aside 
from this, there has been minimal conclusive evidence for lifestyle habits as risk factors for 
PDAC, although a meta-analysis of studies linking alcohol consumption and smoking suggest 
both have a mild correlation with development of the disease (Becker, Hernandez, Frucht, 
and Lucas, 2014). Non-lifestyle biochemical and genetic risk factors will be discussed later. 
Type 2 Diabetes has been demonstrated as a primary association with development of 
PDAC, although typically driven by genetic components coupled with poorly balanced diets 
and low levels of exercise (Huxley, Ansary-Moghaddam, Berrington de González, Barzi, and 
Woodward, 2005). Pancreatitis, or inflammation within the pancreas, is also a significant 
driver of carcinogenesis within the organ, itself typically driven by alcohol consumption or 
presence of gallstones (Bansal and Sonnenberg, 1995; Lowenfels et al., 1993). 
1.1.3 Molecular and genetic characterisation 
The pathophysiological profile of PDAC is well documented and provides mechanistic 
insights on disease establishment and growth - an invaluable tool for the development of 
novel treatment strategies.  
From a molecular perspective, onset and growth of PDAC is driven by a combination of 
aberrant paracrine and autocrine signalling cascades, both within PDAC epithelial nests and 
between the tumour and the adjacent microenvironment. High expression of growth factors 
and their cognate receptors, such as IGF/R, HGF/R, and FGF/R are all drivers of PDAC cell 
growth and invasion (Coleman et al., 2014; Denduluri et al., 2015; Matsuda et al., 2014; 
Matsushita, Gotze, and Korc, 2007; Rucki et al., 2017), alongside broad-acting signalling 
molecules such as TGFβ, β-integrin, and focal adhesion kinase (FAK) (Begum et al., 2017; 
Jiang et al., 2016; Principe et al., 2016). Through activation of pro-tumourigenic signalling 
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pathways such as the MAPK and WNT cascades (Pasca di Magliano et al., 2007), as well as 
repression of pro-apoptotic pathways through JAK/STAT activation (Corcoran et al., 2011), 
these molecules form an integral component driving the rapid progression seen in PDAC. 
PDAC is characterised genetically by somatic mutation of key cell growth and protection 
genes such as KRAS, TP53 and SMAD4. Over 90% of all PDAC cancers contain mutant KRAS, 
and at least 50% have  mutant TP53 (Bailey et al., 2016; Biankin et al., 2012). The 
combination of both mutations accelerates growth through KRAS-mediated MAPK signalling 
whilst removing standard DNA repair and growth arrest systems mediated via TP53. Despite 
the known incidence of mutations, neither gene nor associated product is directly 
targetable, and due to wide-ranging cascade activations, form challenging barriers to 
repression of tumour growth in patients. Mutations in genes such as CDKN2A, SMAD4, and 
ARID1A, further account for driver mutations in >5% of PDAC tumours (Aguirre et al., 2017). 
As well as single genes, mutations in major pathways such as those of chromosome 
modification and DNA damage response are all associated with and causative of PDAC 
development (Bailey et al., 2016; Biankin et al., 2012; Collisson et al., 2011). 
The last decade has seen development of multiple genome-wide gene expression prognostic 
signatures, in an effort to standardise disease classification and more importantly derive 
valuable and significant predictive insights from quantitative genetic meta-analysis. Four 
models in particular have been established and built traction: the Collisson’s, Bailey’s, and 
Moffitt’s (tumour and stroma) classifications (Bailey et al., 2016; Collisson et al., 2011; 
Moffitt et al., 2015).  Each model uses gene expression data directly from pancreatic cancer 
tissue to classify tumours into sub-types, with Moffitt’s model further classifying the stromal 
subtype and associated prognosis. The true prognostic value of each and overlap in gene 
signatures was investigated by Birnbaum et al. using clinical and gene expression data from 
a further 846 primary PDAC samples, classifying the data using each of the above reported 
signatures. Of the four, only Collisson’s signatures (“classical”, “quasi-mesenchymal”, and 
“exocrine-like”) did not demonstrate significant prognostic value (Birnbaum, Finetti, 
Birnbaum, Mamessier, and Bertucci, 2017). Notably Moffitt’s stroma classifier indicated a 
possible contribution of the activated stroma in PDAC progression, with 2-year median OS of 
49% with “normal” stroma signature but only 34% with the “activated” stromal signature. 
Such classification schemes are still to be implemented into routine clinical practice for 
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helping define treatment strategy but may hold particular value in the future through 
investigation of signature correlation with therapeutic responses. 
1.2 Clinical management of PDAC 
1.2.1 Current clinical paradigms 
Relative to other major cancers, PDAC treatment has experienced relatively minimal 
changes in treatment strategy through the last decade. 
PDAC patients present at one of four primary clinical stages, i) local resectable, ii) borderline 
resectable, iii) locally advanced, and iv) metastatic. When patients present with local 
resectable or borderline resectable disease, Whipple resection (pancreaticoduodenectomy) 
surgery remains the only curative approach, with a 5 year survival of over 25% (Vincent et 
al., 2011). Operative mortality from tumour resection is low globally. Despite this, as 80-90% 
of patients present with non-resectable cancer (Varadhachary et al., 2006), this approach is 
rarely suitable for treatment. Instead, therapeutic options capable of targeting both primary 
and secondary sites of tumour growth are required.  
Gemcitabine, a nucleoside analogue therapeutic, has formed a central part of this paradigm 
since approval in 1997, when a comparison to fluorouracil administration demonstrated an 
improvement in median overall survival from 4.4 months to 5.6 months (Burris et al., 1997), 
with a subsequent single agent phase 3 trials demonstrating a median OS range from 5.0 to 
7.2 months (Di Marco et al., 2010). As per the mechanism of other nucleoside analogues 
such as cytarabine, gemcitabine exerts a cytotoxic effect through incorporation into 
replicating DNA strands and inducing replication fork stalling and DNA strand breaks. Acting 
selectively on rapidly growing cells, it exhibits preferential effect on cancer tissue over less 
replicative healthy tissue (Plunkett et al., 1995).  
Recent years have seen the development and introduction of more advanced chemotherapy 
cocktails for treating PDAC, focused on marginal efficacy improvements through complex 
dosing regimens, to best maximise the effect of each agent alone. Few have demonstrated 
significant improvements when compared to gemcitabine alone. Despite this, the past 
decade has led to one primary chemotherapy regimen widely incorporated into clinical 
practice in place of gemcitabine - FOLFIRINOX (FOLinic acid, Fluorouracil, IRINotecan, and 
OXaliplatin). FOLFIRINOX can increase PDAC median OS to 11.2 months but introduces an 
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increased adverse event profile, which can be too harsh for weaker patients, common 
amongst the older population inflicted with this disease (Conroy et al., 2011).  
The combination of albumin-bound paclitaxel (nab-paclitaxel; AbraxaneTM) and gemcitabine 
has also been shown to be advantageous over gemcitabine alone (median OS from 6.7 to 
8.5 months), but similarly to FOLFIRINOX, has an increased side effect profile including 
myelosuppression to be wary of in clinical practice (Von Hoff et al., 2013). 
1.2.2  Novel targeted strategies 
Alongside the development and improvement of broad-acting chemotherapy combination 
strategies, there has been significant evaluation of the value of targeted treatment 
strategies for PDAC, as has demonstrated value in many other cancers. 
Noting the majority of PDAC tumours express high levels of EGFR, there have been multiple 
trials combining approved EGFR inhibitors with gemcitabine. The EGFR inhibitor erlotinib 
was approved by the FDA for advanced PDAC in combination with gemcitabine after a minor 
increase in median overall survival (OS) of 5.91 to 6.24 months, but the EGFR extracellular 
domain-binding antibody cetuximab, did not show significant benefit (Moore et al., 2007), 
perhaps indicating an activity of EGFR that acts independent of activation of the 
extracellular domain  
The highly fibrotic nature of the pancreatic tumour leads to a strict need for pervasive 
vasculature within tumours to provide growth nutrients and support metastatic spread. 
Despite preclinical studies indicating value in combining inhibitors of vascular endothelial 
growth factor (VEGF) receptor, typically required for tumour vasculature, a phase III 535 
patient trial with VEGFR inhibitor bevacizumab with gemcitabine showed no significant OS 
benefit (Kindler et al., 2010).  
With such minimal incremental improvements in PDAC survival from even the most 
successful of trials and regimens, a major challenge remains in addressing perhaps the 
major driver of PDAC, KRAS. Targeting and inhibiting mutant KRAS activity has been a 
primary goal of translational pancreatic cancer research over the past couple of decades, 
but due to the protein’s fully internal and non-kinase, non-directly targetable activity this 
has been a challenge (Downward, 2003; Sun et al., 2012) and various approaches have not 
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been effective. After translation the KRAS protein needs to localise to the plasma membrane 
for activation of downstream proteins. This localisation requires farnesyltransferases to 
farnesylate the nascent protein. A farnesyltransferase inhibitor only increased median OS 
from 5.98 months to only 6.34 months, when compared to gemcitabine alone in Phase III  
(Van Cutsem et al., 2004). Whilst the targeting of KRAS remains elusive in patients, the 
development of advanced drug delivery and targeting technologies over recent years has 
led to new attempts at targeting mutant KRAS in mice. Exosomes loaded with siRNA 
targeting the primary Kras G12D mutation were trialled in orthotopic tumours as well as in a 
genetically engineered mouse model (GEMM) of PDAC with significant survival increases in 
each (Kamerkar et al., 2017). Targeting of downstream effectors of KRAS have also been 
investigated, with the MEK inhibitor selumetinib combined with the AKT inhibitor MK-2206 
compared to FOLFOX in gemcitabine-resistance PDAC patients. With a median OS of 3.9 
months in the experimental arm compared to 6.7 months on FOLFOX, this regimen was not 
progressed (Chung et al., 2017). Despite these challenges, recent years have seen the 
beginnings of development for small molecular inhibitors of KRAS (Ostrem and Shokat, 
2016), which if feasible may hold exciting promise in PDAC treatment. 
Other approaches currently progressing through preclinical development and clinical trials 
include those with approved utility in other major cancers, such as targeting of DNA damage 
response (DDR) pathways. Targeting of DDR pathways, and therefore the cells ability to 
recover from damage, alongside gemcitabine, has shown promise in pancreatic GEMMs, 
laying the foundation for an in-human combination trial (Fokas et al., 2012; S-B Koh et al., 
2018; Siang-Boon Koh et al., 2015; Wallez et al., 2018). Another approach is immunotherapy 
- redirecting the immune system to target tumour tissue.  Despite initial low response rates 
for anti-CTLA-4 and anti-PD-1 therapy in PDAC (Aglietta et al., 2014; Royal et al., 2010; Weiss 
et al., 2018), recent investigations into priming the PDAC tumour for immune targeting may 
yield value (Le et al., 2015). The PDAC desmoplastic stroma plays an important role in 
maintaining tumour immune privilege (Feig et al., 2013; Kraman et al., 2010) and so 
therapeutic approaches to targeting the PDAC stroma to overcome drug resistance (as 
described below) may have the added benefit of enabling immunotherapy.  
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1.2.3 Challenges in treatment resistance 
Independent of the efficacy and value of a therapeutic, if a tumour either is inherently 
resistant or rapidly acquires resistance to it then value can be immediately negated. Drug 
resistance is a major obstacle in PDAC clinical strategy, and a major explanation for the low 
survival rates observed. A range of genetic and molecular markers of resistance have been 
documented (Hagmann, Jesnowski, and Löhr, 2010; K. P. Olive et al., 2009; Voutsadakis, 
2011), as well as entire cellular transformation processes such as epithelial to mesenchymal 
transition (EMT) (X. Zheng et al., 2015). Each marker and panel can inform specific factors 
influencing drug effect and predict clinical efficacy.  
Pancreatic cancer exhibits high levels of inherent resistance to most therapies above and 
beyond that typically seen in other major cancers (Brahmer et al., 2012; Chong and Jänne, 
2013; Rahib et al., 2014; Royal et al., 2010). This is partly due to both intrinsic resistance 
mechanisms, such as altered gemcitabine metabolism via upregulation of cytidine 
deaminase (CDA) (Weizman et al., 2014), and extrinsic mechanisms, such as stroma-
conferred immune evasion signalling and structural barriers to drug efficacy (Feig et al., 
2013; K. P. Olive et al., 2009). 
An ability to target and ablate these resistance mechanisms holds value not only for direct 
effects on tumour growth, but also for the larger potential survival increases for 
combination with already approved strategies such as gemcitabine and FOLFIRINOX. As such 
the past decade has included significant efforts towards identifying, understanding, and 
targeting these mechanisms, yielding some positive results, although alongside many 
associated challenges. 
1.2.4 Molecular basis of resistance 
Understanding the roles and functions of various proteins and genes driving this resistance 
forms an essential foundation to support development of resistance-targeting therapeutics. 
As an initial step to understand these mechanisms, research efforts have focused on 
identifying and validating informative biomarkers for gemcitabine efficacy, both 
pharmacokinetic (PK) and pharmacodynamic (PD). 
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Gemcitabine PK and resistance biomarkers in PDAC relate primarily to indicators of 
enhanced drug metabolism or reduced drug uptake. Overexpression of nucleoside efflux 
transporter molecules such as MRP5 correlates immunohistochemically to resistance to 
gemcitabine (Hagmann et al., 2010), indicating in some patients an increased level of 
gemcitabine efflux may explain reduced levels of efficacy. Similarly, low expression of 
nucleoside uptake molecules such as ENT1 have been correlated with increased gemcitabine 
resistance in PDAC (Spratlin et al., 2004). This may be a major factor driving drug resistance, 
as a cell’s ability to rapidly expunge active molecules via membrane transporters will reduce 
the bioavailability. High expression of gemcitabine metabolising protein CDA correlates with 
gemcitabine resistance levels in patients, suggesting that increased metabolism of the active 
form of gemcitabine, dFdC, to the inactive metabolite dFdU may reduce cytotoxic effects 
(Ohhashi et al., 2008; Weizman et al., 2014).   Downregulation of dCK is associated with 
gemcitabine resistance also (Ohhashi et al., 2008). 
Coupled with this, recent years have highlighted interrogation of EMT as a mechanism 
through which PDAC cells evolve and become resistant to gemcitabine and other 
therapeutics (Rhim et al., 2012; X. Zheng et al., 2015), noting also poor prognosis 
significantly correlated with high expression of EMT-related genes (Aguirre et al., 2017). 
Pancreatic tumours expressing high levels of EMT factors and mesenchymal markers, such 
as ZEB1 and SDF1, are correlated significantly with therapeutic resistance (Arumugam et al., 
2009; Weekes et al., 2012), indicating that perhaps either the more motile properties of 
mesenchymal cells, or signalling cascades induced via EMT may have direct causative 
implications in modulating resistance to gemcitabine. The specific mechanism through 
which EMT modulates resistance to gemcitabine has been explored further, with indications 
that mesenchymal transition can increase expression of nucleoside efflux transporters as 
detailed above. 
While each of above presents opportunity for developing biomarkers with clinical utility in 
informing likelihood of resistance in the clinic, the challenge remains that independent of 
our awareness of resistance, alternate treatment options remain minimal. 
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1.2.5 Approaches to combat resistance 
Leveraging this expanding understanding of mechanisms of treatment resistance, 
therapeutic targeting of resistance has begun to be explored, in particular around stroma-
conferred resistance mechanisms.   
For example, targeted depletion of sonic hedgehog (SHH) in the PDAC stroma with IPI-926 
led to a commensurate depletion in PDAC stromal content itself, which within the KRas G12D; 
P53 R172H; PDX1-cre (KPC) model of pancreatic cancer enhanced delivery and therefore 
efficacy of gemcitabine on murine survival (K. P. Olive et al., 2009). Unfortunately, in a 
clinical trial (NCT01130142), the gemcitabine plus IPI-926 combination paradoxically 
reduced survival in patients when compared to gemcitabine alone (Kenneth P Olive, 2018). 
Following further preclinical investigation, it was revealed that SHH-targeted stromal 
ablation unveiled not only pro-tumourigenic effects of the stroma, but also anti-
tumourigenic restraining effect (Özdemir et al., 2014; Rhim et al., 2014). Therefore, 
indicating the need to target therapeutically more specific elements in the stroma and 
associated resistance mechanism, without compromising any positive anti-tumourigenic 
functions.  
1.3 Role of stroma and tumour micro-environment in PDAC 
1.3.1 Cell type composition and introduction  
Pancreatic tumours have amongst the highest stromal component and density when 
compared to other major cancers (A. Neesse et al., 2011). This dense and fibrotic 
component forms a major unit in the cancer’s arsenal for growth and immune evasion, 
supporting both tumour seeding as well as later stage metastatic transformation. With such 
an active stromal component, pancreatic tumours present as one of the more heterogenous 
major cancers from both inter- and intra-tumour perspectives.  
Intertumourally, heterogeneity is exemplified by the variety of WHO PDAC histological 
characterisations (Bosman, Carneiro, Hruban, & Theise, 2010), as well as the widely 
documented genetic heterogeneity observed across PDAC subtypes (Bailey et al., 2016; 
Donahue et al., 2012; Lili et al., 2014; Moffitt et al., 2015; Waddell et al., 2015). Such 
subtypes, whilst often not completely dissimilar in cellular composition (Adsay et al., 2000; 
Kosmahl et al., 2005; Lüttges et al., 1998), often contribute to a diverse range of clinical 
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outcome and treatment responses (Birnbaum et al., 2017), indicating the importance of 
accurate classifications as part of a physician’s treatment evaluation.  
Intratumourally, the wide range of cell types present in the stroma are a direct example of 
cellular heterogeneity within tumours. Cytogenetic heterogeneity has been observed even 
at in adjacent tumour glands, as has genetic heterogeneity been observed in distinct 
intratumour regions (Nakamura et al., 2007). While such diversity has inspired clinical trial 
design to personalise treatment approach (Chantrill et al., 2015), an underlying lack of 
understanding on the complex roles and interplay of tumour components remains a barrier 
to clinical success (Moffitt et al., 2015). 
Elucidating specific roles of individual cell types within the tumour setting is difficult, 
although functions of the activated fibroblastic component, the extracellular matrix, as well 
immune cells in within the stromal nest have all been widely investigated. 
Cancer-associated fibroblasts (CAFs) are a major mediator of both of pro- and anti-
tumourigenic signalling in the PDAC microenvironment. CAFs are activated forms of 
pancreatic stellate cells (PSCs), themselves a canonical mesenchymal stellate cell with 
morphological and functional similarities to hepatic stellate cells (HSCs) (Erkan et al., 2011). 
In a quiescent non-activated state, PSCs support pancreatic functions and infrastructure 
through production of extracellular matrix (ECM) proteins such as collagen, MMPs, 
fibronectin, and laminin (Jaster, 2004), and through active matrix modelling and turnover, 
support homeostatic functions of pancreatic tissue. Tissue damage, carcinogenesis, and the 
associated release of stimulating factors such as reactive oxygen species and TNFα all serve 
to induce activation of PSCs into CAFs (Apte et al., 1999; Apte, Pirola, and Wilson, 2012; 
Mews et al., 2002), characterised by a morphological transition into myofibroblastic 
phenotypes, inducing rapid proliferation increases and increased production of ECM 
proteins, all of which contribute to the highly fibrotic nature of PDAC. CAFs themselves can 
further cluster into different functional populations, characterised by expression of 
molecular markers such as FAP, which can indicate further roles in modulating immune cell 
activity and growth of cancer cells (Feig et al., 2013; Öhlund et al., 2017). 
Alongside mesenchymal cells, there exists a diverse population of immune and 
inflammatory cells, both resident and accumulated in response to pancreatitis and PDAC 
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development. Immunosuppressive cells such as tumour-associated macrophages (TAMs), 
myeloid-derived suppressor cells (MDSC), and regulatory T cells (Tregs) all contribute towards 
immune evasion within PDAC through a combination of altered tumour metabolism, 
migration patterns, and protections from apoptotic signals (Campbell, Albo, Kimsey, White, 
and Wang, 2005; S. Hinz et al., 2007; Stromnes et al., 2014).  
As part of the ECM, MMPs such as MMP-2 and MMP-9, produced by cancer cells as well as 
CAFs, regulate invasive properties of the epithelial cells within the tumour (Ellenrieder et al., 
2000; Shan et al., 2017), while hyaluronic acid promotes angiogenesis, cell migration, and 
rapid proliferation within the PDAC compartment (Jacobetz et al., 2013). Further, the 
production of the structural protein collagen I in pancreatic cancer each have documented 
roles in supporting the carcinogenic process (Armstrong et al., 2004; Shields, Dangi-
Garimella, Krantz, Bentrem, and Munshi, 2011), altogether exemplifying the major role the 
pancreatic stroma plays in tumour growth and metastatic expansion.   
1.3.2 Pro- and anti-tumourigenic stromal components 
Investigation into the effects of the stroma on pancreatic tumour form and function is 
challenging, given the diverse range of cells involved, alongside difficulty in disentangling 
the roles of each within the greater mass. Nevertheless, a complete understanding of 
cellular roles, and the effects of upregulation or depletion, are key to target identification, 
validation, and downstream drug development.  
While the stroma has broadly pro-tumourigenic roles, there exist a range of essential 
tumour-suppressive processes conferred, alongside immunosuppressive activities of 
resident immune cells detailed above. These include anti-proliferation functions of adipose-
derived stromal cells (Cousin et al., 2009), miRNA-controlled targeted apoptosis (Han et al., 
2018), as well as general increases in EMT and PDAC proliferation and decreases in cell 
differentiation through genetically targeted stroma depletion (Rhim et al., 2014; X. Zheng et 
al., 2015). 
Challenges such as with the IPI-926 trial highlighted above indicate the absolute imperative 
need for thorough understanding of stromal contributions to PDAC development and drug 
resistance, to support identifying techniques to target just those tumour-promoting 
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properties, whilst supporting the maintenance or enhancement of tumour-suppressive 
functions.   
While tumour-suppressive functions of the stroma have been  less documented, tumour-
promoting functions have been numerous and diverse, perhaps due to the relatively recent 
realisation of the extent of tumour-suppressive stromal functions 
From a structural perspective, enhanced collagen and hyaluronan in the ECM as produced 
by CAFs can compress the tumour vasculature and reduce perfusion throughout (Jacobetz et 
al., 2013; Özdemir et al., 2014; Provenzano et al., 2012). This creates a physical barrier for 
drug delivery as well as reducing oxygenation of tumour tissue, creating a hypoxic 
environment supporting tumour growth. 
CAFs have well documented effects on driving tumour growth and development. Firstly, 
production of CXCL12 on FAP-expressing cells stimulates T cell exclusion, therefore 
protecting growing tumours from the deleterious eye of the immune system (Feig et al., 
2013). Secondly, increased production of ECM components such as hyaluronan through CAF 
activation can enhance cell proliferation, migration, and subsequent invasion (Provenzano 
et al., 2012). Finally, production of the prostaglandin COX-2 can drive PDAC proliferation, as 
well as myofibroblastic activity enhancing oxidative phosphorylation through increased 
glucose absorption and lactate production, which in turn increases the invasive potential of 
PDAC cells (Omura et al., 2010; Shan et al., 2017).  
Together there exist multiple mechanisms of tumour promotion within the stroma, although 
targeting them via cellular ablation may lead to deleterious effects given the wide range of 
functions that may be affected. Therefore, identification of subsets for targeting, or 
inhibition of singular pathways where possible, may lead to more predictable clinical 
outcomes. 
1.3.3 Targeting stroma for clinical benefit 
Historically targeted therapy development in pancreatic cancer has been challenging with 
minimal improvement on patient survival. This is true in particular when trialling targeted 
approaches that show clinical benefit in other major cancers, such as has been seen with 
anti-EGFR, AKT and VEGF approaches. The multi-factorial contributions of the stroma to 
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carcinogenesis means targeting of any one mechanism of tumour promotion may quickly be 
nullified through compensatory signalling and growth via one of the multiple other channels 
of growth, immune evasion, and proliferation support. 
There are a range of approaches currently developing both towards and in the clinic, 
focused on disrupting the cancer-stroma relationship, and removing the stroma’s ability to 
support and protect the tumour. Depletion of hyaluronic acid (HA) within the pancreatic 
stroma using a PEGylated human recombinant PH20 hyaluronidase (PEGPH20) increased 
gemcitabine delivery and efficacy through improving vascular perfusion (Jacobetz et al., 
2013). This observation led to successful phase I and phase II trials in patients with advanced 
disease (S. Hingorani et al., 2018; S. R. Hingorani et al., 2016), culminating in a currently 
active phase III trial in stage IV disease (Doherty, Tempero, and Corrie, 2018). Further, focal 
adhesion kinase (FAK) plays a role in driving the highly fibrotic state of PDAC stroma, 
coupled with support of immunosuppressive exclusion of cytotoxic T cells (Furuyama et al., 
2006; Jiang et al., 2016), with its specific inhibition through use of selective FAK inhibitor VS-
4718 limiting tumour growth and progression with the KPC mouse model and improving 
response to a PD-1 antagonist. These data have led to an ongoing phase I trial of the FAK 
inhibitor in combination with gemcitabine and PD-1-targeting pembrolizumab (Wang-Gillam 
et al., 2017). Together these studies form a core of a body of developing clinical studies into 
the utility of stromal targeting in pancreatic cancer.  
While PDAC is typically diagnosed late, stromal remodelling in the disease occurs 
throughout carcinogenesis, pre-seeding the pancreatic niche during inflammatory 
pancreatitis to support PDAC formation (Apte et al., 2004; Whatcott et al., 2015). If these 
stromal mechanisms are better understood and identified at an early stage, prophylactic 
targeting may yield benefit in reducing PDAC incidence. Nevertheless, focusing translational 
efforts on the stromal compartment in PDAC holds real opportunity in exploring novel 
treatment and therapy improving strategies for PDAC. 
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1.4 Use of models to identify and develop new treatment strategies 
1.4.1 Overview 
Breaking down translational drug development into its modular constituent parts, both 
target identification and preclinical lead optimisation lean heavily on the integrity and 
predictive power of in silico, in vitro, and in vivo research models. Each step has an inverse 
relationship between resource requirements and predictive power. For example, 
monoculture in vitro assays can be run high-throughput for screening, but in vivo low-
throughput models of disease such as those in mouse and rat remain best for modelling 
predictive PK/PD in humans. There is a defined need to improve this ratio of cost to power 
for both in silico and in vitro models to better de-risk therapeutic development whilst 
maintaining relatively lower resource requirements. 
1.4.2 In silico approaches for drug target identification 
Improvements in in silico analysis have been driven by an increase in accrued -omics data, 
processing power, as well as machine learning and deep learning models for supporting 
target identification. Large datasets can be mined for correlative indicators of disease 
mechanisms, as well as for tracking response to therapeutics. Machine learning algorithms 
and toolsets have begun to be evaluated within PDAC alongside standard linear and logistic 
regression modelling of disease diagnosis and prognosis. Artificial neural networks (ANNs) 
can both decipher disease mechanisms as well as predict survival from varying clinical and 
histopathological data. When comparing performance to single risk attributes such as 
tumour size, logistic regression has remained superior (Hayward et al., 2010), although the 
real value of ANNs has been in combination of multivariate data and identification of novel 
correlative factors for PDAC progression, such as leukocyte counts (Ansari et al., 2013), or 
improved interpretation of complex output data such as that from elastography (Săftoiu et 
al., 2008). Development of in silico models to predict drug efficacy in PDAC has been 
minimal despite some indications of clinical utility (Kumar, Chaudhary, Singla, Gautam, and 
Raghava, 2014; Ma et al., 2016). As such, the field remains at an early stage with significant 
progress to be made before real applicability of output data in informing clinical selection. 
1.4.3 In vivo model development 
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Murine in vivo models of PDAC remain the cornerstone data point preceding human testing 
for novel treatment strategies. Coupled with a broadly similar biological structure and 
functions between the murine and human pancreas, this system allows for an advanced 
insight into toxicity profiles of novel drugs, itself perhaps the single largest concern to be 
addressed prior to in-human studies. 
The development of predictive murine models for cancer have recently focused on patient 
derived xenografts (PDXs), as well as cell line-derived xenografts. For PDXs, patient tumour 
tissue is isolated and is implanted subcutaneously or orthotopically into immune-
compromised mice and used for subsequent preclinical testing. A major advantage is the 
ability to evaluate therapeutic efficacy in patient tissue within a murine model, and has led 
to validation of therapeutic regimens that subsequently led to clinical investigation 
(Kawaguchi et al., 2017; Lipner et al., 2016) 
While this model allows assessment of individual patient tissue directly, it does not allow 
investigation of effects on human stromal or immune cells, due to the absence of these cells 
within PDX recipient immunodeficient mice. Further the biological differences between the 
human tumour tissue and the initial murine stromal compartments within most PDX models 
limits investigational utility in PDAC when compared to other less stroma-rich cancers, 
where evaluating the role of and effect on the stroma are of less importance. 
This challenge can be compensated for through use of genetically engineered mouse models 
(GEMMs), such as the Kras G12D; p53 R172H; Pdx1-cre (KPC) model in pancreatic cancer, 
whereby both tumour and stroma are genetically matched to each other and the host 
mouse.  In this model, through targeted genetic manipulation, the KPC mouse express 
mutant Kras and mutant Tp53 restricted to pancreatic epithelial tissue (S. R. Hingorani et al., 
2005). This leads to early onset development of focal PanIN and then PDAC, with abundant 
desmoplastic stroma, intact immune system, and metastatic PDAC growth associated with 
the same co-morbidities as in man. This model has been a major tool for PDAC translational 
development, in particular as a system to best understand stromal roles and structures in 
vivo, although additional GEMMs do exist for interrogation of further PDAC properties 
(Gopinathan, Morton, Jodrell, and Sansom, 2015).   
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Whilst murine studies certainly remain an essential component in translational 
development, they are extremely cost and time intensive tools, requiring many months per 
low-throughput study, and therefore not amenable to large scale genetic or chemical 
screening. As such their utility is reserved for higher confidence de-risked therapeutic 
programs.  
There therefore exists a need for models supporting generation of novel biological data, 
unlike in silico modelling, and in a high-throughput and low-cost approach, unlike in vivo 
techniques. It is within this gap that the foundation of preclinical drug development sits, in 
vitro. 
1.4.4 The role of in vitro models in the drug development process 
In vitro models encompass cell-based experimentation performed outside of their normal 
biological context, by definition on glass, in practice plastic and media. Forming one of the 
primary steps within the cancer drug development process, there has been major focus over 
the preceding decades in improving both the models themselves as well as the techniques 
through which we can analyse and interpret their output data.  
The primary advantages of these models traditionally lie within the simplicity of protocol, 
the low-cost of operation, and the capacity to be automated and scaled to interrogate large 
numbers of hypotheses simultaneously.  One challenge though remains significant: the 
extrapolation of data back to the biology of human disease. This challenge is a particular 
barrier in pancreatic cancer, wherein the complex and dynamic interplay of many cell types 
in the tumour microenvironment, and their contribution to drug efficacy and resistance are 
less easily modelled and assayed. 
These advantages noted above have been further solidified over the past decade, through 
the introduction of better cellular characterisation to normalise protocols and improve 
reproducibility, the creation of increasingly smaller scales of experimentation, such as in 
1536-well plate drug screening (Minuesa et al., 2014), as well as the development and 
commercial production of large and powerful machinery with which these processes can be 
automated. Such developments have enabled large scale screens of cancer drugs that have 
identified genomic markers of drug sensitivity (Barretina et al., 2012; Garnett et al., 2012; 
Stransky et al., 2015). 
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Despite this, the challenge remains: improving our ability to accurately recapitulate the 
biological environment in vivo in an in vitro setting to improve translation and functional 
correlation between systems. By achieving this, the power of in vitro models within the drug 
development setting can be exponentially increased, with definitive benefits in 
strengthening the foundation of preclinical data in advance of in vivo experimentation.  
1.4.5 Development of novel in vitro models  
Despite their tenure and value, in vitro models have remained relatively basic, whereby 
monoculture cell line systems are a mainstay of preclinical therapeutic development. These 
can be particularly poor at predicting therapeutic efficacy in cancer, given the absence of 
tumour-specific geospatial architecture and the growth and survival variation introduced 
through growth on plastic. This paucity of prediction is exacerbated in PDAC specifically, due 
the significant contribution of different cell types within the stroma to drug efficacy. 
Nevertheless, in vitro monoculture models are a core of multiple successful preclinical 
investigations in PDAC, as has been seen for the foundation of targeting FAK in PDAC 
(Furuyama et al., 2006; Jiang et al., 2016).  
The challenge of poor predictivity of in vitro data due to the poor representation of tumour 
dynamics has been tackled via one of two methods. Firstly, improvements in cell line 
handling technologies as well as improved characterisation of existing lines has allowed 
large high-throughput monoculture screening to become feasible. This supports generation 
of data on translational efficacy across wider heterogenous cell line panels and minimises 
cell line-specific artefacts of efficacy, with demonstrated value across multiple indications 
(Brammeld et al., 2017; Garnett et al., 2012).  
Secondly, improving the complexity of in vitro models to better represent the tumour 
microenvironment within PDAC allows for a higher probability of identifying therapeutics 
that show efficacy in PDAC. This has been tackled to various degrees. 
To better recapitulate the tumour architecture and geospatial cellular relationships there 
has been a movement towards development of three dimensional (3D) in vitro systems of 
experimentation, such as spheroids, organoids, and hydrogel-based culture, each of which 
has been studied in the context of PDAC.  
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Spheroids are rounded clusters of cells typically produced in a round bottomed low cell 
adhesion plastic well or via the hanging drop method, whereby cells cluster in a droplet 
hanging from the bottom of an inverted plastic cone. While they support investigation into 
clustering properties of tumour cells in monoculture and coculture with other cell types, the 
difficulty in producing uniformly sized and structured spheroids, as wells as being a 
relatively low-throughput system make large scale drug and genetic screening a challenge 
(Friedrich, Seidel, Ebner, and Kunz-Schughart, 2009).  
Organoids represent a novel and rapidly evolving field focused on recapitulating organ-like 
cellular structures in vitro structurally similar to organs themselves (Clevers, 2016). For 
cancer research, tumour organoids have been grown using patient tumour tissue as well as 
tissue isolated from PDX mouse models, often embedded in Matrigel, modelling the ECM 
physical properties in vivo. While morphological variation and a high resource requirement 
remain challenges for the application of this model in high-throughput screening, 
histopathological correlation with donor tissue (Fujii et al., 2016; Sachs et al., 2018), 
including PDAC (Boj et al., 2015) presents an exciting avenue through which tumour 
dynamics can be modelled accurately in vitro. Further, recent studies have demonstrated 
both a correlation between host patient and organoid drug responses (Kawaguchi et al., 
2017) as well as  correlation between clinical efficacy and organoid efficacy for some smaller 
drug screens (Broutier et al., 2017; D. Gao et al., 2014; Verissimo et al., 2016; Vlachogiannis 
et al., 2018). The major burden of proof for organoids will be the ability for organoids to 
better predict therapeutic efficacy than predicted in other lower cost higher throughput in 
vitro assays, which is yet to be determined.  
On a 2D scale, novel models have been developed that maintain the low-cost nature of in 
vitro experimentation while improving and diversifying the biological readouts. For example, 
development and incorporation of assays and plate technologies such as those used for 
transwell assays analysing paracrine signalling interactions, as well as scratch-wound assays 
for evaluating cell invasion properties (Cheng, Kohi, Koga, Hirata, and Sato, 2016; Joost et 
al., 2012). While each has value in understanding deep mechanistic relationships in cancer 
cell growth, applicability to high-throughput screening is less evident, as apoptosis and cell 
viability screens remain the cornerstone of drug efficacy evaluation.  
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1.4.6 Screening techniques for drug development in vitro 
A major value of the low cost and high-throughput nature of 2D in vitro models is the 
amenability to interrogation using large scale genetic and drug screening. Genetic screening 
in particular, when performed on a whole-genome approach, allows assessment of cell 
phenotypes in response to manipulation of every single gene, independent of the existing 
body of literature surrounding it. This allows for novel target identification, which is not the 
case typically for drug screening, where there is a reliance on an existing synthesised drug 
showing unexpected efficacy.  
Genetic manipulation screening techniques have seen rapid development over recent 
decades, with RNA interference techniques such as small interfering RNA (siRNA) and short 
hairpin RNA (shRNA) screening, as well as gene-editing screening techniques leveraging the 
activities of zinc finger nucleases (ZFNs), transcription activator-like effector nucleases 
(TALENs), and CRISPR/Cas9 screening. The current gold standards for mRNA manipulation, 
measured on specificity, stability, and ease of transduction are shRNA-based (Klinghoffer et 
al., 2010), and similar CRISPR-based for direct gene editing (Gaj, Gersbach, and Barbas Iii, 
2013). While both of these techniques can lead to similar hit-calling in cell viability screens, 
both also identify true positive hits unique to that approach (Morgens, Deans, Li, and Bassik, 
2016), exemplifying value in each alone as well as when performed together. Each of these 
techniques is a major tool in identifying novel drug targets through in vitro screening, and 
have been applied in PDAC monoculture already to this end (Kurahara et al., 2016; 
Muzumdar et al., 2017).  
1.4.7 Incorporating stromal analysis into in vitro models in PDAC 
As noted above, modelling the stromal dynamics pervasive in PDAC tumours is a defined 
need in in vitro models used for screening. Consideration of phenotype in the absence of 
these intratumoural dynamics may reduce the number of targets and drugs identified that 
also have efficacy in the presence of the stromal compartment. To this end, incorporation of 
coculture conditions, culturing cancer cells alongside stromal cells, in particular CAFs, has 
formed a major focus of recent in vitro model development in PDAC. 
From the 3D landscape, and in particular with organoids, protocols have begun to be 
developed that incorporate multiple PDAC stromal cell types in culture (Öhlund et al., 2017; 
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Seino et al., 2018) to better build a model representative of the tumour microenvironment, 
including organotypic cultures (Froeling et al., 2009), themselves both cost and time-
intensive techniques not amenable to high-throughput screening. Across additional cancers 
similar models have been further employed with defined correlation with in vivo screening 
results (Ivanov and Grabowska, 2017; Onion et al., 2016). 
2D models of coculture on plastic have used the combination of breast tumour cells with 
stromal fibroblasts for the purpose of drug screening, generating a large dataset around 
ablating stroma-conferred RAF inhibitor resistance in breast cancer cells, with similar studies 
conducted in a multiple myeloma coculture model (McMillin et al., 2010; Straussman et al., 
2012). Given the documented role of stromal cells and tumour geospatial dynamics in 
modulating drug resistance in PDAC (Chauhan et al., 2013; K. P. Olive et al., 2009; Phan et 
al., 2013; Provenzano et al., 2012), it follows there exists a value in incorporating such 
dynamics in vitro for screening, to improve the likelihood of clinical efficacy of therapeutics 
showing promise within the model. Given gemcitabine remains as one of the few single 
agent therapeutics to confer clinical benefit for PDAC patients, leveraging the stromal effect 
on gemcitabine efficacy through an in vitro model may hold value in preclinical drug 
development. 
To this end, an in vitro coculture model of PDAC was previously developed within our lab, by 
culturing epithelial PDAC cells together with CAF-like cells (Xu, 2015). A major finding of this 
model was an ability to induce gemcitabine resistance in PDAC cells in coculture with the 
CAF-like cells, whilst the same PDAC cells were sensitive to gemcitabine in monoculture, 
mirroring coculture-driven resistance phenomena reported in similar coculture models 
across other cancers (Straussman et al., 2012). Noting the significant resistance to 
gemcitabine observed in patients, this model holds potential value as one of the first low-
cost and novel systems of gemcitabine resistance in PDAC, laying the foundation for ongoing 
interrogation of the mechanistic nature of resistance and suitability for high-throughput 
screening within pancreatic cancer.  
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1.5 Project aims 
The aim of this project was to perform mechanistic studies to further evaluate and validate 
a coculture model of gemcitabine resistance in PDAC whilst concurrently leveraging this 
model in a whole genome RNA interference screen to identify drivers of this resistance 
phenomenon, identifying the mechanistic drivers. 
The specific project objectives were threefold: 
1. To understand the nature of gemcitabine resistance conferred within the coculture 
model. 
2. To undertake a whole-genome shRNA depletion screen within the model to identify 
drivers of gemcitabine resistance. 
3. To analyse and validate the screen data to build a list of high confidence targetable 
genes causative of this effect. 
  
34 
 
2.  Materials and methods 
2.1 Materials 
2.1.1 Reagents 
Gemcitabine hydrochloride (Tocris Bioscience) was dissolved, aliquoted, and stored at -20°C 
in DMSO (Merck) at concentration ranges from 1mM to 0.001mM. Oxaliplatin (Merck) was 
dissolved, aliquoted, and stored at 4°C in water in concentration ranges from 100mM to 
0.1mM. 5-Fluorouracil (Merck) was dissolved, aliquoted, and stored at 4°C in DMSO at 
concentration ranges of 100mM to 0.03mM. AZD2014 (Selleck Chemicals) was dissolved in 
DMSO and stored at -80°C in concentration ranges of 1mM to 0.003mM. AZD6738 (under 
MTA as part of a collaboration with AstraZeneca) was dissolved in DMSO and stored at -20°C 
in concentration ranges from 3mM to 0.01mM. Recombinant human HGF and IL-6 were 
obtained from Peprotech (London, UK). Tetrahydrouridine (THU) was sourced from 
Calbiochem (Merck), and DAPI (4′,6-diamidino-2-phenylindole) from Life Technologies 
(California, USA).  
2.1.2 Cell lines 
K8484 cells were generated previously within the Tuveson Laboratory (CRUK CI) from 
KrasG12D; p53R172H;Pdx1--Cre (KPC) mice (S. R. Hingorani et al., 2005; K. P. Olive et al., 2009). 
K8484-GFP expressing cells were generated previously in the Jodrell Laboratory using 
retroviral transduction (using the same protocol as described in section 2.1.5). 3T3 cells were 
purchased from ATCC (NIH/3T3 CRL-1658). TB22150 CAF cells were kindly donated from the 
Neesse Laboratory (University of Goettingen) having been isolated from LSL-
KrasG12D/+;Ptf1a-Cre (KC) mice originally (Hessmann et al., 2017). Human cancer associated 
fibroblasts were isolated originally within the Jodrell Laboratory by Ruiling Xu using the 
tumour outgrowth method of CAF isolation (M G Bachem et al., 1998) from human pancreatic 
tumour specimens removed from Whipple’s operation, collected and provided by 
Addenbrooke’s Hospital Tissue Bank with ethical approval under NRES/11/EE/0011. 
MH17031 cells were isolated previously by Ruiling Xu using an adapted serial trypsinisation 
and differential adhesion method (Albrecht Neesse et al., 2013; Walter, Omura, Hong, 
Griffith, and Goggins, 2008; Xu, 2015). NF18073 cells are pancreatic stellate cells isolated 
previously from normal pancreas of a KrasWT; p53R172H, Pdx1-cre (PC) mouse by Ruiling Xu 
using an adapted Histodenz gradient density centrifugation technique (Max G Bachem et al., 
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2005; Froeling et al., 2011). Human pancreatic cancer cell line MIA PaCa2 was obtained from 
ECACC (Public Health England, Salisbury, UK) with a GFP-expressing clone created using 
retroviral transduction (protocol as per section 2.1.5) within the Narita Laboratory (CRUK CI). 
Fibroblast lines GDF14 and GDF17 were isolated from tumour using the differential adhesion 
method as described by Walter et. al from the GEDA (Genetically Engineered Mouse-Derived 
Allograft) model (Mollard, Frese, Gopinathan, Richards, and Jodrell, 2016; Walter et al., 2008), 
whereby KPC tumour fragments are grown subcutaneously in recipient KrasWT; p53R712H; 
Pdx1-Cre (PC) mice.  All cells were tested and verified as mycoplasma-free by the CRUK-CI 
Biorepository Core Facility.  MIA PaCa-2 cells were verified as authentic by STR genotyping by 
the Biorepository core facility.  At the time of these studies, no STR genotyping panel was 
available to authenticate the mouse cell lines. 
2.1.3 Cell culture reagents 
Cells were maintained in DMEM with L-glutamine (Gibco, 11965092) supplemented with 10% 
(v/v) Fetal Bovine Serum (FBS) (Gibco, 10270) and 1% (v/v) of 100mM Sodium Pyruvate 
(Gibco, 11360). This media was used also for coculture with stromal cells. Cells within 3 
passages of original isolation had medium further supplemented with 2% (v/v) of Penicillin-
Streptomycin 5000U/ml (Gibco, 15070). Sterile Phosphate-Buffered Saline (PBS) was 
purchased from Gibco (20012), sterile 0.05% Trypsin-EDTA from Gibco (25300) also, and 30% 
bovine serum albumin solution in DPBS from Merck (A9576), used for IL-6 and HGF assays (Fig 
3.4). 
2.1.4 Buffers 
Phosphate-Buffered Saline (PBS 1x): 11.9mM phosphate, 137mM Sodium Chloride, 2.7mM 
Potassium Chloride, pH7.4. Prepared by the CRUK CI media kitchen. 
Tris-Buffered Saline (TBS 1x): 137mM Sodium Chloride, 2.7mM Potassium Chloride, 25mM 
Tris, pH7.4. Prepared by the CRUK CI media kitchen.  
Low-salt RIPA buffer: 50mM Tris HCl pH 8.0, 150mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% Sodium Dodecyl Sulphate (SDS). Prepared by the CRUK CI media kitchen. 
Tris-Buffered Saline with 0.1% Tween 20 (TBST): 1ml of Tween 20 (Fisher Scientific, BP337-
100) was added to 1L of TBS and stirred for 10 minutes.  
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FACS sorting buffer: PBS + 2% foetal bovine serum (FBS) + 2mM ethylenediaminetetraacetic 
acid (EDTA, Invitrogen).  
Cell lysis buffer: 10ml low-salt RIPA buffer (CRUK CI media kitchen, recipe above), 0.1% 
sodium dodecyl sulphate (Bio-Rad), 1 cOmplete ULTRA EDTA-free protease inhibitor tablet 
(Roche), 1 PhosSTOP phosphatase inhibitor tablet (Roche).  
Running buffer: 50ml NuPAGE MOPS (3-(N-morpholino)propanesulfonic acid) SDS Running 
Buffer 20X (Thermo Fisher Scientific), 950ml de-ionized water.  
4% Paraformaldehyde in PBS pH7.4 (4% PFA) was prepared by the CRUK CI Media Kitchen. All 
steps were performed in a fume cupboard. To make 1L, 500ml of PBS was added to a glass 
beaker. 40g of paraformaldehyde (Fisher Scientific, 30525) and 35 drops of 5M NaOH were 
added. The solution was heated on a stirrer until the solution reached 50°C. After the 
paraformaldehyde went into solution, the remaining 500ml of PBS was added and the 
solution was allowed to stir overnight at room temperature. The pH was adjusted to pH7.4 
with HCl and sterile filtered. The solution was sub-aliquoted to 10ml per tube and stored at -
20°C for 6 months. Any unused solution after thawing was discarded.  
Immunofluorescence buffer: 333µl BSA (30% in DPBS), 10µl Triton X-100 (Merck Millipore), 
500µl donkey serum (Merck) and 9.157ml PBS. 
HEPES-buffered saline (HBS): 50mM HEPES (Gibco), 280mM NaCl (Merck), 1.5mM Na2PO4 
(Merck), 12mM dextrose (Abcam), and 10mM KCl (Merck).  
2.2 Cell line creation 
2.2.1 Retrovirus-mediated generation of mVenus-expressing K8484 cells 
K8484 cells were transduced to express the yellow fluorescent marker mVenus using a 
protocol adapted from the Narita Laboratory (CRUK CI), using a modified x-mVenus-pLPC 
described previously (Nagai et al., 2002). Retrovirus-producing Phoenix cells (ATCC, CRL-3213) 
were plated in DMEM cell culture media as described above at a density of 2x106 cells in a 
6cm dish at Day 0. On Day 1 a solution of 140µl H2O, 21µl CaCl2, and 7µg pLPC-mVenus DNA 
was created, and mixed dropwise with 166µl borate buffered saline (BBS, Merck). After 10 
minutes of incubation at room temperature (RT), the mixture was added to the medium of 
the Phoenix cells in combination with chloroquine at a 25µM final concentration, which is 
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used to prevent lysosome-mediated degradation of DNA (Luthman and Magnusson, 1983). 
After overnight incubation, on Day 2 medium was gently replaced with 1.5ml of fresh 
medium. 6x105 K8484 mouse PDAC cells were seeded in parallel in a 6cm dish with standard 
cell culture medium.   
On Day 3, media from the Phoenix cells was removed, filtered through a 0.45µm filter to 
remove cell debris. To this filtrate the polycation polybrene was added to a concentration of 
5µg/ml, increasing DNA uptake (Chaney, Howard, Pollard, Sallustio, and Stanley, 1988). Fresh 
media was added to the Phoenix cells and this process was repeated twice further, pooling 
the virus-containing filtrate. Media was then aspirated from the K8484 target cells and the 
Phoenix plate filtrate was added, leaving cells to incubate for 12 hours overnight. On Day 4, 
media was changed to prevent polybrene-induced toxicity.  
On Day 5, K8484 cells were trypsinised and re-seeded under selection with 100µg/ml 
Hygromycin B (Thermo Fisher Scientific), and on Day 10 cells transduction was verified by 
mVenus fluorescence quantification compared to non-transduced K8484 controls using the 
CLARIOstar plate reader.  
2.2.3 Isolation of mouse embryonic fibroblasts 
 All mouse experiments were carried out in the CRUK Cambridge Institute Biological 
Resources Unit, in accordance with the UK Animals (Scientific Procedures) Act 1986, with 
approval from the CRUK Cambridge Institute Animal Ethical Review and Welfare Body. To 
isolate mouse embryonic fibroblasts a pregnant KrasWT; p53R712H; Pdx1-Cre PC mouse 
(AN15CUK030247) were killed humanely and embryos extracted by Aarthi Gopinathan (CRUK 
CI), at embryonic stage E9.5 to E14.5. Approximately 1mm3 of the head section was removed 
for genotyping. Developing organs were identified, excised, and discarded. The remainder of 
the embryo was placed in 1ml 0.25% trypsin (Gibco) and diced finely. The resulting solution 
was incubated for 30 minutes at 37°C with 5% CO2. Trypsin was then quenched with cell 
culture media (Section 2.1.3) supplemented with Pen/Strep (Gibco) and seeded overnight in 
a T75 flask (Corning). A flask was prepared for each isolated embryo, and propagating lines 
were expanded, and banked within 2 passages, prior to experimental use.  
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2.3 In vitro gemcitabine coculture assay 
2.3.1 Cell culture and calculation of drug effect 
At Day 0, 2,000 fluorescently-tagged pancreatic cancer cells (e.g, K8484-GFP or K84840mV) 
were seeded in 96 well clear flat bottom black polystyrene plates (Corning) in 50µl media, 
alongside 20,000 cells of the coculture line (e.g. MH17031), also in 50µl media, for a combined 
total volume of 100µl media. Cells were left to attach for 24 hours, following which, at Day 1, 
100µl of media containing gemcitabine solution or 0.1% DMSO control was added to bring 
the total well volume to 200µl and the final gemcitabine concentration a range from 1µM to 
1mM in the non-control wells. All conditions were run in triplicate wells, alongside a matched 
monoculture control of 2,000 pancreatic cancer cells only. Cells were left to incubate for 72 
hours in a humidified atmosphere of 37°C and 5% CO2. After this period media was aspirated 
and fluorescence per well was measured using either a CLARIOstar or PHERAstar plate reader 
with a filter setting of excitation at 485nm and emission at 520nm (BMG LABTECH). 
Fluorescence levels were used as a surrogate marker for degree of drug cytotoxicity, 
expressed as GI50 (concentration inhibiting cell growth by 50%): 
𝐺𝐼50 =  
(𝑇 − 𝑇0)
(𝐶 −  𝑇0)
 ×  
100
1
 
T0 refers to the fluorescence readout at the point of drug addition (measured using a replicate 
parallel plate seeded at same time as assay plate); T refers to the fluorescence measurement 
at 72 hours post drug addition; C refers to the fluorescence measurement of solvent control 
wells at the same time point. A dose response curve was created by plotting the concentration 
of drug used against the percentage of growth change observed relevant to solvent control, 
using Graphpad PRISM.  
2.3.2 Cell handling and counting 
After trypsinisation cells were resuspended in PBS with 1ml taken for counting using the Vi-
CELL XR system (Beckman Coulter) as per manufacturer instructions.  
2.3.4 Coculture conditioned medium 
On sequential days duplicates of K8484-GFP (950,000 cells) and MH17031 (9.5x106) were 
seeded in 15cm dishes (Corning) with 20ml media. Following 72 hours of growth media was 
collected, filtered through a 0.45µm syringe filter, and mixed 1:1 with fresh media. This 
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solution was then used both for seeding and drug treatment of K8484-GFP cells in 
monoculture in a 96 well plate as per protocol in section 2.2.1. 
2.3.5 Transience of gemcitabine resistance 
K8484-GFP cells in monoculture were seeded at a density of 0.95x106 cells per 15cm petri dish 
(Corning), and in coculture including 9.5x106 cells of MH17031 cells, along with 10ml cell 
culture media. After 24 hours incubation, gemcitabine or DMSO control was added in a 
further 10ml cell culture media. After 72 hours, cells were trypsinised, washed in PBS, filtered 
through a 100µm filter (Thermo Fisher Scientific) to remove cell clumps, and then 
resuspended in 2ml FACS sorting buffer with DAPI (1/5000). Cells were provided to the CRUK 
CI Flow Cytometry core facility where 5x105 live GFP+ cells were sorted from each condition 
on a FACSAria III cytometer (BD Biosciences). Cells were then immediately re-seeded in 
monoculture following the protocol in section 2.2.1, and sensitivity to gemcitabine treatment 
was assessed with a dose response curve as in 2.2.1.  
2.3.6 Gemcitabine metabolism  
Tetrahydrouridine (THU), an inhibitor of cytidine deaminase, was dissolved in methanol 
(Merck) and serially diluted in cell media and added to cell culture at the point of drug addition 
on Day 1 of the gemcitabine cytotoxicity assay in both monoculture and coculture conditions 
to the final desired concentration. 
2.3.7 Combination and synergy screening  
Plates were seeded in duplicate with K8484-mV cells either in monoculture or in coculture 
with MH17031 in 96 well plates at the ratios and volumes as per section 2.2.1. Following 24 
hours of growth, cells were treated with a 6 x 6 grid combining two separate drugs each at six 
difference concentrations, alongside single agent control. Following 72 hours of incubation, 
cell fluorescence levels were read using CLARIOstar, then after calculation of growth 
inhibition relative to control, Combenefit software was used to visualise single agent data and 
synergy (Di Veroli et al., 2016), using both of the Bliss Independence and Loewe models (Bliss, 
1939; Loewe, 1953).  
2.3.8 Calculation of growth rate-adjusted drug efficacy 
Growth-rate adjusted measurement of drug effect was calculated using the model developed 
by the Sorger Laboratory (Hafner, Niepel, Chung, and Sorger, 2016). Fluorescence values are 
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used as input data for the described model of determining relative cell counts between 
conditions, and therefore calculating GR50, the concentration of drug at which the effect 
reaches a GR value of 0.5 based on interpolation of the fitted curve. 
2.4 Cell line characterisation 
2.4.1 Cell morphology imaging 
Live cell culture was visualised using a Nikon Eclipse TS100 bright field microscope, with 
images captured using a Nikon Digital Sight. 
2.4.2 Western blotting sample preparation 
Cells were seeded at a density of 3x105 cells per well in a 6 well plate and incubated for 48 
hours at 37°C and 5% CO2. Media was aspirated, and wells were washed twice in ice-cold PBS. 
5ml of ice-cold TBS was twice added per well and cells were scraped and collected each time 
into a 15ml falcon tube (Merck), and cells pelleted through 5 minutes of centrifugation at 
5,000g. Supernatant was aspirated, and cells were resuspended in 1ml ice-cold TBS, and 
transferred to a 1.5ml Eppendorf tube (Eppendorf). Samples were spun for 5 minutes at 
10,000g at 4°C, supernatant was aspirated, and samples were stored at -80°C until further 
processing.  
Samples were resuspended in 75µl Cell lysis buffer and placed at 4°C for 30 minutes. Samples 
were then sonicated in ice water for 2 minutes (Thomas Scientific), and centrifuged for 10 
minutes at 12,000g at 4°C. Supernatant was then transferred to a fresh 1.5ml Eppendorf tube. 
Protein levels were quantified using a Direct Detect infrared spectrometer (Merck Millipore) 
as per manufacturer’s instructions.  
2.4.4 Western blotting 
Samples to be analysed via western blotting were normalised for protein concentration 
through dilution with Cell lysis buffer. Each sample was combined with 4X Protein Sample 
Loading Buffer (LI-COR Biosciences) and 10X Novex NuPAGE Sample Reducing Agent (Fisher 
Scientific) to bring the total volume to 25µl with a protein concentration of 0.4µg/µl. Samples 
were heated for 10 minutes at 70°C to denature proteins. Samples were then loaded in 
NuPAGE 4-12% Bis-Tris Protein Gels, 1.5 mm, 10-wells (Thermo Fisher Scientific), alongside 
5µl PageRuler Plus Prestained Protein Ladder (Thermo Fisher Scientific). Gels were run in a 
western blot box with 500ml running buffer, with the inner chamber filled with 200ml running 
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buffer mixed with 1ml NuPAGE Antioxidant. Gels were run for 30 minutes at 60V, followed by 
90 minutes at 125V, or until the marker reached the end of the gel cassette. The gel was then 
removed from its case and subjected to a dry protein transfer using an iBlot dry blotting 
system (Thermo Fisher Scientific), as per manufacturer’s instructions. The membrane was 
then blocked for 1 hour with 10ml of a 1:1 mix of TBST and Odyssey blocking buffer (LI-COR 
Biosciences). Membranes were then incubated with primary antibodies overnight at 4°C as 
per Table 2.1 below. Gels were then washed 4 times for 5 minutes each with TBST. Secondary 
antibody incubation was then carried out for 1 hour at room temperature using fluorescent 
antibodies as per Table 2.2 below. Membranes were again washed 4 times for 5 minutes each 
with TBST and left in TBS prior to imaging. Protein presence was imaged using an Odyssey CLx 
(LI-COR Biosciences), and protein bands quantified using the Image Studio software package 
(LI-COR Biosciences). As an addendum, significant experimentation was undertaken using an 
alternate antibody for N-Cadherin (Abcam, ab98952), which was subsequently identified to 
be non-specific based on discordant data when compared to control antibodies in control cell 
lines.  
Antibody Description Manufacturer Catalogue number 
E-Cadherin Rabbit monoclonal 
Cell Signalling 
Technology 
3195 
N-Cadherin Rabbit polyclonal Abcam ab76057 
αSMA Mouse monoclonal Merck A2547 
Vimentin Rabbit monoclonal Abcam SC-7557 
Actin Mouse monoclonal Merck 118K4846 
Actin Rabbit polyclonal Abcam ab1801 
Table 2.1 Primary antibodies used for western blotting.  
Antibody Description Manufacturer Catalogue number 
Goat anti-mouse 
IRDye 680 RD IgG 
(H+L) 
LI-COR Biosciences 926-68070 
Goat anti-rabbit 
IRDye 800 CW IgG 
(H+L) 
LI-COR Biosciences 926-32211 
Table 2.2 Secondary antibodies used for western blotting 
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2.4.5 Immunofluorescence 
Cells were seeding between 15,000 and 30,000 cells per well in a µ-Slide 8 well dish (Ibidi) and 
grown for 24 hours at 37°C and 5% CO2. Cells approximating 70% confluency then had 
medium removed and replaced with 4% paraformaldehyde for fixing for 15 minutes. Wells 
were then washed 3 times for 5 minutes each with PBS. Wells were then blocked with 200µl 
immunofluorescence (IF) buffer and incubated overnight at 4°C with primary antibody 
solution (Table 2.3) with rocking.  
Antibody Description Manufacturer Catalogue number 
DAPI 1µg/ml in IF buffer Thermo Fisher 
Scientific 
D3571 
E-Cadherin Rabbit monoclonal 
Cell Signalling 
Technology 
3195 
N-Cadherin Rabbit polyclonal Abcam ab76057 
αSMA Rabbit polyclonal Abcam ab5694 
Vimentin Rabbit monoclonal Abcam SC-7557 
P53 Goat polyclonal R&D Systems AF1355 
Table 2.3 Primary antibodies used for immunofluorescence  
Wells were then washed 4 times for 5 minutes each in IF buffer with rocking, followed by 1 
hour at room temperature in darkness with a secondary antibody solution (Table 2.4) whilst 
rocking.  
Antibody Description Manufacturer Catalogue number 
Donkey anti-rabbit AF546 IgG (H+L) 
Thermo Fisher 
Scientific 
A10040 
Donkey anti-goat AF647 IgG (H+L) 
Jackson 
ImmunoResearch 
705-605-147 
Table 2.4 Secondary antibodies used for immunofluorescence 
Wells were then washed 4 times for 5 minutes each with IF buffer with rocking, with inclusion 
of 250µl of DAPI solution (1µg/ml) for the first wash only. Wells were then filled with ice-cold 
PBS and stored at 4°C awaiting analysis. Wells were imaged using a Leica SP5 confocal 
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microscope with image analysis performed using the Fiji image processing package within 
ImageJ (NIH). 
2.4.6 RNA Sequencing and data principal component analysis  
RNA-Seq sample preparation was performed by Jo Bramhall in the Jodrell Laboratory (CRUK 
CI). In brief, 1x106 cells were grown in monoculture in a 10cm petri dishes (Corning), with 4 
replicates per cell line. After 24 hours incubation at 37°C with 5% CO2 cells were harvested by 
scraping with PBS followed by centrifugal pelleting and stored at -80°C awaiting further batch 
processing. RNA was extracted using a RNeasy kit (Qiagen), quantified using a Quant-iT RNA 
kit (Thermo Fisher Scientific), with bioanalyser confirmation of sample RNA Integrity Numbers 
(RINs) >9.0.  RNA was then diluted to 10ng/µl, adding 55µl to each well of 96 well plates, and 
transferred to the CRUK CI Genomics core facility for library preparation and sequencing on a 
HiSeq 2500 SE50 (Illumina). Raw sequencing reads were aligned to the mouse genome version 
GRCm38 (Kitts et al., 2016) using the TopHat alignment tool (Trapnell, Pachter, and Salzberg, 
2009). Principal Component Analysis (PCA) was plotted for each sample group by Chandra 
Sekhar Reddy Chilamakuri of the CRUK CI Bioinformatics core facility.  
2.4.7 Polymerase chain reaction for genotyping cell lines 
Cells were grown in cell culture to a confluence of ~70% under passage 10 from isolation. Cells 
were then trypsinised, pelleted, resuspended in PBS and counted. 5x106 cells per sample were 
taken and genomic DNA was extracted using the QIAamp DNA Mini Kit (Qiagen) as per 
manufacturer’s instructions, eluting in 100µl nuclease-free water (Thermo Fisher Scientific). 
DNA concentration was then quantified using a Qubit 2.0 Fluorometer (Thermo Fisher 
Scientific) as per manufacturer’s instructions using the Qubit dsDNA BR Assay Kit (Thermo 
Fisher Scientific). In preparation for PCR, DNA was diluted to a standardised 50ng/µl. 1µl of 
this solution was added to 25µl of Phusion® High-Fidelity PCR Master Mix with GC buffer (New 
England Biolabs) in 0.2ml PCR tubes (STARLAB), as per manufacturers instruction’s, with the 
inclusion of 0.44µM of both forward and reverse primers (Table 2.5).  
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Gene 
target 
Primer 
pair 
Forward 
or reverse 
Sequence (5’ to 3’) Reference 
Kras P001 Forward GTCTTTCCCCAGCACAGTGC 
(Evans et 
al., 2016; 
Zou et al., 
2015) 
Kras P001 Reverse CTCTTGCCTACGCCACCAGCTC  
(Evans et 
al., 2016; 
Zou et al., 
2015) 
p53 P002 Forward AGCCTGCCTAGCTTCCTCAGG 
(Evans et 
al., 2016) 
p53 P002 Reverse CTTGGAGACATAGCCACACTG 
(Evans et 
al., 2016) 
p53 P003 Forward AGCTAGCCACCATGGCTTGAGTAAGTCTGCA 
(Husain et 
al., 2013) 
p53 P004 Forward TTACACATCCAGCCTCTGTGG 
(K. Olive et 
al., 2004) 
p53 
P003, 
P004 
Reverse CTTGGAGACATAGCCACACTG 
(K. Olive et 
al., 2004) 
Table 2.5 PCR primer sequences for p53 and kras genotyping 
Samples were then placed on a thermocycler (CFX96, Bio-Rad) and subjected to 
thermocycling as per Table 2.6 and run out on an E-Gel iBase and E-Gel Safe Imager Combo 
Kit (Fisher Scientific), as per manufacturer’s instructions. Gels were imaged on a Dyversity 2D 
Gel Imaging System (Syngene) using the manufacturer’s GeneSys software package.   
  
45 
 
Step 
Temperature 
(°C) 
Time 
1 95 3 minutes 
2 95 30 seconds 
3 65 30 seconds 
4 72 1 minute 
Repeat steps 2-4 34 times 
5 72 10 minutes 
6 4 Forever 
Table 2.6 Thermocycling conditions for PCR 
2.5 shRNA screen design 
2.5.1 Genome-wide shRNA libraries 
A whole-genome shRNA library consisting of 63,677 shRNAs targeting a combined 18,402 
genes was ordered from transOMIC technologies (Huntsville, US), leveraging the shERWOOD 
algorithm to optimise for potency whilst minimising potential off-target effects (Knott et al., 
2014). Each of 7 pools was subcloned into MSCV-based LMH vectors, with shRNA expression 
under the control of a long terminal repeat (LTR) retroviral promoter. Vectors also drive 
expression of mCherry and the hygromycin resistance gene for selection. Nicolas Erard 
(Hannon Laboratory, CRUK CI) excised shRNAs from original LMN vectors using BGlII and MluI 
restriction enzymes (New England Biolabs). These cassettes were then ligated into LMH 
vectors cut with the same enzymes, purified on MinElute columns (Qiagen) and transformed 
into MegaX DH10B T1R electrocompetent cells (Thermo Fisher Scientific), with at least 5x106 
transformants per pool. DH10B cells were expanded and viral plasmid extracted (Qiagen 
Plasmid DNA Purification Kit) for use in virus production. The shRNA library used for the 
validation screen (Section 4.10) was prepared similarly.  
2.5.2 Virus production 
Phoenix-Eco viral packaging cells were plated in 15cm dishes at 50% confluency. After 24 
hours of incubation at 37°C and 5% CO2, cells were transfected via the calcium-phosphate 
method (Kingston, Chen, and Rose, 2003). A transfection mix was created (60µg viral vector 
for shRNA library, 7.5µg VSV-G, 200µl of 20nM pasha siRNA, 187.5µl 2M CalCl2, water added 
to a total volume of 1.5ml) and added to equal volume 2X HBS buffer. The solution was 
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aliquoted and adjusted to pH of ~7.0. The mixture was bubbled using a Stripette (Corning), 
incubated for 15 minutes at room temperature and added to the packaging cells with 7.5µl 
chloroquine to a total media volume of 17ml. Cell cultures were incubated overnight at 37°C 
after which media was replaced and sodium butyrate (Merck) was added to a concentration 
of 1mM to increase transfection efficiency (Gorman, Howard, and Reeves, 1983). After 30 
hours media was collected and filtered through a 0.45µm filter (Merck) collecting the virus, 
then stored at 4°C awaiting further use.  
2.5.3 Cell lines 
K8484 cells were used as the foundation infected cancer cell for the screen. For coculture 
conditions, MH17031 cells were transduced retrovirally to express both the diphtheria toxin 
receptor (DTR) as well as the fluorescent market ZsGreen and the neomycin resistance gene 
driven by the mouse phosphoglycerate kinase 1 (PGK1) promoter (LMN-PGK, Hannon Group, 
CRUK CI). Viral vector production was carried out using Phoenix-Eco cells (ATCC, CRL-3214), 
with MH17031 cells transduced at a low multiplicity of infection to ensure singly transduced 
cells and selected for 10 days with 300µg/ml of geneticin (Thermo Fisher Scientific). 
2.5.4 Screen infection and selection 
The shRNA library for the primary screen was split across 7 pools of ~9,000 shRNAs per pool. 
For each pool, the virus titre was calculated through test infections of K8484 cells, optimising 
for an approximate 30% infection rate, to minimise likelihood of two shRNA vectors infecting 
one cell. The infection efficiency was evaluated after 48 hours incubation by flow cytometry 
using a MACSQuant Analyzer 10 (Miltenyi Biotec), quantifying the proportion of cells 
expressing mCherry.  With this titre larger scale infections were then performed in triplicate 
in 15cm petri dishes, through incubation of 10x106 K8484-Mv cells along with the correct virus 
titre and 8µg/ml polybrene (Merck) along with 16ml of cell culture media. Successfully 
infected cells were then selected for 7 days with 500µg/ml Hygromycin B (Thermo Fisher 
Scientific). 
2.5.5 Cell culture protocol 
Each infected pool of K8484 cells (K8484-inf) was split into 5 samples. One timepoint zero 
sample (collected immediately for sequencing), two monoculture samples (plus gemcitabine 
and plus DMSO control), and two coculture samples (plus gemcitabine and plus DMSO 
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control). For the monoculture screen 5x106 cells were seeded across 5 15cm dishes with 20ml 
media. After 24 hours of growth, 40µl of 5µM gemcitabine stock was added to experimental 
dishes (to 10 nM final concentration), with 40µl of DMSO added to control dishes. After 72 
hours treatment, cells were split, counted on the Vi-CELL XR (Beckman Coulter), and reseeded 
again with 5x106 cells per condition with fresh gemcitabine or DMSO. This cycle was repeated 
6 times before trypsinisation and harvesting of gDNA from the final cell population. For 
coculture conditions, 5x106 K8484-inf cells were seeded alongside 50x106 MH17031-DTR 
cells, again across 5 15cm dishes. After 24 hours of incubation, 40µl of a 50µM gemcitabine 
stock was added to experimental dishes, bringing the gemcitabine concentration to 100nM. 
Similarly, 40µl DMSO was added to each control dish. After 72 hours of treatment, cells were 
trypsinised, counted, and relative counts of K8484-inf cells to MH17031-DTR cells were 
assessed using mCherry and ZsGreen fluorescence detected on the MACSQuant Analyzer 10. 
Through this calculation, 5x106 of the K8484-inf cells were again seeded across 5 15cm dishes, 
with fresh MH17031-DTR cells added to bring the total of these cells to 50x106 across the 
sample. After 6 cycles of this process, MH17031-DTR cells were selectively depleted using 
100ng/ml diphtheria toxin (Merck) over 96 hours, following which remaining cells were 
trypsinised and harvested for subsequent processing with monoculture counterparts.  
2.5.6 Screen sequencing 
Genomic DNA from each of the samples, including the timepoint zero group, was extracted 
using the QIAamp DNA Blood Maxi Kit (Qiagen), as per manufacturer’s instructions. shRNA 
cassettes were amplified from each population by PCR (forward primer: 5’-
AGAATCGTTGCCTGCACATCTTGGAAAC-3’, reverse primer: 5’-
CTGCTAAAGCGCATGCTCCAGACTGC-3’) using KOD Hot Start DNA Polymerase Kit (Merck) with 
2µg gDNA, all in 96-well skirted white PCR plates (Thermo Fisher) (1: 5 minutes at 95°C; 2: 30 
seconds at 95°C; 3: 30 seconds at 55°C; 4: 30 seconds at 72°C; 5: Cycle to step 2 24 times; 6: 
5 minutes at 72°C; 7: Hold at 4°C). From this PCR 1ml of pooled reaction mix was purified using 
a QIAquick PCR Purification Kit (Qiagen) as per manufacturer’s instructions, to remove non-
amplicon reaction components. Secondary PCR was then performed to add barcoded Illumina 
adapters (forward primer P7-BCX-TS-Mir-Loop: 5’-
CAAGCAGAAGACGGCATACGAGATNNNNNNGTGACTG 
GAGTTCAGACGTGTGCTCTTCCGATCTTAGTGAAGCCACAGATGTA-3’, reverse primer P5-mir3: 
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5’-AATGATACGGCGACCACCGAGATCTACACCAGCAGTATGTTGAAGTCCGAGGCAGTAGGCA-3’ 
(Ns represent 6bp barcodes)). Two PCRs of 500ng amplicon were performed per sample in 
the same 96-well PCR plates (1: 5min at 95°C; 2: 30sec at 95°C; 3: 30sec at 52°C; 4: 30sec at 
72°C; Cycle to Step 2 24 times; 5: 5min at 72°C; 6: Hold at 4°C). The resulting reaction solution 
was run on a 1.5% agarose gel with the ~150bp amplicon excised using a QIAquick Gel 
Extraction Kit (Qiagen) as per manufacturer’s instruction, with DNA again purified using a 
MinElute PCR Purification Kit. Each sample was then quantified using a Qubit 2.0 fluorometer, 
pooled, with precise quantification prior to sequencing then performed by Nicolas Erard by 
qPCR using a KAPA library quantification kit (Illumina). The pooled samples were then run on 
a HiSeq 4000 (Illumina) with a custom read 1 primer (5’- 
CAGCAGTATGTTGAAGTCCGAGGCAGTAGGCA-3’) to a depth of at least 10x106 reads, by the 
CRUK CI Genomics core. Reads were mapped to a custom index made of the mouse shRNA 
sequences present in all pools using bowtie (Langmead, Trapnell, Pop, and Salzberg, 2009).  
2.5.7 Validation screen 
A custom library of 8,306 shRNAs targeting 1,973 genes was ordered from transOMIC 
technologies and used to infect K8484 cells as per sections 2.4.1, 2.4.2, and 2.4.4. Section 
2.4.5 was replicated for this pool, again cycling 6 treatments of gemcitabine in both 
monoculture and coculture plus DMSO controls and sequencing the shRNA populations 
within surviving cells at the end of the experiment, as per section 2.4.6.  
2.6 Analysis of shRNA screen data 
2.6.1 Differential expression scoring 
Differential expression of shRNAs between each culture condition compared to timepoint 
zero was performed, to identify the shRNA enrichment and depletion profiles within each 
sample, similar to as performed previously (Mendes-Pereira et al., 2012). Differential 
expression scoring was performed by Chandra Sekhar Reddy Chilamakuri in the CRUK CI 
Bioinformatics core facility, using both DESeq2 (Love, Huber, and Anders, 2014), an R 
Bioconductor package, as well as median Z scores (Cheadle, Vawter, Freed, and Becker, 2003). 
Genes were considered significantly differentially expressed for DESeq2 scoring indicated 
targeting shRNAs had an adjusted p-value of ≤ 0.05, log2 fold change ratio of normalized reads 
before and after treatment was less than 0, and ≥ 50% of shRNAs targeting that gene fit the 
first two criteria. Similarly, genes with 50% of targeting shRNAs with a median Z score value 
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of ≤ -2 were considered significantly depleted when compared to the timepoint zero sample. 
Comparison of gene lists between conditions and between scoring methods were compared 
using Venny (Oliveros, 2007). 
2.6.2 Pathway and network analysis 
Gene set enrichment analysis (GSEA) (Mootha et al., 2003; Subramanian et al., 2005) was 
performed also by Chandra Sekhar Reddy Chilamakuri using GSEA PreRanked with the ranked 
list as input , analysed across each of the Molecular Signature Database v6.1 gene sets (A. 
Liberzon et al., 2011; A Liberzon et al., 2015). MetaCore (v5.0, Thomson Reuters) was used 
for broad level pathway analysis of genes, as well as PANTHER v13.1 (Mi et al., 2017; Mi, 
Muruganujan, Casagrande, and Thomas, 2013) for identification of protein sequence-based 
clustering of screen data.  
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3.  Development and validation of an in vitro 
coculture model of gemcitabine resistance in 
pancreatic cancer. 
 
3.1 Introduction 
The aim was to explore and interrogate further an in vitro coculture model of gemcitabine 
resistance in pancreatic cancer as developed previously by Ruiling Xu (Xu, 2015) in the 
Jodrell laboratory, to identify mechanisms driving gemcitabine resistance both within this 
model and within pancreatic cancer in general, identifying novel tumour ablation strategies 
that may have value in the clinic. Within this model it is shown that PDAC cells in 
monoculture are sensitive to the nucleoside analog gemcitabine, a mainstay of pancreatic 
cancer treatment. In contrast, when cultured in combination with cancer-associated 
fibroblast-like cells (FLCs), PDAC cells become resistant to gemcitabine. Within this chapter, 
both cancer and FLC cells are derived from separate KPC mice, as described in Chapter 2.1.2, 
both cell lines being immortal in cell culture. This model has potential as an in vitro system 
recapitulating the resistance to gemcitabine observed in the clinic, and therefore providing a 
medium through which the mechanisms of pancreatic cancer drug resistance can be 
understood. 
The model developed comprises a 96-hour protocol (Fig 3.1). Upon seeding of cells and 
culturing for 24 hours, gemcitabine is added to culture medium for 72 hours, at which point 
cell growth in solvent control wells and gemcitabine-exposed wells are compared, as a 
surrogate for PDAC cell survival. 
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Figure 3.1 Schematic of PDAC cell co-culture assay used to investigate gemcitabine 
resistance within fluorescently-tagged cancer cells. PDAC cell lines isolated from the KPC 
mouse and fluorescently tagged (GFP or mVenus) are grown in coculture with a secondary 
cell type for 24 hours. This coculture is then incubated with gemcitabine for 72 hours. PDAC 
cell growth over this period is assessed via measurement of fluorescence levels comparing 
treated samples and controls, using a spectrofluorometer (Section 2.3.1). 
3.2 Gemcitabine resistance induced in a coculture model of pancreatic cancer 
To explore the pre-existing model and associated cellular resistance to gemcitabine, the 
model was reproduced by me and the conferred resistance effect confirmed (Fig 3.2).  In 
monoculture the mouse PDAC cell line K8484-mV, which were isolated originally from the 
KPC mouse epithelial fraction and tagged with mVenus, the gemcitabine GI50 was 15nM ± 
1.8nM. This contrasts to the sensitivity observed when K8484-mV cells were cocultured with 
MH17031 cells, a fibroblast-like line from the KPC mouse, with gemcitabine GI50 over 15-fold 
greater:  231nM ± 63nM. This therefore demonstrates a coculture-induced resistance effect. 
This result lays the foundation of the model for interrogation, to better understand the 
observed resistance mechanism. 
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Figure 3.2 Sensitivity of K8484 cells to gemcitabine in monoculture and coculture. K8484-
mV PDAC cells grown in monoculture and coculture with MH17031 cells through a 72-hour 
growth assay with gemcitabine incubation. Cell growth in test wells was assessed in 
triplicate as a ratio to growth of cells with DMSO solvent control. Each point represents 
mean of triplicate biological and triplicate technical replicates, ±SE.  
With this demonstration of a complex in vitro model of gemcitabine resistance, the goals 
were to elucidate the mechanism and nature of the phenomenon, using both hypothesis-led 
experimentation (this chapter) coupled with broader unbiased explorative assessment 
(Chapter 4).   
3.3 Extra-cellular signalling as a medium to confer gemcitabine resistance 
Gemcitabine resistance in K8484-mV cells in coculture suggests that a form of inter-cellular 
communication between the cell types may drive this effect. Potential mechanisms include 
resistance conferred via secreted factors between cells, or via direct cell-cell interaction.  
To assess the role of secreted factors, conditioned medium from K8484 and MH17031 
coculture was collected and evaluated for its ability to induce gemcitabine resistance in 
K8484 cells in monoculture. Following 96 hours of coculture cell growth, medium was 
collected, filtered, and then added to a fresh monoculture of K8484 cells at v/v with fresh 
medium, minimising the dilution of conditioned medium, and therefore efficacy, of the 
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secretome of interest. Conditioned medium was neither frozen nor refrigerated, but 
collected fresh, to preserve the functionality of any unstable or sensitive signalling 
molecules that may be present. K8484 cells were then incubated with gemcitabine, and 
sensitivity assessed relative to K8484 cells in monoculture without conditioned medium (Fig 
3.3).  
No significant induction of gemcitabine resistance was observed through the addition of 
conditioned medium. This result corroborates data generated by Ruiling Xu within the lab 
using a transwell assay of both PDAC cells and fibroblast-like cells (FLCs) (Xu, 2015). In the 
transwell assay the two cell types are grown on opposite sides of a molecularly permeable 
membrane. This allows the transport of secreted molecules between cell types but 
maintains physical separation between the cells themselves. Taken together, these data 
suggest that a secreted factor is unlikely to be a primary driver of the coculture gemcitabine 
resistance effect, and that either some form of quorum sensing (gene regulation controlled 
by cell density) or direct cell-cell contact is more likely a driver. 
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Figure 3.3 Effect of coculture-conditioned medium on K8484-GFP gemcitabine sensitivity. 
K8484 cells were grown in parallel in both the absence and presence of coculture-
conditioned medium with a dose range of gemcitabine. Sensitivity to gemcitabine was 
assessed using fluorescence as a surrogate marker for cell growth. For conditioning, medium 
was collected from dishes of K8484 and MH17031 coculture after 72 hours, mixed 1:1 with 
fresh media, and immediately incubated with K8484 cells. Each point represents mean of 
triplicate biological and triplicate technical replicates, ±SE.  
3.4 Evaluation of IL-6 and HGF as modulators of gemcitabine resistance 
In parallel with the conditioned medium experiments, two candidate secreted factors were 
tested for their ability to modulate gemcitabine sensitivity in the model, based on existing 
literature: interleukin-6 (IL-6) and hepatocyte growth factor (HGF). Both molecules when 
secreted from fibroblast-like cells in tumour stroma have been documented as drivers of 
drug resistance (Duluc et al., 2015; Straussman et al., 2012). This provided two initial 
candidates for evaluation within this model.  
Human recombinant forms of both factors (cross-reactive as according to manufacturer) 
were added exogenously to K8484 monocultures, recognising the effect of human HGF in 
activating mouse MET as previously documented (Francone et al., 2007). Both factors were 
tested across three concentrations of gemcitabine spanning the range used typically within 
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the coculture model. Neither was associated with significant resistance to gemcitabine, in 
fact both trending towards increasing sensitivity as opposed to resistance (Fig 3.4A). 
In addition, neither IL-6 nor HGF induced gemcitabine resistance in monocultures of MIA 
PaCa-2 and Panc-1, two human PDAC lines, or an additional KPC mouse-derived PDAC line, 
DT8082-GFP (Fig 3.4B). This result does not explicitly discount these molecules as 
influencers of resistance in this model, as there remains a possibility that human 
recombinant forms did not cross-react efficiently with the mouse cognate receptors, 
therefore leading to insufficient concentration to induce change, although it serves as an 
initial indicator that an independent mechanism may be involved. 
 
Figure 3.4 Effect of hypothesis-driven modulators of drug efficacy through exogenous 
addition in PDAC monoculture. (A) K8484 cells grown in monoculture with three doses of 
gemcitabine alongside recombinant IL-6 (red), HGF (blue), or a BSA control (green). Effect of 
each protein in modulating gemcitabine effect at each dose was assessed. (B) Effect of IL-6 
(red) and HGF (blue) in modulating gemcitabine efficacy (100nM) in an additional KPC PDAC 
line (DT8082-GFP), and two human PDAC lines (MIA PaCa-2-GFP and Panc1) was assessed 
using the sulforhodamine B assay using cellular protein levels as a surrogate for cell survival. 
Each point represents mean of triplicate biological and triplicate technical replicates, ±SE. 
3.5 Transience of resistance induced within the coculture assay 
Under the premise that direct cell-cell contact appeared to be required to induce the 
observed resistance to gemcitabine, the next step was to develop a more holistic 
understanding of the nature of the change within the PDAC cells. One hypothesis was that 
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the coculture condition drives a more stable change in biological status of the PDAC cells, 
whether via RNA subtype, protein, epigenetic, or similar regulation.  
To test this hypothesis the transience of the resistance effect within the PDAC cells was 
evaluated. K8484-GFP cells were grown for 96 hours in monoculture or coculture with 
MH17031 cells, plus gemcitabine. K8484-GFP cells were then isolated from the total 
population using flow cytometry sorting for GFP-fluorescent cells. This sorted population 
was then re-seeded immediately in monoculture and incubated with gemcitabine over 72 
hours.  
When comparing the gemcitabine GI50 of this population with standard K8484 monoculture, 
there was no significant change in sensitivity, independent of the original level of 
gemcitabine dosing and resistance level of the K8484-GFP cells (Fig 3.5). Therefore, this 
suggests that the conferred gemcitabine resistance in coculture is a transient effect, 
requiring constant cell-cell interaction between both cell types. This indicates that the driver 
of the effect may be more likely a proteomic or transcriptomic alteration as opposed to 
genetic, given these biological units are built and degraded constantly within cells. 
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Figure 3.5 Transience of gemcitabine resistance when removed from coculture.  K8484-GFP 
cells were grown in monoculture and coculture with MH17031 and gemcitabine (0, 10 or 100 
nM). Following 72 hours of drug exposure, surviving K8484-GFP cells were isolated using 
flow cytometry and fluorescence, and re-seeded in monoculture for 24 hours, then followed 
by 72 hours of gemcitabine exposure (6 concentrations), with sensitivities assessed by 
57 
 
fluorescence. Each point represents mean of triplicate biological and triplicate technical 
replicates, ±SE. 
3.6 Modulation of gemcitabine metabolism as a driver of resistance 
Whilst the exact mechanism driving resistance to gemcitabine in this model is unknown, the 
mechanism through which gemcitabine in general induces a cytotoxic effect is, including the 
molecules driving activation and metabolism of the drug (Alvarellos et al., 2014; Plunkett et 
al., 1995). As a cell internalises gemcitabine (via nucleoside transporters) it is 
phosphorylated from dFdC to dFdCMP by deoxycytidine kinase (dCK) (Fig 3.6), and through 
two further phosphorylation steps the activated form of gemcitabine, dFdCTP, is created. 
dFdCTP exerts effect by being incorporated into replicating DNA inducing chain termination 
through inhibition of DNA polymerase activity (Plunkett et al., 1995). Gemcitabine effect can 
be abrogated through deamination of the initial dFdC form, induced by cytidine deaminase 
(CDA) to become dFdU, which is exported from cells and excreted. This deamination is a 
documented mechanism through which cells can become resistant to the drug (Funamizu et 
al., 2010; Weizman et al., 2014). Thus, another hypothesis through which K8484 cells are 
resistant to gemcitabine in coculture is that MH17031 cells may upregulate CDA in K8484 
cells and therefore decrease intracellular concentration of the cytotoxic dFdCTP. 
Alternatively, CDA in MH17031 cells could deaminate dFdC making it unavailable for the 
K8484 cells. 
 
 
Figure 3.6 Schematic for intracellular gemcitabine metabolism and activation pathway. 
To investigate this hypothesis, the coculture assay was performed with the addition of 
tetrahydrouridine (THU), a commercially available competitive CDA inhibitor. Through 
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addition of THU to the assay, any effect of CDA in metabolising gemcitabine would be 
minimised, therefore maximising dFdC levels available intracellularly. Further, as THU 
inhibits CDA in an allosteric manner (Stoller, Myers, and Chabner, 1978), its effect on 
minimising CDA metabolic activity on dFdC may be a product of stoichiometry with 
gemcitabine. As such two concentrations of THU were investigated in combination with 
gemcitabine. 
Combination of THU and gemcitabine in the coculture model with MH17031 leads to no 
demonstrable change in K8484 sensitivity to gemcitabine, suggesting that within this model, 
elevated CDA activity is not a key driver of resistance to gemcitabine (Fig 3.7).  
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Figure 3.7 Effect of CDA inhibition on K8484-GFP gemcitabine sensitivity in coculture 
assay. Two concentrations of tetrahydrouridine (THU), inhibitor of CDA, were assessed for 
effect on gemcitabine sensitivity in K8484-GFP coculture with MH17031 through a 72-hour 
assay. Each point represents mean of triplicate biological and triplicate technical replicates, 
±SE. 
3.7 Comparison of coculture with mouse and human cells 
These investigations indicate a transient gemcitabine resistance mechanism relying on cell-
cell contact in mouse PDAC coculture, not driven by upregulated CDA activity, by IL-6 or by 
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HGF expression. Given the function of translational research in identifying treatment 
strategies for human patients, it was of value to further investigate whether the mechanism 
was a product of mouse cells or conserved in human counterpart cell lines.  
The ability of mouse MH17031 cells to confer resistance to a human PDAC line in coculture 
was investigated, using the MIA PaCa-2 human cell line. Similar to the effect observed when 
in coculture with a mouse PDAC line, MH17031 drove a >50-fold increase in gemcitabine 
GI50 in MIA PaCa-2 cells, when compared to MIA PaCa-2 in monoculture (Fig 3.8A). This 
indicates the effect is conserved between the mouse K8484 line and a human PDAC line, 
and therefore holds potential value in human disease. 
The next step was to assess whether a human counterpart of MH17031 could confer the 
same resistance effect to PDAC cells. Isolation and culture of human fibroblasts from the 
cancer stroma is a challenge given the non-transformed state of the cells, coupled with the 
rarity and value of human tissue. Despite this, a fibroblast line had previously been isolated 
from human PDAC tissue by Ruiling Xu using the tumour outgrowth method, HuCAF2650.  
Culture of HuCAF2650 with K8484 cells induced no significant resistance to gemcitabine in 
the epithelial line, in contrast to the resistance conferred in coculture with MH17031. This 
indicates that this resistance-inducing effect may be restricted to mouse cell lines like 
MH17031. Of note, HuCAF2650 had a significantly slower growth rate when compared to 
MH17031 (doubling time of 14 days vs 1 day) appearing to reach replicative senescence 
significantly quicker. Both of these factors may influence the cell’s ability to reach density 
levels required for quorum effects (density-based cell signalling) or provide sufficient cell 
surface area to induce cell-cell contact-driven resistance effects on the PDAC cell. 
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Figure 3.8 Occurrence of resistance phenomenon using human CAFs and PDAC cells with 
murine counterparts. (A) Human GFP-tagged PDAC line MIA PaCa-2-GFP growth in 
monoculture and coculture with MH17031 with gemcitabine exposure over 72 hours; (B) 
K8484-GFP cell growth in monoculture and coculture with human CAF line HuCAF2650 with 
gemcitabine incubation over 72 hours. Each point represents mean of triplicate biological 
and triplicate technical replicates, ±SE. 
3.8 Characterisation of MH17031 morphology 
Demonstrating a gemcitabine resistance effect derived from coculture of the MH17031 with 
K8484 cells, a similar result was observed by Ruiling Xu, Jo Bramhall (Jodrell laboratory) and 
I with additional fibroblastic lines isolated in a similar way. Subsequent investigations 
focused on profiling the specific subtype of mouse fibroblast-like cells capable of driving this 
effect, under the premise that it is a form of stroma-conferred effect exhibited specifically 
from cancer-isolated fibroblasts. 
In addition to MH17031 cells, three mouse fibroblast lines were either isolated or purchased 
via commercial vendor. NF18073 cells are non-activated normal mesenchymal cells 
(pancreatic stellate cells) isolated from the normal pancreas of KRAS WT; P53 R172H; Pdx1-
cre (PC) mice – non-tumour bearing siblings of KPC mice. MEF28412C cells are mouse 
embryonic fibroblasts isolated using differential adhesion from dissected embryos of PC 
mice. 3T3 cells are a canonical fibroblast line isolated originally from Swiss albino mouse 
embryo tissue. Together this panel allows comparison of MH17031 KPC derived fibroblast-
like cells to a fibroblast line from a similar genotype (NF18073) and a similar mouse 
(MEF38412C), and to a canonical fibroblast line with regular use in academic investigations 
(3T3), and K8484 cells, to provide a more direct epithelial vs mesenchymal comparison. 
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A primary step in profiling these cells was to investigate whether morphologies differed in 
culture, and the extent to which MH17031 cells mirrored other defined mesenchymal cell 
lines. Typical mesenchymal cells exhibit elongated bodies, spindle-like appendages, and 
minimal clustering at dense growth. This is distinct from epithelial cells, which typically are 
more rounded/cobblestone in cell shape and grow in defined clusters. 
Each cell line was grown at early passage to a confluency of 70-90%, with size and shape 
observed on a bright-field microscope. K8484 cells in culture exhibit each of these epithelial 
characteristics, growing in small rounded clusters with minimal visible appendages (Fig 3.9). 
This is in contrast to each of the fibroblastic lines, all exhibiting the above mesenchymal 
features such as spindle-like protrusions and less clustered growth. Within the fibroblast-
like cell lines though, MH17031 exhibited fewer extreme levels of each of these properties, 
with a moderate degree of clustering and smaller appendages. Overall, they appeared 
distinct from each of the other fibroblasts and K8484 cells, with an overall profile 
approximating a general mesenchymal profile. 
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Figure 3.9 Cell culture morphologies for K8484 KPC tumour cell line and MH17031  KPC 
fibroblast-like cell line alongside canonical fibroblasts – commercial 3T3 fibroblasts, PC 
mouse-derived pancreatic stellate cells  NF18073 and PC mouse-derived mouse embryo 
fibroblasts MEF38412C. 
3.9 Ability of different mesenchymal cells to confer gemcitabine resistance in coculture 
The rationale behind phenotypically characterising a mesenchymal cell line panel is to 
provide correlation data for deciphering the properties of MH17031 that allow induction of 
gemcitabine resistance in the coculture model. The primary data point required here is 
degree of resistance to gemcitabine conferred in coculture. To obtain this each of the cell 
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lines within the panel above was introduced into coculture with K8484 cells, with the degree 
of gemcitabine resistance conferred by each evaluated. 
As shown previously, MH17031 increased gemcitabine GI50 of the K8484 cells over 15-fold 
to 269nM. Each of the other cell lines had either no effect on K8484 sensitivity, or even 
increased it, with coculture of 3T3 cells specifically reducing the GI50 by 31%, to 11nM (Fig 
3.10). This result suggests that the resistance effect observed is a product of a specific cell-
cell interaction requiring MH17031 cells and similarly derived cells.  
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Figure 3.10 Effect of different fibroblasts in conferring gemcitabine resistance to K8484 
cells in coculture. Each fibroblast line was grown in coculture with K8484 cells at a 10:1 ratio 
for 24 hours, followed by 72-hour incubation with gemcitabine. Sensitivity of K8484 cells to 
gemcitabine within each condition was assessed via fluorescence reads on cell growth. Each 
point represents mean of triplicate biological and triplicate technical replicates, ±SE. 
3.10 Characterisation of protein marker expression MH17031 cells 
With the further evidence that only a subtype of KPC-derived mouse fibroblast-like cell line 
could confer resistance, and morphological characteristics serving as only a minimally 
discriminating property, phenotypic protein markers were assessed to better elucidate the 
classification of resistance conferring cells. For this purpose, the presence and quantity of 
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four proteins were investigated, E-Cadherin, N-Cadherin, alpha smooth muscle actin 
(αSMA), and Vimentin. Of this panel, E-Cadherin is a canonical epithelial marker, with 
expression typically restricted to this cell type alone (Gumbiner, 1996). Both N-cadherin and 
Vimentin conversely are canonical mesenchymal markers (Sudo et al., 2013), with N-
Cadherin postulated to be upregulated as E-Cadherin is downregulated during the process 
of epithelial to mesenchymal transition (Niessen, Leckband, and Yap, 2011). αSMA is 
documented as a highly expressed protein within activated CAFs in particular (Sappino, 
Skalli, Jackson, Schürch, and Gabbiani, 1988). 
Protein levels were assessed using Western Blot in each of K8484, MH17031, and NF18073 
cell lines. When assessing levels and presence of E-Cadherin, surprisingly (given its quasi-
mesenchymal morphology by bright field microscopy) MH17031 had five-fold higher E-
Cadherin expression when compared to K8484 (Fig 3.11A). NF18073 has non-detectable E-
cadherin, as expected for normal pancreatic stellate cells. Given the epithelial profile of cells 
typically expressing this marker, mutually exclusive with canonical mesenchymal cells, this 
result indicated MH17031 cells to exhibit at minimum a partial epithelial profile, distinct 
from their predominantly mesenchymal morphology in culture. 
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Figure 3.11 Protein expression levels for a panel of epithelial and mesenchymal markers. 
Intracellular protein expression levels were assessed and quantified (comparing expression 
relative to Actin levels) using Western Blot in K8484, MH17031, and NF18073 cells, for each 
of (A) E-Cadherin, (B) αSMA, (C) N-Cadherin, and (D) Vimentin. 
αSMA was expressed in NF18073 normal pancreatic stellate cells, with minimal to no 
expression seen within K8484 and MH17031 cells (Fig 3.11B). Given αSMA is widely 
documented as a primary marker for the activation of stromal fibroblasts specifically, this 
result suggests that the NF18073 line may be the only true fibroblast line within this group.  
While primary pancreatic stellate cells like NF18073, isolated by density gradient 
centrifugation due to their high lipid vesicle content, are expected not to express αSMA, it 
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has been reported that these cells do activate αSMA during culture in vitro (Erkan et al., 
2011). This again suggests MH17031 cells to either be epithelial in subtype, or at a minimum 
containing a major epithelial subpopulation within it. 
Of interest, N-Cadherin expression was detected within each of the three lines, with two to 
three-fold higher levels within NF18073 and MH17031 lines when compared to K8484 cells 
(Fig 3.11C). This result contradicts the dogma of E-Cadherin and N-Cadherin expression 
being mutually exclusive but supports a hypothesis that MH17031 cells exist either again as 
a mixed population, or perhaps within an intermediary state between epithelial and 
mesenchymal classifications. 
Finally, with respect to expression of vimentin, another canonical mesenchymal marker, 
each cell line demonstrated comparable expression levels, with the epithelial K8484 cells 
having higher levels of this protein than NF18073 (Fig 3.11D). This result, coupled with the 
three above, solidifies the finding that while NF18073 do exhibit a classical mesenchymal 
signature as anticipated, both K8484 and MH17031 cells exhibit a more nuanced profile, 
with expression levels indicating a gradient between pure epithelial and pure mesenchymal 
classical signatures. As noted, this could arise either from mixed cell populations or through 
intermediate cell states, which can be further elucidated through investigation of protein 
localisation within cell populations, using a technique such as immunofluorescence.   
3.11 Investigating protein localization using immunofluorescence 
The above data suggest that the specific identity of MH17031, the single resistance-
conferring cell examined herein, is not as purely mesenchymal as morphology as the initial 
extraction methodology would infer. It was therefore then imperative to determine 
whether cell populations were homogenous and therefore bulk protein levels, assayed using 
a western blot, an accurate reflection of the protein state of the cell populations.  
To achieve this, immunofluorescence (IF) was used for each of E-Cadherin, N-Cadherin, 
αSMA, Vimentin, and P53. Tp53 mutations such as that in KPC tumours (R172H) stabilise the 
protein enabling P53 to be detected by antibody binding methods, whereas wild type P53 
has very short half-life and is typically undetectable. Thus, tumour cells are expected to be 
P53 positive on antibody staining, but other non-transformed cells are not. The added value 
of IF as a technique to complement western blotting here is an ability to visualise where 
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within a cell a protein is localizing too, which for a membrane-bound protein such as E-
Cadherin, allows distinct confirmation of likelihood of antibody specificity.  
 
Figure 3.12 Protein localisation and expression analysis using immune-fluorescence. 
Localisation and expression level of a panel of epithelial and mesenchymal proteins were 
assessed using immuno-fluorescent antibody tagging in K8484 KPC tumour cell line,  
MH17031  KPC fibroblast-like cell line and PC mouse-derived pancreatic stellate cells  
NF18073. Cells were incubated with specific primary antibodies, tagged with counterpart 
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secondary fluorescent antibodies, and imaged using a Leica SP5 confocal microscope (scale 
bar = 100µm). 
Using IF, E-Cadherin was detected in both K8484 and MH17031, with no detectable 
expression in NF18073 (Fig 3.12), consistent with Western blots. More specifically, E-
Cadherin expression in the former two lines was localised to the cell membrane, and 
further, to cell-cell interaction points, or adhesions. This finding is consistent with known 
expression and localisation data for E-Cadherin, further confirming the significant presence 
of this marker within K8484, and the definite presence of this protein within MH17031. Also, 
it was clear that the overwhelming majority of the cells in the MH17031 culture were E-
cadherin positive, suggesting that a mixed population is unlikely. 
Similarly, for N-Cadherin, the total expression level within each cell line broadly correlated 
with that seen in western blotting. Vimentin was detected in almost all cells in all 3 cell lines, 
with multiple distinct punctas per cell within the cytoplasmic region.  
αSMA expression also correlated with the Western blot data, with strong expression in 
NF18073, localised within apparent actin filaments as expected (B. Hinz, Dugina, Ballestrem, 
Wehrle-Haller, and Chaponnier, 2003). Expression in K8484 was minimal, as expected for a 
pure epithelial line, and was also barely detectable in MH17031.  
These data altogether suggest with confidence that the MH17031 cell line may not be 
fibroblastic in origin, but perhaps epithelial, given the high level of homogenous E-Cadherin 
expression in addition, but with some mesenchymal features. 
To explore this further, the expression level of P53 was interrogated, under the premise that 
were a cell to have the mutant form of the gene, an increased protein burden would be 
observed through accumulation (Yue et al., 2017; T. Zheng et al., 2013). Within the KPC 
mouse model, cells expressing Pdx1 may recombine the transgenes and thus express both 
mutant Tp53 and Kras, and therefore engage in carcinogenesis. Pdx1 is typically only 
expressed in pancreatic cells; therefore, for a KPC-derived cell line to be mutant for P53, it 
would likely be a tumour cell line. 
Using IF to assess the above point, as expected K8484 cells were strongly positive for 
(mutant) P53 protein, whereas in NF18073 P53 was undetectable, as expected from their 
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origin in normal pancreas in a PC mouse. MH17031 cells were strongly P53-positive, 
indicating these cells to be tumour in origin. This challenges an initial assumption in this 
project as to the subtype of these cells, which was that MH17031 were cancer-associated 
fibroblasts (CAF). As previously discussed, from a purely morphological perspective, coupled 
with the technique used for their initial isolation, this cell line exhibits defined mesenchymal 
characteristics, such as spindle-like appendages and minimal rounded clustering in culture 
growth. However, protein markers indicate MH17031 to be at least partly epithelial.  The 
co-existence of both epithelial and mesenchymal characteristics is a widely documented and 
investigated phenomenon through the process of epithelial to mesenchymal transition 
(EMT). Investigation as to whether MH17031 had engaged in the EMT process was 
warranted, to support identification of the specific features of cell lines that drive the 
observed gemcitabine resistance-inducing phenomenon. 
3.12 Applicability of EMT as mechanism for MH17031 marker expression 
The value of techniques such as western blotting and immunofluorescence is an ability to 
assess the active protein state at a given point in time within the cell. This is not as feasible 
with purely transcriptomic analysis, due to the highly variable and often non-correlative 
relationship between the expression of mRNAs compared to the presence and activity of 
their associated proteins (Yansheng Liu, Beyer, & Aebersold, 2016). Nevertheless, an 
underlying value of transcriptome evaluation techniques such as RNA-Seq, when compared 
to protein techniques as mentioned above, is the lack of reliance on intermediary molecules 
such as antibodies to detect and quantify expression levels.  
To better understand the origin and nature of the MH17031 cell line, and whether there is 
credibility in the hypothesis that this cell line may be a tumour cell line rather than a CAF 
that has undergone EMT and hence confers gemcitabine resistance in coculture, the 
expression level of transcripts for a range of epithelial, mesenchymal, and EMT-associated 
genes was investigated (Fig 3.13), leveraging an existing RNA-Seq dataset for each of K8484, 
MH17031, and NF18073. This was generated in the Jodrell lab by Frances Richards and Jo 
Bramhall. Genes related to epithelial, mesenchymal, and EMT-associated cells were 
quantified, interrogated, and contrasted between each of these cell lines. 
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In concordance with the above protein data, both K8484 and MH17031 expressed E-
Cadherin transcript (and epithelial marker keratin 19), whereas NF18073 had no detectable 
expression, as before indicating MH17031 to be a phenotypically epithelial cell (Fig 3.13). 
To assess the degree of mesenchymal identity within these cells, the expression levels of N-
Cadherin, Vimentin, and αSMA were investigated. Expression data was tightly correlated to 
protein data, with similar expression levels of each N-Cadherin and Vimentin observed 
across each of the three cell lines. In concordance with above, NF18073 expressed the 
highest levels of αSMA, with expression in K8484-GFP also higher than in MH17031, further 
decreasing the likelihood that MH17031 is a true CAF cell line, using existing dogmas of 
origin and activation. The high level of αSMA expression in NF18073 though suggests this 
cell type to be an activated fibroblast. This is a transition documented to often occur 
following culturing of an isolated fibroblast line, so does not necessarily indicate that 
NF18073 was activated prior to isolation (Rhim et al., 2012). This profile though is consistent 
with a profile expected of a true CAF. Given this cell line does not confer resistance to 
gemcitabine within the coculture model of resistance, these results combined suggest that a 
true phenotypic CAF, or activated pancreatic fibroblast, as determined by protein and RNA 
transcript data, does not have an effect in inducing gemcitabine resistance within this 
model. 
Leveraging the breadth of data available using RNA-Seq, the expression of additional 
stromal and EMT markers was evaluated within each of these three cell lines, to better 
understand whether EMT is truly a driver of the MH17031 cell type.  
CXCL12 is a signalling molecule expressed within the stromal compartment of pancreatic 
tumours (Feig et al., 2013), subsequently secreted into the extracellular matrix within which 
it binds with its cognate receptor CXCR4 within the tumour microenvironment. This binding 
event induces the apparent exclusion of T cells from the pancreatic tumour nest, as a 
mechanism of immune evasion employed by pancreatic tumours. Given the widely 
documented expression of CXCL12 within the stromal cells specifically (Guo et al., 2016; Roy 
et al., 2014; Singh et al., 2012), the expression of this marker can be used to differentiate 
between stromal and epithelial cells within pancreatic cancer.  
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Figure 3.13 RNA expression levels for a panel of epithelial, mesenchymal, and EMT genes. 
RNA Seq data for each of K8484-GFP (KPC tumour cell line), MH17031 (KPC fibroblast-like 
cell line), and NF18073 (PC mouse-derived pancreatic stellate cell line)  was interrogated and 
contrasted for expression of a panel of genes to inform epithelial and mesenchymal status of 
cells, as well as likelihood of EMT activation. Each point represents mean of quadruplicate 
technical replicates, ±SD. 
Aligning with data above, only NF18073 expressed significant levels of CXCL12, whereas 
neither K8484 nor MH17031 expressed levels above the lower limit of quantification. This 
again indicates neither of these cell lines to be stromal in phenotype, but further indicating 
NF18073 to be an activated pancreatic fibroblast now exhibiting a CAF-like phenotype. 
A primary goal of the transcriptomic analysis was to investigate whether there was any 
indication of MH17031 being a different cell type than purely epithelial, which perhaps 
drives the mechanism allowing this cell type to confer gemcitabine resistance in our 
coculture model. One hypothesis, matching a phenomenon documented within PDAC is 
EMT (X. Zheng et al., 2015). EMT is known to be driven primarily by a small panel of genetic 
master regulators, namely Snai1, Snai2, Twist1, and Zeb1 (Lamouille, Xu, and Derynck, 
2014). Interestingly when looking at transcript data for each of these genes in the three 
lines tested thus far, only NF18073 shows significant expression within each. For each of 
Snai1 and Snai2, neither K8484 nor MH17031 had significant expression, and for Zeb1 both 
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expressed at approximately 50% of the level of NF18073. As expression of Zeb1 is found in 
defined non-epithelial cells also, it is not necessarily exclusively expressed in EMT cells 
(Sangrador et al., 2018). 
Across the majority of the panel assessed above, there were no clear discrimination points 
between K8484 and MH17031, although meta-analysis of the global expression data using 
principal component analysis indicates that all three lines remain transcriptomically distinct 
from one another (Fig 3.14). The expression of one EMT-related factor though, Twist1, 
showed a significant difference between the lines. MH17031 expressed levels of Twist1 at 
about 65% of the level of NF18073, whereas in K8484 there was no detectable level of 
transcript. Whether this factor is indeed a driver or strong causative factor for EMT, or 
perhaps merely correlative, it does serve to suggest that MH17031 cells may have a 
moderate mesenchymal phenotype driven by a position on the gradient of EMT progression. 
 
Figure 3.14 Principal component analysis for each RNA-Seq sample group. Each circle 
represents one of 4 replicates per cell line.  
3.13 EMT expression data in human PDAC patients 
Correlating transcriptomic expression in mouse cells with phenotypes of translational value 
in human patients is a difficult exercise and requires significant validation steps.  One tool 
thought to de-risk the predictive power of murine translational studies is correlation of 
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identified targets and mechanisms with expression-linked survival data in patients, through 
some of the publicly available datasets, such as TCGA (Aguirre et al., 2017), a catalogue of 
key genomic changes and correlated survival analysis for 33 cancer types.  
Factoring this in, TCGA data for pancreatic cancer patients, transcriptome data from a total 
of 172 tumour samples, can be investigated for markers of EMT to assess whether their 
expression level can serve as a prognostic factor for the disease, and therefore hold more 
validity as a target coming from murine studies. 
For patients within the top quartile of expression versus those within the bottom quartile, 
neither ZEB1 nor SNAI1 show any significant difference in survival between the quartiles (Fig 
3.15 B, C). This suggests that at least with regards to survival only, independent of treatment 
received and other predictive factors, there is no clear correlation of survival with 
expression of these genes alone.  
Of interest though, both TWIST1 and SNAI2 show correlation between high levels of 
expression and decreased survival rates within patients (Fig 3.15 A, D), suggesting a 
potential functional role of these genes in either acceleration of disease progression or 
inhibition of therapeutic efficacy. In the mouse RNA-Seq data presented above, Twist1 is 
highly expressed within the MH17031 cells, whereas not within the K8484 line. This alone 
might suggest a functional role of Twist1 in inducing gemcitabine resistance, but, as with 
each of the EMT markers evaluated, NF18073 cells also highly express Twist1, despite an 
inability to confer resistance to gemcitabine within the coculture model documented. 
Together these data from patients hint at a driving role of EMT factors in worsening disease 
prognosis for PDAC patients, but when coupled with the RNA-Seq data also presented, 
indicates the activity of any one of these factors is unlikely to be a primary contributor to 
the gemcitabine resistance effect conferred by MH17031 cells within our coculture model 
specifically. 
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Figure 3.15 TCGA survival data for PDAC patients segregated into top and bottom 
quartiles of tumour EMT gene expression levels. Top quartile of expression = red line; 
Bottom quartile of expression = blue line. 
3.14 Genomic characterisation of MH17031 cells 
Recognising the plasticity of transcriptome and proteome profiles within cells, often 
changing significantly in response to changes in cellular environment, I attempted to identify 
the genetic origin of the MH17031 cells, by investigating the genotype encoded in the DNA. 
As discussed previously, the KPC mouse model is genetically engineered to express mutant 
Tp53 and mutant Kras in the epithelial/acinar cell compartment of the mouse pancreas. This 
is driven by expression of cre recombinase under the promoter for Pdx1, leveraging the lox-
stop-lox model of recombination (S. R. Hingorani et al., 2005). Within this model, two lox 
sites are positioned either side of a genomic cassette containing a stop codon. Within KPC 
mice these cassettes are positioned within the code for both exogenous mutant Kras and 
within Tp53, disrupting its expression. Expression of cre recombinase catalyses the excision 
of this cassette, leaving behind just a small LSL scar of ~30 base pairs, inducing expression of 
the mutant gene (Fig 3.16, 3.17). 
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Figure 3.16 Cre recombinase-driven Kras mutation system in the KPC mouse model. (A) KPC 
mice have a single copy of a G12D-mutated Kras gene in place of one wild-type allele. 
Expression is blocked due to insertion of an LSL cassette. (B) Upon Pdx1-driven cre 
recombinase expression the LSL cassette is excised, with cells then expressing Kras G12D. The 
P001 primer pair is designed to amplify from either side of the LSL cassette. When non-
recombined, the amplification of this region is minimal due to the large distance between 
primers (>5kb). When recombined, an amplicon of ~325bp is produced, compared to a 
~285bp long amplicon in the wild-type form of the gene without an inserted lox region.  
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Figure 3.17 Cre recombinase-driven Tp53 mutation system in the KPC mouse model. (A) 
KPC mice have two copies of a R172H-mutated Tp53 gene in place of both wild-type alleles. 
Expression is blocked due to insertion of an LSL cassette containing a stop codon. (B) Upon 
Pdx1-driven cre recombinase expression the LSL cassette is excised, with cells then 
expressing Tp53 R172H. The P002 primer pair is designed to amplify from either side of the 
LSL cassette. When non-recombined, the amplification of this region is minimal due to the 
distance between primers (>5kb). When recombined, an amplicon of ~325bp is produced, 
compared to a ~285bp long amplicon in the wild-type form of the gene without an inserted 
lox region. The P003 primer pair is designed to amplify from within the LSL cassette over one 
lox site. When the cassette is present and non-recombined an amplicon of ~300bp is 
produced, whereas in wild-type or recombined cells no amplicon is produced given the 
absence of the primer binding site within the gene. Finally, P004 is a positive PCR control 
primer pair set within the intronic region of Tp53, present in both mutant, wild-type, 
recombined, and non-recombined cells. Presence of an amplicon of ~170bp indicates sample 
integrity. 
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Tumour cells isolated from this mouse model having arisen from a pancreatic epithelial cell 
will contain recombined transgenes and be mutant for each of Kras and Tp53, whereas cells 
from other origins within the mouse should be heterozygous for non-recombined and wild-
type alleles for both genes. 
To assess this, PCR was performed across each of the loci for these genes, with primers 
designed to produce amplicons accurately discriminating between cells that either have 
mutant (recombined LSL) and/or wild-type expression for each of these genes. 
To investigate Kras status, a pair of primers designed to amplify from either side of the LSL 
cassette was used.  
 
Table 3.1 Primer design and amplification strategy for Kras and Tp53 genotyping. 
For the three lines tested, only K8484 amplified mutant Kras, with both MH17031 and 
NF18073 only amplified the wild-type Kras amplicon (Fig 3.18A). This suggests that of the 
three only K8484 is truly a KPC tumour cell line. Because MH17031 is derived from a KPC 
mouse it would be expected to be heterozygous for the non-recombined LSL-Kras allele, but 
no amplification would occur at this site as distance between primers would be too great 
(>5.5kb).  Retrospective analysis of RNA-Seq data generated by the lab indicated that 
MH17031, alongside K8484 cells, does express a level of mutant Kras. The apparent absence 
of the mutant form within MH17031 may be a product of PCR sensitivity, or heterogenous 
cell populations to different degrees between samples tested.   
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Figure 3.18 Kras mutation status assessed via PCR. Mutant Kras expression assessed via 
amplification over recombined LSL site, and wild-type Kras (~325bp = mutant, ~285bp = wt). 
Next, three pairs of primers around the Tp53 locus were used. The first pair was designed 
similar in principle to the Kras pair above, wherein they amplified from either side of the LSL 
cassette. For this primer pair Tp53 cells with the mutant form will express a single amplicon 
of ~320bp, the wild-type gene with a recombined LSL site, as opposed to a single amplicon 
of ~285bp if Tp53 is wild-type.  
Like the LSL Kras locus in KPC mice, which is a heterozygous ectopic insertion, LSL-Tp53 it is 
also heterozygous in the mouse, but previous analysis of KPC tumours and tumour cell lines 
indicates that the wild type Tp53 allele is typically lost in the tumours so that the only Tp53 
allele is the recombined R172H mutant transgene. 
Within the cell panel both K8484 and MH17031 contained exclusively the mutated 
(recombined) form of the Tp53 gene (Fig 3.19A), whereas NF18073 contained the non-
recombined Tp53 allele, noted as per confirmed sample integrity in Figure 3.19C. 
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This result was consistent through repeats and alternate primer pairings. This suggests one 
of two things: either MH17031 cells may be epithelial, with inefficient recombination of the 
Kras locus, or perhaps also that they are mesenchymal, but leaky expression of cre-
recombinase induced recombination of the Tp53 locus, which was then selected for given a 
competitive growth advantage.   
Validating this finding further, when using primers to amplify from within the Tp53 LSL 
cassette, only NF18073 results in an amplicon (Fig 3.19B), indicating that only this cell line of 
the three has a non-recombined LSL cassette at the Tp53 locus, and therefore suggesting 
that both K8484 and MH17031 cassettes have undergone recombination removing the 
primer adhesion sites. 
To ensure observed results (in particular absence of amplicons) were a true product of 
genetic characteristics, and not merely a product of degenerated template, a final pair of 
primers was used to amplify from within a non-mutated intron of Tp53, for which each cell 
line should produce an amplicon of ~170bp in length. All three lines showed this, therefore 
adding validity to the divergent data above (Fig 3.19C). 
Taken together, these data suggest that MH17031 cells may not be a typical epithelial KPC 
tumour cell line, but perhaps an intermediary or mesenchymal line mutant for Tp53 
selected for due to a competitive growth advantage derived from this mutation. Coupling 
these data with protein and transcriptomic data exhibiting a strongly epithelial profile, it is 
possible that MH17031 is derived from an epithelial lineage, but without full recombination 
of the Kras LSL locus, perhaps through inefficient recombination in response to Pdx1 
expression. Cre-mediated recombination is a stochastic process, so it is not surprising that 
some cells may recombine only one of the two possible transgene loci. 
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Figure 3.19 Tp53 mutation and LSL recombination status assessed via PCR. (A) Mutant 
Tp53 expression assessed via amplification over recombined LSL site, positioned within wild-
type Tp53 (~325bp = mutant, no band = non-recombined LSL cassette or sample issue); (B) 
Non-recombined LSL cassette in Tp53 via amplification across cassette boundary (~300bp = 
non-recombined cassette, no band = recombined cassette, no cassette, or sample issue); (C) 
Assessing sample quality via PCR amplification within non-modified intron of Tp53 (170bp = 
sample present, no band = sample issue). 
3.15 Effect of density growth in monoculture in driving gemcitabine resistance 
If MH17031 are derived from an epithelial or quasi-epithelial cell line originally, therefore 
the ability to confer resistance to gemcitabine within this coculture model may be a product 
of epithelial characteristics more so than a mesenchymal phenotype.  
It was therefore necessary to investigate whether coculture of K8484 cells with another 
cancer line would drive the same resistance phenomenon observed when in coculture with 
MH17031. To do this, mirroring cell seeding ratios and conditions, the fluorescent K8484 
line, K8484-mV, was grown in coculture with the non-fluorescent counterpart, K8484-WT, 
therefore maintaining the ratio of the fluorescent cells to be measured to the non-
fluorescent cells as used within the standard assay. 
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When grown together, mirroring conditions outlined above, K8484-mV cells had a 10-20-
fold increase in gemcitabine GI50 (Fig 3.20A). This increase is equivalent to that seen in 
MH17031 coculture.  Thus, a dense layer of KPC cancer cells was able to confer resistance 
on the co-seeded cancer cells. 
The next step was to identify whether a relationship exists between cell number seeded and 
degree of resistance. To test this, K8484-mV cells were seeded at varying ratios to K8484-
WT cells, namely 1:10, 1:5, 1:2.5, and 1:1. Sensitivity to gemcitabine was assessed as before 
by using another standard cell survival assay, sulforhodamine B, which measures total 
protein levels as a surrogate for cell number.  
There was an apparent direct relationship between seeding density and degree of conferred 
resistance to gemcitabine. At the lowest seeding ratio of 2,000 cells per well, or standard 
monoculture, gemcitabine GI50 was 22nM (Fig 3.20B). As this density increased to 5,000 and 
10,000, cells per well, GI50 increased to 52nM and 1uM, and respectively, and 50% GI was 
not reached at 20,000 cells per well (Emax ~87% GI). This level of resistance was above that 
seen in coculture with MH17031 at a 20,000:2,000 cell seeding ratio, possibly indicating that 
cell density may be a true primary driver of the observed resistance phenomenon. This 
could be a product of one of two reasons: either cell density drove an artificial-assay 
dependent change in resistance levels, given the metrics used to assess survival, or that cell 
density drove a functional change within the K8484 cells that itself modified their sensitivity 
level to a nucleoside analog like gemcitabine, and may indeed represent a driver of 
resistance either in KPC mice in vivo and potentially in PDAC patients in the clinic. Discerning 
this effect is therefore an essential requirement to validating the translational value of this 
model, independent of the precise origin of cell lines used.  
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Figure 3.20 Effect of high-density K8484 monoculture in modulating gemcitabine 
sensitivity. (A) Sensitivity to gemcitabine assessed for K8484-mV cells grown in monoculture 
(blue), coculture with MH17031 (black), and with K8484-WT (red); (B) Sensitivity to 
gemcitabine of K8484-mV cells grown for 24 hours at varying initial seeding densities 
followed by 72 hours incubation with drug. Each point represents mean of triplicate 
biological and triplicate technical replicates, ±SE. 
3.16 Contribution of proliferation rate to gemcitabine resistance phenomenon 
The mechanism of action for gemcitabine is to integrate into replicating DNA strands, 
inducing stalled replication forks replication arrest, and DNA strand breaks. Sufficient DNA 
damage induces cell death. This mechanism induces an effect specifically on cells 
undergoing replication (i.e. in S phase), and as such a gradient of effect can exist dependant 
on cell proliferation rate, with more highly proliferative cells more sensitive the drug’s effect 
(Yip-Schneider, Sweeney, Jung, Crowell, and Marshall, 2001). 
Noting this, a potential factor discriminating the sensitivity of K8484 cells in coculture with 
different cell types may be a product of proliferation rate differences, whereby a condition 
in which K8484 grows at a lower rate may give an artificial indication of gemcitabine 
resistance. To investigate whether this is likely to be a contributing factor within the 
reported effect, growth rates of K8484-mV cells in each of sensitive and resistance 
conditions were compared, to identify a cell line-independent effect. 
Growth rates of K8484-mV cells were assessed specifically between monoculture and 
coculture with each of NF18073, MEF38412C, and MH17031, the former two of the 
coculture conditions not inducing resistance to gemcitabine, as previously demonstrated in 
Figure 3.10.  
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Proliferation rate was significantly higher (p=0.0025) for K8484-mV cells in monoculture 
when compared to coculture with MH17031 (27-fold and 12-fold increases in cell number, 
respectively), with only a moderate decrease in rate when in coculture with each of 
NF18073 and MEF38412C (21-fold and 19-fold increases in cell number respectively) (Fig 
3.21A). This result may partially be anticipated given the increase in total cell number per 
well in each of the coculture conditions, which itself might impede K8484 cell growth. The 
significantly decreased rate of K8484-MV in MH17031 coculture in particular may be a 
product of the high proliferation rate of the epithelial-like MH17031 cells themselves, which 
could compete with the K8484 cells through the entirety of the 72-hour assay. To determine 
whether the gemcitabine resistance in coculture was simply the result of inhibited 
proliferation, growth rate was correlated with gemcitabine GI50 for each coculture condition 
(Fig 3.21B)  
A low growth rate was correlated with increasing gemcitabine GI50, and therefore resistance 
(Fig 3.21C). With statistical analysis performed on the degree of correlation using 
Spearman’s method, the relationship was calculated at a correlation coefficient of 0.67. This 
indicates a definite relationship between both, but concurrently suggests that growth rate is 
not the sole influencing factor in sensitivity to gemcitabine, with MH17031 inducing greater 
resistance than can be accounted for by inhibition of K8484-Mv proliferation alone.  
Therefore, cell type-specific mechanisms may still contribute to modulating gemcitabine 
sensitivity in K8484 cells, within this specific model.  
The challenge of decoupling effects of cell proliferation on drug sensitivity from true 
sensitivity between cell lines and conditions is not a novel one and has been reported 
previously as a caveat and hurdle for in vitro translational drug development (Chauffert et 
al., 1998; Y. Fang, Sullivan, and Graham, 2007). Varying different methods have been 
developed to try discount this confounding effect (Fallahi-Sichani, Honarnejad, Heiser, Gray, 
and Sorger, 2013). One particular valuable tool for performing this analysis specifically is 
that developed by Hafner et al, GR50 (Hafner et al., 2016). 
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Formula 3.1 Calculating GR values in endpoint drug-response data. Growth rate-
normalised drug efficacy can be calculated across conditions using a formula recently 
developed (Hafner et al., 2016). For each condition, the relative cell count is defined as 
𝑥(𝑐)/𝑥𝑐𝑡𝑟𝑙, where 𝑥(𝑐) is the count in the presence of drug at concentration c and 𝑥𝑐𝑡𝑟𝑙 is the 
50%-trimmed mean of the count for control cells. 𝑥0 is the 50%-trimmed mean of the cell 
count from a timepoint zero sample, measured prior to drug exposure. 
GR50 is a metric for drug efficacy that factors in the proliferation rate of cells being assessed, 
to quantify and discount these discordant values from true comparisons of efficacy between 
conditions, calculated as per Formula 3.1. This tool supports addressing the question posed 
above, allowing for scaled and direct analysis of gemcitabine sensitivity effects between 
culture conditions.  
Leveraging the same end-point data for the gemcitabine assay within each of the four cell 
type combinations detailed above, GR50 values were calculated within each condition, 
therefore producing growth rate-decoupled quantifications of sensitivity to gemcitabine. 
Through this model there remained a distinct and significant resistance effect driven 
specifically in the coculture with MH17031 cells, that was not the case for each of the other 
conditions (Fig 3.21D).  Thus, reduced K8484-mV proliferation caused by dense culture did 
not account for all of the gemcitabine resistance in coculture with MH17031. Indeed, even 
in coculture with MH17031, the K8484-mV cells underwent more than 3 population 
doublings in the presence of gemcitabine, which would be expected to be sufficient for this 
S-phase-specific drug to be effective. 
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Figure 3.21 Evaluating the contribution of proliferation rate to coculture-driven 
gemcitabine resistance. (A) Growth rate multiple of K8484-mV cells in monoculture as well 
as coculture with different lines. Each point represents mean of triplicate biological and 
triplicate technical replicates, ±SE.; (B) Mean (± SE) gemcitabine GI50 of K8484-mV cells in 
monoculture and coculture with different cell types; (C) Correlation between gemcitabine 
growth rate and GI50 plotted for all experiments from (A) using the Spearman method; (D) 
K8484 growth rate-adjusted gemcitabine sensitivity metric GR50 calculated and plotted for 
K8484 monoculture and coculture with each line from (A). Each point represents mean of 
triplicate biological and triplicate technical replicates, ±SE. 
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3.17 Effect of cell density on conferring resistance to oxaliplatin and 5-fluorouracil in 
coculture 
Uncoupling the confounding effect of proliferation rate on gemcitabine sensitivity is a 
challenge, although data above indicates proliferation is not the sole factor modulating 
resistance in this model. Another potential confounding factor in identifying true 
mechanistic resistance is cell seeding density, which has been reported to modulate drug 
sensitivity in certain models (Chauffert et al., 1998) . A simple and effective method through 
which this confounding factor can be decoupled from true drivers to a gemcitabine-specific 
resistance effect is through investigation of drug efficacy changes with cell density using 
additional different yet mechanistically similar agents to gemcitabine. 
Oxaliplatin is a platinum-based cancer chemotherapy regularly tested in combination with 
gemcitabine for pancreatic cancer patients (Alberts et al., 2003; Demols et al., 2006). It 
exerts its effect through non-enzymatic conversion into reactive species such as monoaquo 
and diaquo DACH platinum (Raymond, Faivre, Woynarowski, and Chaney, 1998). Upon 
activation, these molecules covalently bind with guanine and cytosine moieties of DNA, 
leading to cross-linking, and therefore inhibition of DNA synthesis and cellular replication. 
Therefore, for oxaliplatin, proliferation rate would similarly modulate efficacy as seen with 
gemcitabine. Within this model, by investigating oxaliplatin GI50 changes with seeding 
density of K8484 in monoculture, and through comparison with the significant effect of 
density on gemcitabine GI50 (Fig 3.21B), the degree of influence of density as an assay 
artefact driving gemcitabine resistance can be investigated. 
Through the same 72-hour assay, no comparably significant modulation of oxaliplatin 
sensitivity is observed with increasing cell density, with only a 3-fold increase between 2,000 
cells per well and 20,000 cells per well, through 72 hours (Fig 3.22A). This stands in contrast 
to gemcitabine, where a 50-fold increase in gemcitabine was observed between only the 
2,000 cells per well and 10,000 cells per well conditions. This result indicates both that cell 
density and proliferation rate are not likely primary drivers of the gemcitabine resistance 
effect observed, but instead that a cellular modulation in certain cocultures, be it perhaps 
proteomic or epigenetic, drives an effect within K8484 cells that drives resistance to 
gemcitabine specifically.  
87 
 
A further and similar comparison was investigated using 5-fluorouracil (5-FU) at varying cell 
densities. 5-FU is a nucleoside analogue, similar to gemcitabine, acting specifically on 
replicating cells. Its primary cytotoxic function is through its inhibition of thymidylate 
synthase (TS) (Longley, Harkin, and Johnston, 2003). TS is required for the synthesis of 
thymidine, one of the four core nucleotides required for DNA synthesis and replication. 
Between the highest and lowest seeding densities, a 9-fold increase in K8484 resistance to 
5-FU was observed (Fig 3.22B), greater than the 3-fold increase observed using oxaliplatin. 
This suggests that a nucleoside analogue-specific resistance mechanism may be prevalent. 
However, when compared to the shift in gemcitabine sensitivity through scaled seeding 
densities, cell sensitivity to 5-FU is significantly less affected. This result indicates that 
independent of the specific modulation of K8484 cells at density or in coculture with 
MH17031, the change appears to be unique to gemcitabine. This suggests a true resistance 
effect less likely to be a direct product of assay characteristics, and perhaps a true reflection 
of gemcitabine resistance mechanisms observed in the dense tumour seen in mice and 
patients. 
  
Figure 3.22 Effect of cell density in inducing resistance to alternative chemotherapeutic 
agents. K8484-mV cells grown for 24 hours at different initial seeding densities followed by 
72 hours incubation with either oxaliplatin (A) or 5-fluorouracil (B). Each point represents 
mean of triplicate biological and triplicate technical replicates, ±SE. 
3.18 Assessment of effect of true CAFs on conferring resistance to gemcitabine. 
An initial hypothesis within this project was that CAFs confer a specific functional change 
within KPC PDAC cells to induce resistance to gemcitabine in coculture. Through 
investigations detailed above, the original CAF-like cell line, MH17031, appears from 
genotypic, protein, and transcriptomic markers to more likely an epithelial cell in origin, 
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with expression of several mesenchymal markers. The original hypothesis of a CAF driving 
this resistance effect was partly supported by existing literature documenting their role in 
modulating drug efficacy in complex culture conditions (Hwang et al., 2008).   
To assess whether within this model a true CAF is capable of inducing resistance to 
gemcitabine, a true and validated pancreatic CAF was required. As no cell line of this type is 
available commercially, alternate methods of CAF accrual were required. To leverage 
existing published and peer reviewed documentation of a true pancreatic cancer associated 
fibroblast, aliquots of TB22150 KC CAF were sourced from Albrecht Neesse’s lab (Uni 
Goettingen) for validation within our model. This line was isolated from the KC mouse, a 
pancreatic cancer GEMM similar to the KPC mouse with mutant Kras expression in 
pancreatic epithelial cells driven here from P48, but without any Tp53 mutation. This model, 
and associated CAFs, have been demonstrated to contribute to a resistance-conferring 
effect through “scavenging” of gemcitabine within the tumour, and therefore reducing the 
levels of drug available for uptake and effect in tumour cells (Hessmann et al., 2017).  
Morphologically TB22150 cells exhibit classical mesenchymal phenotypes, notably elongated 
cellular protrusions, and minimally clustered growth at density (Fig 3.23A). To directly assess 
their contribution to gemcitabine sensitivity within our coculture model, the cells were 
grown with K8484 cells in the coculture protocol. Within this assay TB22150 cells quite 
significantly induce resistance to gemcitabine with a GI50 of 204nM for the K8484 cells 
within the coculture (Fig 3.23B). This result mirrors that seen for K8484 cells either in 
coculture with MH17031 or at high-density monoculture.  
To further validate TB22150 cells and the observed results, the Kras and Tp53 genotype was 
assessed using an identical protocol as used for validation of MH17031 genotype in Section 
3.14. As expected (because it should not contain the corresponding transgene) TB22150 was 
wild type for Tp53 (Fig 3.24B). Notably though, and in contrast to the reported genotype of 
this line, the cell line amplified mutant Kras (Fig 3.24A), mirroring a genotype expected from 
a KC pancreatic epithelial cell, and not a pure mesenchymal cell. This result contrasts with a 
conclusion on the genotype from validation within the initial publication, although a deeper 
interrogation of the original published Figure (CAF2 in Supp Fig 1C, Hessmann et al) suggests 
there may be a minor proportion of this cell line that was Kras mutant, and which may have 
since expanded in culture– mirroring the challenges faced in isolation of MH17031 as a pure 
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CAF population. Other groups working with KPC tumours have also found it virtually 
impossible to isolate wild type Kras and Tp53 CAFs from these tumours, either because 
minor mutant contaminants have such a growth advantage, or perhaps because some 
recombination could occur in vitro (Kris Frese, Cancer Research UK Manchester Institute, 
unpublished data). 
 
Figure 3.23 Characterising and evaluating TB22150 KC CAFs within the coculture model. 
(A) Morphology of TB22150 cells grown in vitro; (B) TB22150 cells assessed in the coculture 
assay for ability to confer gemcitabine resistance to K8484 cells (green line). Each point 
represents mean of triplicate biological and triplicate technical replicates, ±SE. 
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Figure 3.24 Assessing Kras and Tp53 genotype for TB22150 KC CAFs. (A) Mutant Kras 
expression assessed via amplification over recombined LSL site, and wild-type Kras (~325bp = 
mut, ~285bp = wt); (B) Mutant Tp53 expression assessed via amplification over recombined 
LSL site, positioned within wild-type Tp53 (~325bp = mut, no band = non-recombined LSL 
cassette or sample issue); (C) Non-recombined LSL cassette in Tp53 via amplification across 
cassette boundary (~300bp = non-recombined cassette, no band = recombined cassette, no 
cassette, or sample issue); (D) Assessing sample quality via PCR amplification within non-
modified intron of Tp53 (170bp = sample present, no band = sample issue). 3T3 cells serve as 
a wild-type control for both genes. 
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3.19 In-house isolation and evaluation of a true CAF in the coculture model 
A challenge with sourcing of a pure CAF line is the array of documented divergent 
techniques for their direct isolation from tumour tissue. Published reports include tumour 
outgrowth, differential adhesion, and differential trypsinisation protocols, each technique 
leveraging discerning growth properties of CAFs compared to non-CAF cells for their 
isolation (L. Fang et al., n.d.; Han et al., 2015; Albrecht Neesse et al., 2013).  Given the 
difficulties we have had in isolating true CAFs from KPC tumours, we attempted to obtain 
CAFs from an alternative source.  The Genetically Engineered Mouse-Derived Allograft 
(GEDA) model, developed in the Jodrell lab (Séverine Mollard, Frances Richards, 
unpublished), uses a subcutaneous implantation of KPC tumour fragments into recipient PC 
mice.  Previous studies by Kris Frese (Tuveson lab, unpublished) demonstrated that the 
intratumoural αSMA+ CAFs in GEDA tumours are derived from the host not the donor 
tumour.  To attempt to isolate CAFs, GEDA tumour tissue (AN16CUK004877, 16/4877) was 
segmented for isolation of CAF populations using each of differential adhesion and 
trypsinisation techniques, by Sandra Bernaldo de Quirós Fernández. 
Multiple cell populations were grown out from this GEDA tumour tissue using each of the 
above techniques. Following seeding and growth, single cells were isolated from each 
population using flow cytometry and seeded in single wells of a 96 well plate. Upon clonal 
expansion cell lines exhibiting the most classical and homogenous mesenchymal 
morphologies were banked and expanded further. To ensure each population was 
homogenously non-epithelial, Kras and Tp53 status was assessed within each. From an 
initial cohort of 19 cell lines isolated as above, only 2 lines, GDF14 and GDF17 both had 
mesenchymal morphologies (Fig 3.25A) and were verified wildtype status for Kras and 
presence of a non-recombined LSL cassette within Tp53 (Fig 3.25B). Both were isolated 
using the differential adhesion method of fibroblast isolation. Each other line had presence 
of mutant Kras populations (indicating contamination with KPC tumour cells). This 
interestingly demonstrates the inadequacy of morphological characterisation serving the 
foundation of mesenchymal classification, and the ability for epithelial cells to exhibit 
mesenchymal properties. This plasticity perhaps indicates a potential source of confounding 
data and misaligned CAF classification in the wider literature. 
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To further confirm the identity of both GDF14 and GDF17, αSMA expression was 
investigated using western blotting. Similar to NF18073, both cell lines expressed high levels 
of αSMA, in contrast to both K8484 and MH17031 cells, both of which have minimal 
expression (Fig 3.25C). While αSMA expression in NF18073 indicates these cells may have 
been activated post culture, given GDF14 and GDF17 were isolated from tumour tissue, the 
expression of this marker suggests that both are canonical CAF cells. Independently, they 
appear to be true mesenchymal cells, without epithelial origins. 
These GEDA-derived CAFs were investigated in the coculture model for their ability to 
confer gemcitabine resistance to K8484 cells. Neither cell line induced significant changes in 
K8484’s sensitivity to gemcitabine (Fig 3.25D). Therefore, under the premise that each of 
these cell lines is indeed a true CAF, the hypothesis that this cell type can confer resistance 
to gemcitabine in our coculture model appears to be false, and in fact conferred resistance 
is a property of epithelial tumour cell growth at density. The underlying challenge of 
experimentation such as this is the opaque and varied classification techniques for 
identification of CAF cells within pancreatic cancer. To address this, larger panels of these 
fibroblast-like cells might be used in such experimentation to try identify whether the 
resistance effect is linked perhaps to specific subtypes of CAFs, which in turn can provide 
more insight into the functional heterogeneity of CAFs.  
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Figure 3.25 Isolating and characterising CAFs from GEDA mice within the coculture model. 
(A) Cell morphology of GDF14 and GDF17 grown in vitro; (B) Kras and Tp53 genotype 
assessed via PCR (P001: Mutant Kras expression assessed via amplification over recombined 
LSL site, and wild-type Kras (~325bp = mut, ~285bp = wt)) (P003: Non-recombined LSL 
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cassette in Tp53 via amplification across cassette boundary (~300bp = non-recombined 
cassette, no band = recombined cassette, no cassette, or sample issue); (C) αSMA protein 
expression assessed using western blot in GDF14 and GDF17 cells alongside K8484, 
MH17031, and NF18073; (D) Effect of GDF14 (purple) and GDF17 (black) in conferring 
gemcitabine resistance to K8484 cells when compared to monoculture (blue). Each point 
represents mean of triplicate biological and triplicate technical replicates, ±SE. 
3.20 Value of model in predicting known gemcitabine synergies and exploring novel ones 
The goal of this project was to develop a model of gemcitabine resistance that has value as a 
system for identifying agents that can sensitize cancer cells to gemcitabine, that may be 
predictive of therapeutic efficacy both in vivo and in patients.  
Independent of the characterisation of the specific cell type driving this effect, the effect 
appears to be real and a product of cell type-specific interactions with pancreatic cancer 
murine epithelial cells. Factoring this in, the model was evaluated for its alignment with 
known therapeutic agents demonstrating synergy with gemcitabine either in mice or 
patients, to indicate an underlying predictive power of the model.  
As a mainstay of pancreatic cancer treatment for the last fifty years, gemcitabine has 
formed a central focus in ongoing development of novel treatment strategies for patients. 
Combinatorial strategies of using multiple agents alongside nucleoside analogues such as 
gemcitabine have helped enhance overall efficacy for patients. FOLFIRINOX is an example of 
such a cocktail, treatment patients concurrently with folinic acid, fluorouracil, irinotecan, 
and oxaliplatin. A challenge though with such treatment regimens is increased side effects 
incurred through multiple non-targeted agents. As such, the past decade has seen a focus 
on leveraging combination strategies with more targeted agents, better addressing specific 
alterations within cancer cells through biomarker-driven therapeutic selection (Rahib et. al, 
2016; Sheahan et. al, 2018). 
One combination that has seen value in vivo, with prospects for a clinical trial within 
pancreatic cancer, is gemcitabine alongside AZD2014, a dual MTOR1/2 inhibitor. Pre-clinical 
studies have demonstrated a mild synergistic effect between both agents both in vitro and 
directly in KPC mice (Driscoll et al., 2016; Frese et al., 2012; Morran et al., 2014). The exact 
mechanism through which this synergy is derived is not clear, although as the MTORC 
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complex lies downstream of oncogenic KRAS activity, as an effector of PI3K, combination 
with gemcitabine may serve two functions in decreasing viability of Kras-mutant pancreatic 
cancer cells. 
To assess the validity of our in vitro coculture model, a combination of gemcitabine and 
AZD2014 was trialled for efficacy on K8484 cells when in coculture with MH17031. As a 
single agent in coculture AZD2014 demonstrated mild effect on K8484 cells (GI50 = 330nM) 
(Fig 3.26E), similar to single agent data seen in KPC mice referenced above. When combined 
with gemcitabine, a mild level of synergy is observed at ~30nM gemcitabine alongside 3-
10nM AZD2014 (Fig 3.26B, C). This slight increase aligns with combination data from KPC 
mice, where the combination of agents had a median survival in KPC mice of 280 days 
compared to 195 days for AZD2014 alone, 147 days for gemcitabine and 132 days for 
untreated (Driscoll et al., 2016). This result indicates the coculture model herein developed 
may have power to predict combinations of value for in vivo studies in KPC mice. 
Uncertainty though remains due to the low number of cell lines for which this effect is 
observed, as well as the relatively low degree of synergy calculated. Additional 
experimentation here might include an expanded cell line panel for interrogation, as well as 
expanded dose ranges around the apparent synergistic concentration combinations to 
better evaluate the magnitude of the synergy. 
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Figure 3.26 Combination of gemcitabine and AZD2014 in coculture model. (A) Percentage 
growth relative to solvent for control for a 6x6 gemcitabine and AZD2014 combination 
range; Synergy quantification calculated in Combenefit using the Bliss Independence model 
(B) and the Loewe model (C) (blue = combinations demonstrating significant synergy); Single 
agent dose response curves for each of gemcitabine (D), and AZD2014 (E) for which each 
point represents mean of triplicate biological and triplicate technical replicates, ±SE.. 
Gemcitabine’s mechanism of action is to incorporate into replicating DNA, induce stalling of 
the replication fork, and therefore cause damage to DNA. Cells rely on a plethora of factors 
to repair such DNA, one of which is ATR (Ataxia telangiectasia and Rad3 related) (Blackford 
and Jackson, 2017). High levels of ATR expression is linked to decreased survival in PDAC 
patients, potentially a product of cancer cells’ ability to mitigate DNA damage and therefore 
cell death induced by gemcitabine. Pre-clinical murine studies in our lab have further 
indicated the combination of ATR kinase inhibitor AZD6738 to potentiate gemcitabine effect 
(Wallez et al., 2018),laying the foundation for human clinical studies within pancreatic 
cancer specifically. 
Recapitulating this combination in our coculture model was a final step to assess whether 
combinations with defined pre-clinical or clinical value could be accurately evaluated in this 
setting. AZD6738 as a single agent has minimal effect on K8484 cells in coculture, even at 
concentrations up to 3µM (Fig 3.27E). This is likely a product of inhibition of ATR alone, 
without the concurrent DNA damage induced by a nucleoside analog such as gemcitabine, 
unable to significantly effect growth potential of K8484 cells. Once in combination, quite 
significant levels of synergy are observed again at ~30nM of gemcitabine with a range of 
AZD6738 doses between 0.3 – 3uM (Fig 3.27B, C). This dose range has been demonstrated 
by our lab to be approximately equivalent to the EC50, and therefore likely resulting 
specifically from inhibition of ATR, as opposed to off-target effects that might be observed 
at high concentrations  
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Figure 3.27 Combination of gemcitabine and AZD6738 in coculture model. (A) Percentage 
growth relative to solvent for control for a 6x6 gemcitabine and AZD6738 combination 
range; Synergy quantification calculated using the Bliss Independence model (B) and the 
Loewe model (C) (blue = combinations demonstrating significant synergy); Single agent dose 
response curves for each of gemcitabine (D), and AZD6738 (E) for which each point 
represents mean of duplicate biological and triplicate technical replicates, ±SE.. 
3.21 Conclusion 
The goal and output of this chapter was to interrogate and document the characteristics of 
the in vitro model of gemcitabine resistance in PDAC developed originally within the Jodrell 
lab. Having described the nature of the resistance effect as transient in nature and reliant on 
cell-cell contact, I further demonstrated that the cell line driving the effect is not a CAF, as 
first proposed, but rather more likely an epithelial cell in origin having since developed more 
mesenchymal morphological features.  
Demonstrating also that true pancreatic CAFs do not appear to drive resistance in this 
model, I hope to have exemplified the real challenges that exist in proper cell line isolation 
and characterisation within this space, and the potential pitfalls that may have hampered 
previous investigations. Future experimentation into CAF form and function, as well as 
intercellular interactions, would benefit greatly from  more detailed characterisation of the 
different CAF and fibroblast-like intracellular subtypes in PDAC. 
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Despite the challenges around cellular identity though, I have demonstrated that the 
resistance effect observed is real, and perhaps a product of a quorum-sensing phenomenon 
within the model. Taken altogether, synergy with gemcitabine plus AZD6738, and 
gemcitabine plus AZD2014 indicates that independent of an understanding of the specific 
cell type inducing resistance to gemcitabine in this model, it remains predictive of 
therapeutic combinations with in vivo efficacy.  Using this coculture model may enable 
reduction of the numbers of animal required for in vivo testing of drug combinations, with 
ethical and financial benefits.  
Further, the development of a novel model of gemcitabine resistance in pancreatic cancer in 
vitro, with demonstrated efficacy data correlated to clinical studies, presents as a valuable 
system for high throughput therapeutic target identification requiring significantly lower 
resource investment when compared to in vivo studies or more complex multi-dimensional 
in vitro models.  
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4. An shRNA screen to investigate gemcitabine 
sensitivity in a coculture model of PDAC 
 
This shRNA screen project was carried out in collaboration with Dr Nicolas Erard, a previous 
PhD student in Professor Greg Hannon’s laboratory at the CRUK Cambridge Institute. For this 
thesis, I will outline my specific contributions to this project. The cloning of the shRNA 
libraries and retrovirus production were performed by Nicolas. The subsequent passaging of 
infected cells in mono and coculture was a collaborative effort between Nicolas and myself, 
as well as the gDNA extraction and PCR of shRNAs and sequencing library preparation. 
Sequencing was undertaken by the CRUK Cambridge Institute Genomics Core, with read 
normalisation and differential expression scoring performed by Chandra Sekhar Reddy 
Chilamakuri from the CRUK Cambridge Institute Bioinformatics core. All figures are a product 
of my own analysis. 
4.1 Introduction 
A primary challenge of translational research in pancreatic cancer, and associated target 
identification, is the difficulty in recapitulating the conditions found inside the tumour in a 
biologically correlative manner, amenable to high-throughput target validation. Our 
coculture model of PDAC gemcitabine resistance opens a novel and scalable modality for 
exploration into the genetic mechanisms driving resistance. Traditionally, such 
investigations are either hypothesis-driven targeted interrogations, or broader in scope -
omic characterisations.  
The former is valuable as a tool to drill into the intricacies of a phenotype’s mechanism but 
relies on the presence and integrity of targets identified previously. This therefore limits 
experimental scope for identifying truly novel targets and mechanisms. 
Broader -omic-based techniques can remove bias in target identification and validation, by 
interrogating entire genomes, proteomes, transcriptomes, among others, for phenotypic 
alterations of interest. Tools such as RNA-Seq and Cell Type specific labeling using Amino 
acid Precursors (CTAP) take an observational approach to investigation, identifying targets 
and phenotypes of interest through differential transcript and protein levels respectively 
(Gauthier et al., 2013; Wang, Gerstein, and Snyder, 2009). 
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To investigate the mechanism of gemcitabine resistance observed in the in vitro coculture 
model detailed in Chapter 3, I undertook a whole-genome shRNA screen (Fig 4.1). Despite 
considering both proteomic and RNA-Seq-based screening techniques for their 
observational value, the direct manipulation possible via shRNA screening was considered to 
be more effective in identifying single gene contributors to the observed gemcitabine 
resistance effect. Specifically, I used a short hairpin RNA library comprised of seven pools of 
around 10,000 shRNAs each, targeting approximately 19,000 genes within the mouse 
genome. This library, by infecting the pancreatic cancer cells, and exposing to gemcitabine, 
can support identification of genes driving resistance to gemcitabine within the model, using 
a dropout viability format (Diehl, Tedesco, and Chenchik, 2014; Sims et al., 2011). The 
screen involves assessing shRNA depletion through six gemcitabine or DMSO control cycles, 
in both monoculture and coculture, compared to timepoint zero (Figure 4.1). Different 
concentrations of gemcitabine were used for coculture and monoculture, 100nM and 10nM 
respectively, to approximate gemcitabine GI50 within each growth condition (Fig 3.2). 
This approach has direct interrogative translational value to complement observational 
broad-based approaches. Whereas observational approaches rely on correlation to infer 
function, an shRNA depletion screen instead looks at phenotypic impact of gene knock-
down to decipher function. Therefore, there is less reliance on correlative observations, and 
instead a focus on true functional effects conferred from genome manipulation. 
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Figure 4.1 Schematic for whole-genome shRNA screen used to interrogate gemcitabine 
resistance mechanism in coculture. K8484 pancreatic cancer cells, isolated from KPC 
tumours, were infected with a murine whole-genome shRNA library. Following selection with 
hygromycin for infected cells, and multi-passage depletion of cells targeting cell survival-
essential genes, genomic DNA was extracted, and subsequent populations split into mono- 
and coculture arms, the latter to be grown alongside MH17031-DTR cells. Each arm was 
treated with six cycles of gemcitabine (72 hours) at a gemcitabine concentration between 
GI25 and GI50 values (10 nM gemcitabine for monoculture condition, and 100 nM for 
coculture condition, or DMSO control). Following the final cycle, the coculture condition was 
treated with 100ng/ml diphtheria toxin for 96 hours to deplete MH17031-DTR cells to less 
than 10% of the total population. Genomic DNA was extracted from the K8484 cells, and 
following DNA sequencing, shRNA representation was compared to the time timepoint zero 
sample to identify depleted shRNAs. 
4.2 Design and preparation of screening protocol 
To undertake a whole-genome shRNA screen interrogating gemcitabine resistance 
mechanism in a coculture model of pancreatic cancer, two novel cell lines were created. 
Firstly, a mouse PDAC line infected with a whole genome shRNA library (K8484-inf), along 
with a modified MH17031 line engineered for selective ablation in coculture models, to 
allow leveraging their resistance-conferring effect whilst also supporting selective depletion 
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at the end of the assay to create a pure K8484-inf population. This is required to maximise 
shRNA levels within genomic DNA for normalising alongside the monoculture control 
protocol. 
For the PDAC cell line, K8484 cells were used, due to extensive validation and 
characterisation in our lab both genetically and using protein markers (Chapter 3), as well as 
in relation to gemcitabine sensitivity in both mono- and co-culture with MH17031. The line 
was retrovirally infected with a mouse genome-wide shRNA library from Transomic 
Technologies, using shRNA designed using the SHERWOOD algorithm for maximising shRNA 
potency and minimising off-target effects (Knott et al., 2014), creating the K8484-inf line. 
The library contained 63,677 shRNAs covering 18,402 genes within the mouse genome, 
coupled with a panel of shRNAs targeting human olfactory receptor genes to serve as 
negative controls. Each gene had an average of 3.46 unique shRNAs targeting it (Fig 4.2), 
adding confidence in identifying true positives and minimising false positives resulting from 
off-target effects in the subsequent sequencing analysis. 
 
Figure 4.2 The number of shRNAs targeting each gene within the whole-genome library 
used. 
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Once created, the line was expanded in culture and selected with 500µg/ml hygromycin for 
96 hours to approximate a pure fully transfected population, verified through homogenous 
expression of mCherry, a fluorescent marker expressed within each cell successfully infected 
with an shRNA. Cells were then grown for seven days to allow for dropout of shRNAs 
targeting genes required for cell survival. Genomic DNA was then extracted from an aliquot 
of this population and stored at -80C, to serve as a timepoint zero sample to be included in 
future analysis. 
The second line to be created was a modified MH17031 line. As the data of interest at the 
end of this shRNA depletion screen is the shRNA qualitative and quantitative profile within 
the K8484-inf cell line, it is imperative that sequencing depth and coverage from the line is 
maximised, ensuring even slight, yet still statistically significant, changes are recorded. To 
support this, MH17031 needs to be selectively ablated from the coculture conditions prior 
to gDNA extraction at the end of the screen. To achieve this, MH17031 cells were 
transduced with a plasmid expressing human diphtheria toxin receptor (DTR), ZsGreen 
fluorescent protein, and a neomycin resistance cassette (MH17031-DTR).  
4.3 Scaling of coculture resistance phenomenon to 15cm dishes 
To assess drivers of gemcitabine resistance at the genome-wide level, it was necessary to 
scale up the coculture resistance assay, to enable ultra-high-throughput screening, by 
proportional scaling of the 96 well plate assay to 15cm plates, maintaining ratios of cell lines 
and media volume to surface area. A comparison was performed by investigating the 
percent growth inhibition of cells in monoculture and coculture at both 10nM and 100nM 
gemcitabine, between the standard 96 well assay format and the scaled assay in 15cm 
dishes. Growth of K8484 cells in coculture with 100nM gemcitabine in 96 well format and 
15cm dish format were 64% and 62% when compared to DMSO control respectively (Fig 
4.3). In monoculture with 100nM a gemcitabine growth rate of only 22% was observed 
when compared to non-treated control, therefore indicating that a coculture-driven 
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resistance effect is maintained in the scaled assay in 15cm dishes.
 
Figure 4.3 Maintenance of coculture-conferred resistance to gemcitabine in 15cm dish 
assay. Degree of effect of two doses of gemcitabine on K8484 survival in both monoculture 
and coculture (with MH17031) in (A) 96 well plates and (B) 15cm dishes over 72 hours 
treatment, relative to growth in a DMSO untreated control. 
4.4 Primary genome-wide shRNA screen to investigate genetic drivers of gemcitabine 
resistance in coculture 
The underlying principle of this shRNA depletion screen is that by comparison of population 
shRNA profiles at the start of the screen and after the drug cycles, shRNAs that are depleted 
throughout represent genes that normally serve to confer gemcitabine resistance in the 
cells. Further, by identifying those shRNAs depleted in the coculture model plus gemcitabine 
specifically, a list of genes involved in the specific coculture-driven resistance mechanism we 
have observed is elucidated. 
For each condition, six cycles of 72 hours gemcitabine or DMSO control treatment were 
performed. After each cycle cells were split and reseeded to conserve the 10:1 MH17031-
DTR:K8484-inf seeding ratio, typically requiring fresh MH17031-DTR cells, given the higher 
proliferation rate of K8484-inf. 
To ensure cells maintained proliferative potential throughout the screen, and did not 
undergo replicative senescence, cell growth rates were monitored throughout. Mirroring 
proliferation rates seen in the original 96 well format (Fig 3.21), K8484-inf cells in 
monoculture in the 15 cm dishes proliferated 30-50X over 96 hours (24 hours of growth 
post-seeding prior to 72 hours gemcitabine treatment) (Fig 4.4). In coculture, both PDAC 
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and MH17031 cells proliferated at a reduced rate, of 1.2X – 3.5X over the 96 hours. Notably, 
this reduced rate has been discounted as the only driver of gemcitabine resistance in 
previous work detailed in Chapter 3. 
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Figure 4.4 Cell growth rates through screen cycles. The percentage of cells with mCherry 
expression at each cycle was used as a surrogate marker of K8484-inf cell numbers, with the 
remaining population ascribed as MH17031-DTR cells. Cell numbers were counted using Vi-
CELL (Beckman Coulter), and percentage of populations fluorescent for mCherry measured 
with MACS Quant (Miltenyi Biotec). 
4.5 Sensitivity to gemcitabine through screen progression and cycling. 
It was also important to ensure that the expected degree of gemcitabine sensitivity was 
maintained throughout each cycle. To assess this the growth rate of K8484-inf cells in both 
monoculture and coculture plus gemcitabine was compared to their counterpart in DMSO 
only. A reduction in survival of approximately 20-40% was anticipated, replicating that 
observed previously during screen validation (Fig 4.3). In monoculture there was a slight 
decrease in sensitivity between the first cycle and the fifth (Fig 4.3A), and conversely in 
coculture there was a minor increase in sensitivity (Fig 4.3B). Nevertheless, through all 
cycles and all conditions there were no major outliers when compared to the validation 
experiment sensitivities. Minor changes may be ascribed to factors such as increases in 
proportion of population resistance to gemcitabine over time, or changes in proliferation 
rate and viability as cells undergo continuous passaging. As such, there is further confidence 
that the output of the screen is a true reflection of genetic drivers of gemcitabine 
resistance, and not merely an artefact of intra-screen growth changes. 
106 
 
 
Figure 4.5 Gemcitabine sensitivity variation through screen cycles. Sensitivity of K8484-inf 
cells to gemcitabine through each screen cycle in both (A) monoculture and (B) coculture 
conditions, inferred through growth rate relative to untreated DMSO controls.  
4.6 Post-screen sample preparation and sequencing 
Upon completion of the screen, shRNA profiles for each assay condition and replicate were 
to be assessed, to identify enrichment and depletion changes incurred through the screen 
and allow for comparative analysis between conditions. As a first step, genomic DNA was 
extracted from surviving K8484-inf cells, to provide template for shRNA amplification, 
sequencing, and downstream analysis. For the coculture conditions this extraction was 
preceded by a 96-hour exposure to 100ng/ml diphtheria toxin for selective ablation of the 
MH17031-DTR cells, purifying a K8484-inf population. This genomic DNA was used to 
amplify out the shRNA cassette, following by a separate barcoding PCR to individually label 
each condition and each replicate within it for pooled sequencing. Samples were sequenced 
using Illumina HiSeq to a depth of at least 10 million reads. 
Sequencing reads were analysed by first mapping to an index of each shRNA sequence and 
gene name, as provided by the shRNA library manufacturer, Transomic Technologies. 
Differential expression analysis was then performed by comparing shRNA representation in 
107 
 
each condition to the timepoint zero set. Differential expression was quantified using two 
separate tools, DESeq2 (Love et al., 2014), and median Z scores. DESeq2 is a purpose-built 
analytical tool for carrying out differential analysis of high-throughput sequencing data, 
using shrinkage estimators for expression variance and fold change to account for low 
sample number differential expression scoring calculations. Median Z scores are created 
using a function to calculate the mean and standard deviation of each shRNA, defining a Z-
score where Z measures the number of standard deviations of the shRNA expression level is 
from the population median (DE scoring performed by Chandra Sekhar Reddy Chilamakuri, 
CRUK Cambridge Institute).  
With genome-wide data, the threshold of what is termed a “hit” or not can be adjusted 
along a gradient, depending on the degree of confidence required and number of candidate 
shRNAs required for subsequent analytical steps, such as pathway analysis. Given the 
purpose of this primary screen in identifying a large list of genes of interest to inform later 
more targeted screening protocols and factoring in the confounding issue of off-target-
driven false negatives and positives, hit scoring criteria were set to be minimally restrictive. 
For DESeq2, shRNAs were considered as hits if they had a Log2(FoldChange) of ≤ 0 and an 
adjusted p value of ≤ 0.05. Similarly, for median Z scoring, shRNAs were termed a hit with a 
median Z score of ≤ -2, therefore an shRNA representation of a minimum of two standard 
deviations below the median shRNA representation value. Further, for a gene to be 
recorded as a hit, at least 50% of shRNAs targeting that gene needed to be hits, or if only 
one shRNA was targeting that gene, it had to be significantly depleted (Table 4.1).  
 
Gene hit criteria 
DESeq2 Median Z score 
≤ 0.05 padj ≤ -2 Z score 
< 0 Log2(FoldChange) ≥ 50% targeting shRNAs hitting 
≥ 50% targeting shRNAs hitting  
Table 4.1 Hit calling criteria using normalised primary shRNA screen data, for both DESeq2 
and median Z score differential expression analysis methodologies. 
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The subset of most interest within this screen was the coculture condition plus gemcitabine. 
By identifying genes that are significantly depleted in this subset when compared to 
timepoint zero, and not depleted in any of the other three conditions, it is possible to 
identify genes which may have a functional role in driving the observed resistance in the 
original model of coculture-driven resistance. This coculture condition plus gemcitabine had 
the highest number of significantly depleted shRNAs using both scoring methodologies, with 
2,357 shRNAs depleted using DESeq2 and 5,563 shRNA depletion hits using median Z scores 
(Table 4.2), with an associated 291 genes significantly depleted with DESeq2, and 959 genes 
with median Z score.  The distributions of ShRNAs in DESeq2 analysis and median Z score 
analysis are shown in Figures 4.6 and 4.7 respectively. Notably, for DESeq2 analysis there 
were over eight times the number of shRNAs identified as depleted relative to timepoint 
zero in the coculture plus gemcitabine condition compared to the monoculture plus DMSO 
condition, and over three times the number relative to the monoculture plus gemcitabine 
condition. These differences are potentially a product of the presence and concentration of 
drug used, whereby higher doses of gemcitabine may induce changes in gene expression 
within cells through their enhanced dependence on resistance-driving genes for survival. 
Additionally, with a higher GI50 in the coculture plus gemcitabine condition, there exists a 
larger range of gemcitabine GI50s that cells can be sensitised to, and therefore an increased 
ability to exhibit statistically significant change versus the DMSO control.  
Condition 
Median Z score DESEq2 
shRNAs genes shRNAs genes 
Coculture + gemcitabine 5563 959 2763 291 
Coculture + DMSO 2741 448 1043 159 
Monoculture + gemcitabine 2064 298 738 78 
Monoculture + DMSO 1545 212 345 38 
Table 4.2 Number of shRNAs and genes significantly depleted within the coculture and 
monoculture conditions +/- gemcitabine. Compared to timepoint zero, from primary ShRNA 
screen of 63,677 shRNAs covering 18,402 genes within the mouse genome. 
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Figure 4.6 shRNA differential expression scoring between conditions using DESeq2. 
Significantly differentially expressed shRNAs (red dots) called using R Bioconductor package 
DESeq2 for coculture plus (A) gemcitabine, (B) DMSO, and monoculture plus (C) gemcitabine 
and (D) DMSO. shRNAs with a Log2FoldChange value of less than 0 indicate depletion 
through the screen, whereas those greater than 0 indicate enrichment. 
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Figure 4.7 shRNA differential expression scoring between conditions using Median Z 
Scores. Significantly differentially expressed shRNAs called using Median Z Scores for 
coculture plus (A) gemcitabine, (B) DMSO, and monoculture plus (C) gemcitabine and (D) 
DMSO. shRNAs were ranked based on Median Z Score value (standard deviations from 
population median expression), with shRNAs with a ≤-2 or ≥2 value (marked by red lines) 
considered significantly depleted or enriched, respectively. 
4.7 Evaluation of positive and negative screen controls 
To build confidence in hits resulting from the screen, it was important to verify that both 
technical and biological controls within the screen hold true. 
To assess this, four genes were assessed. As positive biological controls, Chek1 and Atr were 
selected. Each has been documented that through inhibition in vitro and in vivo sensitivity 
to gemcitabine is increased (Siang-Boon Koh et al., 2015; S. Liu et al., 2017; Parsels et al., 
2009; Prevo et al., 2012; Wallez et al., 2018),. Further, both have been targets of successful 
preclinical drug development programs, with molecules inhibiting their function currently or 
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previously being investigated in clinical trials (Banerji, Jones, and PLummer, 2017; Plummer 
et al., 2016). As a negative technical control, Prss2 was selected, a serine protease 
expressed exclusively in hormone-producing glandular cells (J. Gao et al., 2010). Hence it is 
not expected to modulate gemcitabine resistance in this model, as it is unlikely to be 
expressed in the cell types used. Finally, Dck was used as a negative biological control. Dck 
codes for deoxycytidine kinase, a key enzyme required for the phosphorylation and 
activation of gemcitabine  (dFdC) to dFdCMP (Ohhashi et al., 2008; Saiki et al., 2012). 
Therefore, through inhibition of its activity, cells are likely to become more resistant to 
gemcitabine, and shRNAs targeting this gene would enrich through the assay cycles as 
opposed to depleted like Chek1 or Atr. 
Using the DESeq2 calling methodology, two of the four shRNAs targeting both Chek1 and Atr 
were significantly depleted, therefore as genes being called as hits (Fig 4.8). Prss2 shRNAs 
showed minimal fold change variance when compared to the total mean, with no shRNA 
being significantly depleted or enriched. Finally, for Dck three of the seven targeting shRNAs 
were significantly enriched through the assay. So, while Dck as a gene did not match the 
criteria for being a hit, it did demonstrate a trend towards enrichment overall. Similarly, for 
median Z scores (Fig 4.9), both Chek1 and Atr were depleted hits, with Prss2 showing 
minimal change in either direction, and Dck again showing a trending but non-significant 
enrichment. Taken together the as-predicted results for the control genes add confidence 
that any novel hits coming out of the screen may have true mechanistic involvement in the 
gemcitabine resistance effect, and therefore hold potential translational value. 
112 
 
 
Figure 4.8 DESeq2 differential expression of select control shRNAs in coculture plus 
gemcitabine. shRNA differential expression data for positive (Atr, Chek1), technical (Prss2), 
and negative (Dck) controls was analysed, each targeting shRNA plotted as a single dot (red 
= significantly enriched or depleted). 
 
Figure 4.9 Median Z Score-called differential expression of select control shRNAs in 
coculture plus gemcitabine. shRNA differential expression data for positive (Atr, Chek1), 
technical (Prss2), and negative (Dck) controls was analysed, each targeting shRNA plotted as 
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a bar, y axis representing Median Z Score value. shRNAs above and below the red dotted line 
represent significantly enriched to depleted shRNAs respectively. 
4.8 Meta-analysis of screen data 
Verifying through controls that screen data holds validity, the real value of the project is 
investigation into novel genes being identified as influencers of the coculture resistance 
phenomenon. Specifically, those genes only depleted in the coculture indication plus 
gemcitabine. 
Beginning with a library of 18,402 genes, with over 7,000 shRNAs significantly depleted in 
the coculture plus gemcitabine condition across both scoring methodologies, it is imperative 
to segment and filter the total data into more actionable and valuable sets delivering clear 
insights into the biology behind the phenotype. To do this, a list was created of each gene 
scored as a hit within each assay condition, for each of the two differential expression 
scoring methodologies. Upon collation, each gene set was contrasted against each other set 
across each of the other three conditions. 
Initially, it was apparent that there were a higher number of hits being scored using median 
Z score when compared to DESeq2 to call differential expression across conditions (1513 to 
496 genes across all conditions respectively). This is not unexpected, and a product of the 
selection of hit calling thresholds for each methodology, as observed previously (Mendes-
Pereira et al., 2012). For the coculture plus gemcitabine condition for each tool, 
approximately 50% of the total hits across conditions were unique and absent from each of 
the other conditions, as per Figure 4.11 below. This provides a valuable confirmation that 
each scoring tool has no obvious skew towards certain conditions when compared against 
the other. 
As each methodology used to score differential expression inevitably introduces its own set 
of technical biases (Conesa et al., 2016; Finotello and Di Camillo, 2015; Soneson and 
Robinson, 2017) the inclusion of a range of scoring tools on the same dataset can provide an 
even more robust insight into the genes of interest (Mendes-Pereira et al., 2012). This 
assumes that for a gene to be scored as a hit between tools, it is more likely a true positive, 
as despite factoring in technical variations in calling hits between tools, it remains a hit in 
each. Applying this principle, I investigated the common hits between scoring tools for each 
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culture condition (Fig 4.10). 
 
Figure 4.10 Overview of common hits called between differential expression scoring tools 
for each screen condition. 
Within coculture plus gemcitabine 17.5% of hits were shared between DESEq2 calls and 
median Z score calling, or 186 genes. This represented only 19.4% of the median Z score 
hits, but 63.9% of the DESeq2 hits. This mirrors figures seen in other shRNA depletion 
screens using similar scoring methodologies (Mendes-Pereira et al., 2012). This subset of 
genes therefore warrants focus as potential true positives for gemcitabine sensitizers but 
does not warrant discounting of the non-common hits, given the propensity of the technical 
biases in scoring false negatives. 
This dataset and segmentation can be interrogated in a wide variety of ways, depending on 
the underlying hypothesis being tested. For this project, the most interesting dataset 
remains those genes only depleted in coculture plus gemcitabine and not in the other 
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conditions. To identify the number and proportion of significantly depleted genes unique to 
this condition the gene sets for each were compared for and segmented on commonality 
(Fig 4.11). For each scoring methodology the hits unique to the coculture plus gemcitabine 
condition made up approximately 50% of the total depleted genes across conditions (763 
genes for median Z score, 241 genes for DESEq2, with 137 genes common to both methods), 
providing a refined yet diverse subset for further analysis and interrogation.  These lists of 
genes are in Appendix 6.1 and 6.5. 
 
Figure 4.11 Venn diagram of genes scored as hits within each scoring methodology and 
each condition. Gene hits unique to the coculture plus gemcitabine condition only lie within 
red squares. These genes were used for further downstream pathway and network analysis.  
4.9 Pathway and network analysis of hits from coculture + gemcitabine 
Meta-analysis of screen data from a quantitative perspective aids the filtering of results 
from an un-biased perspective, building a list of genes likely to be involved in the observed 
phenotype. As genes are filtered down, introduction of more qualitative hypothesis-driven 
analysis can support further elucidation of genes with translational and actionable value. 
This can be performed using many techniques, such as pathway analysis, domain analysis, 
and survival analysis. 
4.9.1 GSEA 
To identify patterns of depletion in the coculture plus gemcitabine condition, gene set 
enrichment analysis (GSEA) was performed. GSEA is a computational tool to investigate 
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whether pre-assembled gene sets are significantly differentially expressed between two 
conditions (Subramanian et al., 2005), in this case coculture plus gemcitabine when 
compared to the timepoint zero control – specifically the list of 763  Z score hits and 241 
DESq hits (total 867 genes, with overlap (listed in Appendix 6.1)) unique to the coculture 
plus gemcitabine condition (Fig 4.11). The “hallmark gene sets” were investigated in 
particular (Figure 4.12), which comprises a range of gene signatures representing canonical 
biological processes, annotated from the molecular signatures database version 3 (Arthur 
Liberzon et al., 2011). 
From this panel, ShRNAs for multiple gene sets in both DNA repair and MYC signalling were 
significantly depleted (Appendix 6.2), both of which have documented evidence on their 
value as targets for combination therapy to sensitise to gemcitabine in cancer (Crul et al., 
2003; Lewis, Voelkel-Johnson, and Smith, 2016; Seo et al., 2014). In addition, the MTORC1 
signalling geneset was also one of the most significantly depleted sets, despite Mtorc1 not 
being scored as a hit from the screen originally. Within this MTORC1 geneset, contributing 
depleted genes included Aurka (Aurora Kinase A) and Asns (Asparagine synthetase), the 
former of which have been the subject of pre-clinical and in-human drug development 
efforts as a sensitizer to gemcitabine (Azzariti et al., 2011; Hata et al., 2005; Raymond et al., 
2014), and the latter of interest due to promising pancreatic cancer clinical data around the 
combination of gemcitabine with eryaspase, an L-asparaginase, which hydrolyses asparagine 
(Hammel et al., 2017). Other genesets of interest include TGF beta signalling, wherein both 
Tgfb1 and its cognate receptor Tgfbr1, as well as Smad3 and Smad7, downstream effectors 
of TGF-β1, were enriched in the coculture plus gemcitabine, correlating with reports of their 
contribution to cancer cell survival and growth (Culhaci et al., 2005; Melisi et al., 2008). 
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Figure 4.12 Gene Set Enrichment Analysis (GSEA) for the coculture plus gemcitabine 
condition (the 867 genes that were hits in z score and/or DESeq2) compared to timepoint 
zero shRNA representations. To identify specific gene networks with significant depletion in 
coculture plus gemcitabine, patterns of differential expression was assessed using GSEA, 
across a combination of hypothesis-driven and unbiased computationally curated networks. 
(A) The ranked depletion of gene sets within the “Hallmark” networks based on degree of 
depletion within networks compared to timepoint zero, alongside (B) an illustrative GSEA 
plot summarising the degree and gradient of depletion of specific genes within the a specific 
“Hallmark” gene set. 
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4.9.2 MetaCore 
Similarly, MetaCore (Thomson Reuters), a software suite for functional analysis of genome-
wide expression data, was used to further investigate biological processes of note depleted 
in the screen, comparing and contrasting with both the coculture and monoculture plus 
drug conditions, as well as within their total sets combined. Each gene network and pathway 
indexed within MetaCore collates data from on average of 50 genes. Due to a total of only 
827 genes assessed for pathway convergence (the total number of genes depleted in the 
coculture plus gemcitabine condition only) the degree of depletion within specific gene 
processes or networks was limited, often only two or three genes within a pathway 
depleted to highlight the pathway as one of interest. Nevertheless, this tool provides a 
further guiding indicator of pathways worth further exploration. As with the GSEA findings, 
within each culture condition plus drug it is pathways around cell cycle and checkpoint 
control that through depletion sensitise to gemcitabine, further correlating the screen data 
with known successful combinatorial strategies in pancreatic cancer (Fig 4.13). For example, 
the “Cell cycle_G2-M” network leads depletion level within this geneset. Within this 
grouping, it is a depletion of genes such as Chek1, Brca1, Erk1, as well as Aurka and Rps6ka1, 
that lead to network depletion level, all of which are known chief mediators of cell cycle 
progression in cancer (Bartek and Lukas, 2003; Chambard, Lefloch, Pouysségur, and 
Lenormand, 2007; Deng, 2006; Fu, Bian, Jiang, and Zhang, 2007; Smith et al., 2005).  
Similarly, two pathways relating to cellular response to DNA damage present as highly 
depleted (“DNA damage_checkpoint” and “DNA damage_DBS repair”), which as mediators 
of cell cycle progression when repairing DNA, corroborate the findings of the cell cycle-
specific pathways mentioned above.  
Conversely, the “Proteolysis Ubiquitin-proteasomal proteolysis”, the 5th ranked depleted 
network does not have an obvious role in modulating gemcitabine efficacy. A network of 
166 genes, it is only 21 genes within this network that through depletion contribute to the 
total network score. These genes often have minimal interaction and maintain diverse 
functions, with the depleted genes within this set including DDR-related genes such as 
Bard1 and Hsp90, as well as Siah2, an E3 ubiquitin-protein ligase regulating cellular response 
to hypoxia, and Usp7, a direct antagonist of MDM2, the E3 ubiquitin ligase for P53. As such, 
whilst network analysis holds value in highlighting broad patterns of co-depletion and inter-
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relatedness, a further step of interrogation into the specific drivers within these subsets is 
required. An expanded list of the specific depleted genes per MetaCore network can be 
found in Appendix 6.4. 
 
Figure 4.13 MetaCore pathway analysis for hits specific to the coculture plus gemcitabine 
condition (827 gene set that were hits in z score and/or DESeq2).  
4.9.3 PANTHER 
Pathway and network analysis tools such as GSEA and MetaCore derive value through 
aligning data with previously documented and annotated gene sets. This fundamentally 
introduces a degree of bias by informing network relationships from pre-existing biological 
documentation. To remove an element of this bias from the analysis, network clustering 
was undertaken using predicted evolutionary relationships between genes through analysis 
of sequence divergence, powered by the PANTHER classification system and bioinformatic 
algorithms (Mi et al., 2017, 2013). Looking at the coculture condition plus gemcitabine gene 
set, clustering and classifying by predicted molecular function (Figure 4.14), extracellular 
binding and signalling (Table 4.3), along with molecular transporters (Table 4.4) were each 
indicated as functional classes depleted within the set. Further within the binding subsets it 
was the receptor binding subset with the highest representation. Within the transporter 
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subset it was those genes coding for transmembrane transporters that were most highly 
represented (Fig 4.14). These results suggest cells may be leveraging some form of novel 
extracellular signalling and engagement from coculture and density growth to drive the 
observed resistance phenomenon. These cell surface proteins may potentially represent a 
set of actionable genes of interest. Further genesets analysed include those within the 
catalytic subgroup as defined by PANTHER, as have been collated in Appendix 6.3. 
 
Figure 4.14 PANTHER pathway analysis highlighting actionable gene sets of interest within 
the coculture plus gemcitabine condition (the 867 genes that were hits in z score and/or 
DESeq2). (A) PANTHER (Protein ANalysis Through Evolutionary Relationships) (Mi et al., 
2017)(Lewis et al., 2016)  was used to identify underlying protein classes correlating with 
depletion in the coculture plus gemcitabine screen condition. Each class was further 
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interrogated as per (B) and (C) to refine to a qualitative gene list amenable to identification 
of hypothesis-driven targets. 
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PANTHER: Binding > Protein binding > Receptor binding 
Gene code Details 
Apof Apolipoprotein F 
Cck Cholecystokinin 
Cd28 T-cell-specific surface glycoprotein CD28 
Crh Corticoliberin 
Efna4 Ephrin-A4 
Elf1 Ephrin-A2 
Elmod3 ELMO domain-containing protein 3 
Fgf3 Fibroblast growth factor 3 
Gcg Glucagon 
Ghr Growth hormone receptor 
Gm13271 MCG146419 
Hamp2 Hepcidin-2 
Klra3 Killer cell lectin-like receptor 3 
Nrg2 Pro-neuregulin-2, membrane-bound isoform 
Pdgfa Platelet-derived growth factor subunit A 
Pdgfd Platelet-derived growth factor D 
Plcg2 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 
Prl8a6 Prolactin-8A6 
Scg5 Neuroendocrine protein 7B2 
Sema4b Semaphorin-4B 
Sirpa Tyrosine-protein phosphatase non-receptor type substrate 1 
Tnfsf11 Tumor necrosis factor ligand superfamily member 11 
Traf3 TNF receptor-associated factor 3 
Table 4.3 Genes encoding for receptor-binding proteins whose ShRNAs are depleted 
selectively in the coculture model plus gemcitabine, classified using PANTHER. 
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PANTHER: Transporter activity > Transmembrane transporter 
Gene code Details 
Abcc9 ATP-binding cassette sub-family C member 9 
Apof Apolipoprotein F 
Aqp3 Aquaporin-3 
Atp6v0b V-type proton ATPase 21 kDa proteolipid subunit 
Atp6v1b2 V-type proton ATPase subunit B, brain isoform 
Cacna1f Voltage-dependent L-type calcium channel subunit alpha-1F 
Clic1 Chloride intracellular channel protein 1 
Clns1a Methylosome subunit pICln 
Fkbp10 Peptidyl-prolyl cis-trans isomerase FKBP10 
Gm14496 Protein Gm14496 
Kcnj14 ATP-sensitive inward rectifier potassium channel 14 
Orai1 Calcium release-activated calcium channel protein 1 
Sec14l2 SEC14-like protein 2 
Serinc3 Serine incorporator 3 
Slc14a1 Urea transporter 1 
Slc1a2 Excitatory amino acid transporter 2 
Slc38a2 Sodium-coupled neutral amino acid transporter 2 
Slc6a7 Sodium-dependent proline transporter 
Slc7a15 Aromatic-preferring amino acid transporter 
Tcirg1 V-type proton ATPase subunit a 
Timm17b Mitochondrial import inner membrane translocase subunit Tim17-B 
Vmn2r11 Protein Vmn2r11 
Vmn2r110 Protein Vmn2r110 
Vmn2r26 Vomeronasal type-2 receptor 26 
Vmn2r50 Protein Vmn2r50 
Vmn2r57 Protein Vmn2r57 
Vmn2r77 Protein Vmn2r77 
Vmn2r94 Protein Vmn2r94 
Vmn2r95 Protein Vmn2r95 
Table 4.4 Genes encoding for transmembrane transporter proteins that are depleted 
selectively in the coculture model plus gemcitabine, classified using PANTHER. 
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4.10 Design and implementation of a validation screen to refine gene target list 
There are major inherent challenges around biological and technical biases and 
reproducibility in large scale high-throughput screens, including for technologies such as 
CRISPR and RNA interference. This can drive a high false positive rate, often a product of off-
target effects, the latter of which is widely documented as a confounding factor in data 
analysis (Jackson and Linsley, 2010). The primary risk of using shRNAs in a depletion screen 
is off-target effects, wherein an shRNA will appear to be depleted when an off-target non-
specific effect decreases the viability of a cell type either in general or when exposed to 
gemcitabine. To counter this in the primary multiple unique shRNAs were included per gene, 
only scoring a gene as a hit when a majority of its shRNAs were significantly depleted.  
However, the large number of hits required further filtering to identify the most robust hits 
to follow up. 
Taking a more refined panel of genes highlighted as potentially causative of gemcitabine 
resistance in the initial screen, a second more targeted validation screen was designed. For 
this screen, 1,973 genes were collated from a variety of sources, including all hits coming 
from the initial coculture and monoculture plus gemcitabine conditions, the gene sets from 
the most significantly depleted GSEA networks, as well as some hypothesis-driven panels, 
such as enzymes involved in the gemcitabine metabolic and transport processes.  These 
were combined with a panel of 200 human olfactory receptors to serve as negative controls. 
Within this screen there was an average of 4.21 shRNAs targeting each gene (Fig 4.15), as 
opposed to 3.46 for the initial screen, thereby serving to minimise off-target related false 
positives. 
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Figure 4.15 The number of shRNAs targeting each gene within the validation screen library 
used. 
The screen protocol was replicated as per before, with six cycles of gemcitabine used for 
each condition of coculture and monoculture either plus gemcitabine or plus DMSO control. 
Data was analysed for differential expression within each condition using the same two 
scoring methodologies as above, DESeq2 and median Z scores. 
Hit rates across each condition, except for coculture plus gemcitabine, were all significantly 
lower than in the initial screen, a product of validation screen library being built specifically 
to interrogate the hits arising from the coculture plus gemcitabine condition primarily.For 
the coculture plus drug condition, 17.2% of the library shRNAs were scored as significantly 
depleted when combining scoring methodologies, when compared to only 8.5% from the 
initial screen, indicating the targeted focus on this condition was evident in the output data 
(Table 4.5, Fig 4.16, 4.17). 
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Condition 
Median Z score DESEq2 
shRNAs genes shRNAs genes 
Coculture + gemcitabine 1343 299 1317 281 
Coculture + DMSO 221 40 164 11 
Monoculture + gemcitabine 210 39 118 7 
Monoculture + DMSO 157 35 66 5 
Table 4.5 Number of shRNAs and genes in the validation screen (1973 genes targeted in 
total) significantly depleted within the coculture and monoculture conditions +/- 
gemcitabine, when compared to timepoint zero. 
 
Figure 4.16 Differential depletion and enrichment of shRNAs in the validation screen 
calculated using Median Z Score.  
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Figure 4.17 Differential depletion and enrichment of shRNAs in the validation screen 
calculated using DESeq2.  
Reproducing the outcome from the initial screen, both Chek1 and Atr both were scored as 
significantly depleted in the coculture plus gemcitabine condition, again adding confidence 
to the biological relevance and translational value of hits coming out (Fig 4.18). Similarly, 
Dck as a biological negative control, as its depletion increases gemcitabine resistance, was 
significantly enriched in the validation screen. Results held true through both for DESeq2 
and median Z score scoring methodologies. 
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Figure 4.18 Differential expression of validation screen control shRNAs. (A) Differential 
expression levels of positive controls Atr and Chek1 alongside negative control Dck from 
validation screen data, using both Median Z Scores. A value of ≤-2 is considered significant 
depletion of the corresponding shRNA. (B) Differential expression levels of the same shRNAs 
scores using DESeq2, with significant enrichment or depletion (padj ≤ 0.05) represented using 
red dots. 
Interrogating the validation screen data there were 299 genes significantly depleted using 
median Z scores, which is 31% of the number called from the original screen. This contrasts 
with the DESeq2 output, wherein the 281 genes depleted in the validation screen was 
similar to the number called in the original screen (291). The median Z score total is reduced 
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to such an extent given the validation screen gene list had a strong skew towards genes with 
a role in the gemcitabine resistance effect, therefore the median expression level within the 
pool would be skewed similarly. As Z score is a relative score based on the median 
expression level in the entire population, a cut off of a < -2 Z score is significantly more 
restrictive. Whereas for DESeq2, with MA plots across conditions show similar distributions 
when compared to the timepoint zero population, indicating that calls of significance 
remain valid within the validation screen. 
  
 
Figure 4.19 Validation screen common hits between differential expression scoring 
methodologies in coculture plus gemcitabine condition exclusively. 
Of interest was the consistency of hit calling for each scoring methodology between the first 
screen and the validation screen. For median Z scores, approximately 43% of the hits 
exclusive to coculture plus gemcitabine in the validation screen were also hits in the original 
primary screen, whereas for DESeq2 this figure was lower at 17% (Fig 4.20). The additional 
hits called from the validation screen may be a product of the additional shRNAs added per 
gene in the validation screen involved in the networks and pathways of interest, which did 
not themselves significantly deplete in the primary screen but are associated with pathways 
that did exhibit depletion. Overall, the combined hit list from the validation screen supports 
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more thorough investigation into select biological process highlighted from the initial 
screen. 
 
Figure 4.20 Common hits for DE methodologies between the initial whole-genome screen 
and the subsequent validation screen. Shared hits between initial shRNA screen and 
validation screen in the coculture plus gemcitabine condition only for each of (A) Median Z 
Score and (B) DESeq2 differential expression scoring techniques. 
4.11 Qualitative identification of highest confidence genes driving gemcitabine resistance 
effect in coculture 
The goal of the validation screen is to support filtering the screen data into as refined and 
high confidence a data set as possible. Analysis and integration thus far of validation screen 
data has focused on those hits called exclusively in the coculture plus gemcitabine 
condition, and common between differential expression scoring methodologies. While this 
approach holds value, the inclusion of a direct comparison to hits conserved in monoculture 
plus gemcitabine also supports control comparisons and identification of target genes with 
value in both culture settings. 
To leverage these datasets to build final refined hitlist, all hits exclusively in the coculture 
plus gemcitabine condition were collated, as well as those present in this condition but not 
exclusive to it, using both scoring methodologies, across both screens. These sets were then 
compared to identify genes consistently called within all four sets, under the hypothesis that 
these genes, maintaining significant depletion, factoring in all technical and biological 
biases, would be the highest confidence hits. 
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The subset exclusive to coculture plus gemcitabine was comprised of 10 genes in total (Fig 
4.21A, Table 4.5). Included within the set was Chek1, validating the group as a positive 
control. The wider set including all hits from coculture plus gemcitabine common between 
scoring tools was expanded to 19 genes, which included Atr, a further positive control for 
the screen. Of note amongst both sets were a variety of genes with published evidence 
supporting a synergy through inhibition with gemcitabine treatment, including Desi1, Eif3e 
and Orai1. Of the 19 genes, 8 have commercially available inhibitors, with genes such as 
Arhgef5 with literature backing synergy with gemcitabine in pancreatic cancer (Takeda et 
al., 2016).  
 
Figure 4.21 Common gene hits between the primary and validation screen using each 
scoring methodology for the coculture plus gemcitabine condition. (A) Commonality of all 
hits exclusive to coculture plus gemcitabine, and (B) commonality of all hits for coculture plus 
gemcitabine, independent of presence in any other conditions.
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Gene P value* 
Coc + 
gem only 
Role in 
PDAC 
Reference 
Effect on gem 
sensitivity 
Reference Commercial inhibitor UniProt description 
Chek1 0.00398 Yes Yes 
(Sahu, Batra, and 
Srivastava, 2009) 
Yes 
(Siang-Boon Koh et 
al., 2015; Liang, Zhao, 
Ma, and Guo, 2017) 
AZD7762 
Checkpoint Kinase 1. Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest and activation of DNA repair in 
response to the presence of DNA damage or unreplicated DNA.  
Eif3e 0.0111  Yes (Doldan et al., 2008)     AZD2014 
Eukaryotic Translation Initiation Factor 3 Subunit E. Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for 
several steps in the initiation of protein synthesis. Bound to S6K1 in inactive state, activated through mTOR phosphorylation of S6K1 (Holz, Ballif, Gygi, 
and Blenis, 2005).  
Atr 0.0234  Yes 
(Fokas et al., 2012; S. 
Liu et al., 2017) 
Yes 
(S. Liu et al., 2017; Prevo 
et al., 2012; Wallez et al., 
2018) 
AZD6738, 
VE-821 
Ataxia Telangiectasia And Rad3-Related Protein. Serine/threonine protein kinase which activates checkpoint signalling upon genotoxic stresses such as 
ionizing radiation (IR), ultraviolet light (UV), or DNA replication stalling, thereby acting as a DNA damage sensor.  
Hsp60 0.0251  Yes 
(Mahajan, Gupta, 
Wagh, Karpe, and 
Tikoo, 2011; Piselli et 
al., 2000) 
  
Mizoribine (Itoh, 
Komatsuda, Wakui, 
Miura, and Tashima, 
1999; Meng, Li, and Xiao, 
2018) 
Heat Shock Protein Family D (Hsp60) Member 1. Chaperonin implicated in mitochondrial protein import and macromolecular assembly. Together with 
Hsp10, facilitates the correct folding of imported proteins.  
Desi1 0.0528 Yes Yes (Kang et al., 2014) Yes 
(Qiao et al., 2016; 
Zhu et al., 2012) 
Triptolide DeSUMOylating Isopeptidase 1. Protease which deconjugates SUMO1, SUMO2 and SUMO3 from some substrate proteins.  
Arhgef5 0.0751 Yes Yes (Komiya et al., 2016) Yes (Takeda et al., 2016)   Rho Guanine Nucleotide Exchange Factor 5. Guanine nucleotide exchange factor which activates Rho GTPases. Strongly activates RHOA and RHOB. 
Acer3 0.0921 Yes          Alkaline Ceramidase 3. Hydrolyses only phytoceramide into phytosphingosine and free fatty acid. Does not have reverse activity. 
Polr1b 0.183           
Subunit of the RNA polymerase I. DNA-dependent RNA polymerase catalyses the transcription of DNA into RNA using the four ribonucleoside 
triphosphates as substrates.  
Rmdn1 0.211 Yes          Regulator of microtubule dynamics protein 1. 
Lrp2 0.234 Yes Yes (Jones et al., 2008)      
Low density lipoprotein-related protein 2. Multiligand endocytic receptor. Acts together with CUBN to mediate endocytosis of high-density lipoproteins. 
Mediates receptor-mediated uptake of polybasic drugs such as aprotinin, aminoglycosides and polymyxin B. 
Supt5h 0.29 Yes          
SPT5 Homolog, DSIF Elongation Factor Subunit. Component of the DRB sensitivity-inducing factor complex (DSIF complex), which regulates mRNA 
processing and transcription elongation by RNA polymerase II.  
Rnf182 0.453 Yes          
Ring Finger Protein 182. E3 ubiquitin-protein ligase that mediates the ubiquitination of ATP6V0C and targets it to degradation via the ubiquitin-
proteasome pathway. 
Cox1 0.462  Yes (Omura et al., 2010)     Indomethacin Cyclooxygenase-1. Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. 
Srrm2 0.75           
Serine/arginine repetitive matrix 2.  Involved in pre-mRNA splicing. May function at or prior to the first catalytic step of splicing at the catalytic centre of 
the spliceosome. 
Orai1 0.856 Yes Yes 
(Kondratska et al., 
2014) 
Yes 
(Kondratska et al., 
2014) 
AnCoA4 
ORAI Calcium Release-Activated Calcium Modulator 1. Ca2+ release-activated Ca2+ (CRAC) channel subunit which mediates Ca2+ influx following 
depletion of intracellular Ca2+ stores and channel activation by the Ca2+ sensor, STIM1. 
Mvd 0.927          6-Fluoromevalonate Mevalonate Diphosphate Decarboxylase. Performs the first committed step in the biosynthesis of isoprenes. 
Tmem178b N/A           Transmembrane Protein 178B. 
Krtap16-8 N/A Yes          Keratin Associated Protein 16-8. 
Zfp213 N/A           Zinc finger protein 213. 
Table 4.6 List of 19 gene hits conserved between screens and scoring methodologies in the coculture plus gemcitabine condition. *P value refers to significance 
of survival differences for top and bottom quartiles of TCGA PDAC gene expression.
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From this list of 19 genes, the majority have little or no published literature exploring their 
biological function (Table 4.6), making qualitative data-driven analysis of their translational 
value a challenge. To compensate for this, expression data for pancreatic ductal 
adenocarcinoma was investigated from The Cancer Genome Atlas, a catalogue of key 
genomic changes and correlated survival analysis for 33 cancer types (Cancer Genome Atlas 
Research Network et al., 2017), to evaluate correlations between top and bottom quartiles 
of expression with survival of patients with PDAC. Only four genes showed significant 
differences between the quartiles: Chek1, Atr, Eif3e, and Hsp60 (Hspd1), with high 
expression correlating with worse survival in all 4. Given the known therapeutic value of 
targeting Chek1 and Atr (Banerji et al., 2017; Prevo et al., 2012; Wallez et al., 2018), Eif3e 
and Hspd1 were of interest, both with commercially available inhibitors targeting the 
pathway, and documented roles in PDAC pathophysiology (Table 4.6). 
 
Figure 4.22 Kaplan–Meier survival plots for TCDA PDAC data comparing top and bottom 
quartile gene expression for each of (A) CHEK1, (B) EIF3E, (C) ATR, and (D) HSP60. These 4 
genes showed significant difference (P values in Table 4.6) 
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4.12 Conclusion 
I have here leveraged the unbiased, explorative, and high-throughput properties of an 
shRNA depletion screen to identify drivers of gemcitabine resistance in high-density 
conditions in pancreatic cancer, leveraging the coculture model of resistance documented 
and characterised in Chapter 3. An initial primary genome-wide screen allowed for 
prioritisation and targeting of specific networks and pathways potentially implicated in the 
resistance effect. These included those involved in previously documented causative 
pathways such as DNA damage response, as well as novel yet hypothesis-driven functional 
groups such as those involved in cell-cell molecular transportation and extracellular 
signalling. Noting the challenge of the volume of resulting data for high-confidence analysis 
as well as potential for false positive results arising from screens of this size, a smaller more 
targeted validation screen was undertaken, here investigating further gene lists and 
networks selected from the primary screen as potentially causative of the resistance effect. 
Through analysis of this dataset, using two differential expression scoring methodologies 
and comparisons with equivalent conditions in the initial screen, a high-confidence subset of 
19 genes, some of which are potentially actionable, was identified. Within this subset both 
Chek1 and Atr remained, two of the strongest positive controls within this model with 
validated positive translational data in vivo as well with preparations for human clinical 
programs ongoing (Banerji et al., 2017; Wallez et al., 2018). Amongst the other 17 genes, 7 
have previously documented roles in PDAC pathophysiology, and 6 with commercially 
available inhibitors, and 5 with previous studies demonstrating synthetic lethality with 
gemcitabine in PDAC in vitro. Subsequent pre-clinical validation of these subsets would 
include testing existing inhibitors where available, perhaps preceded by genetic knockdown 
and knockout techniques for more specific investigations into gene functions in the context 
of coculture gemcitabine resistance. The strength of the positive and negative controls 
through this project provide confidence that novel less understood genes and pathways 
highlighted here may indeed be drivers of gemcitabine resistance in pancreatic cancer yet 
undiscovered and warranting further pre-clinical focus and validation.  
A valuable line of further investigation focused on the continuation of above, would be 
deeper interrogation of the specific sensitising effects of each of the 19 genes identified 
here within the coculture model of resistance. As well as testing with individually expanded 
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shRNA sets, one could also expand the cell lines within which these effects are tested, 
alongside use of other genetic manipulation techniques such as CRISPR or siRNA. Such 
investigations might further expand the nuances of each gene’s effect on the resistance 
phenotype and serve as valuable data informing future in vivo experimentation. 
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5. Discussion 
 
5.1 Introduction 
Cancer drug development is both a time and cost intensive process, coupling robust efficacy 
studies with evaluations of toxicity tolerability profiles within patients. With less than 4% of 
all oncology-focused compounds entering Phase I clinical trials emerging the other end as 
approved compounds (Wong, Siah, and Lo, 2018), the failure rate is a significant challenge. 
This challenge is exemplified at its fullest within pancreatic cancer, wherein low approval 
rates compound the lack of improvement in patient survival over the last 40 years (Cancer 
Research UK, 2014a). This is further exacerbated by a lack of tools supporting pre-clinical 
development that can accurately predict efficacy outcomes by high-throughput approaches, 
whilst maintaining low cost. This project aimed to both improve the translational value and 
mechanistic understanding of pre-clinical models of drug development in PDAC, as well as 
leverage said models to build a novel list of high-confidence targets worth investigating 
further as mediators of gemcitabine resistance in patients with pancreatic cancer. 
5.2 Conferred resistance to gemcitabine within our model is transient and requires direct 
cell-cell contact. 
Mechanisms through which pancreatic tumours develop or maintain resistance to 
gemcitabine have been widely postulated and demonstrated in various models of the 
disease, such as a via depletion of intratumoural levels of the drug by non-cancer cells 
(Hessmann et al., 2017) as well as via enhanced abilities to restore the DNA damage induced 
by the drug (Siang-Boon Koh et al., 2015; S. Liu et al., 2017). Having developed a novel 
coculture model of gemcitabine resistance to PDAC within our lab, an initial step of this 
project prior to target identification and drug development was to better understand the 
specific conditions through which this effect was conferred, and the degree of influence 
each characteristic of the assay held in driving this effect.  
Previous studies suggest that cancer cells can develop therapeutic resistance via secreted 
factors derived from non-tumour cells within the tumour microenvironment (Albrecht 
Neesse et al., 2013; Omura et al., 2010; Straussman et al., 2012; Weekes et al., 2012). This 
model has been further postulated to drive gemcitabine resistance within pancreatic cancer 
in particular, leveraging the pancreatic CAF secretome (Duluc et al., 2015). The relevance of 
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this mechanism within our model was investigated in multiple ways. Firstly, I demonstrated 
that neither MH17031-conditioned medium (CM) nor CM from the coculture of both K8484 
and MH17031 cells was capable of inducing resistance in K8484 monoculture, nor secondly 
did exogenous addition of recombinant IL-6 or HGF induce any change, the former reported 
by Duluc et al as per above, the latter in a high throughput screen of CAF-driven resistance 
across cancers (Straussman et al., 2012). Further, previous work in our lab by Ruiling Xu 
assessed the effect of the MH17031 secretome via a transwell assay, to no effect (Xu, 2015). 
While these results are indicative of a secreted factor unlikely to be a key driver of the 
resistance effect, they also come with caveats. Were a causative secreted factor to either 
have a low half-life, and therefore not remain active in CM, or require paracrine signalling of 
a distance less than 1mm (transwell assay distance between cells), then neither of these 
assays would drive a resistance effect. Alternative tools that could have been used and not 
be affected by these properties include a micromachined silicon substrate created by Hui & 
Bhatia for the purpose of contact-independent close proximity coculture (Hui & Bhatia, 
2007). 
Together these data suggest that within our coculture model direct cell-cell contacts are 
required for driving the conferred gemcitabine resistance. The discordance with above data 
in PDAC may be derived from the observation in the Duluc paper that only CAFs expressing 
high levels of the somatostatin-1 receptor effected gemcitabine resistance via its secretome. 
Within both K8484 and MH17031, no detectable levels of this transcript were noted in RNA-
Seq data (J. Bramhall, F. Richards, unpublished), suggesting perhaps a different subset of 
cells are investigated here. Similarly, my experiments show that the conferred resistance is 
transient, and requires constant cell-cell contact between K8484 cells and the resistance-
conferring line. This effect may mirror that observed in vivo, given growing tumour cells are 
constantly exposed to concurrently proliferating mesenchymal cells within the micro-
environment. 
Through addition of tetrahydrouridine (THU) within the coculture model I was able to 
evaluate the role CDA activity has in driving resistance to gemcitabine. THU is a competitive 
inhibitor of CDA, and therefore can prevent metabolism of active gemcitabine metabolites 
upon cell entry. High expression of CDA has been noted previously as a correlative factor 
linked to gemcitabine resistance in PDAC (Funamizu et al., 2010; Weizman et al., 2014). I 
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found that THU had no effect in sensitising cells to gemcitabine in coculture, across a wide 
concentration range. This mechanism of gemcitabine resistance in PDAC has been reported 
previously as a macrophage-driven phenomenon (Weizman et al., 2014), but not within 
fibroblast-like cells, which may indicate a CDA-modulated effect is not relevant in this duo-
culture. Further, recent work by Hessmann et al showing pancreatic CAFs sequester 
gemcitabine away from cancer cells suggests that independent of CDA activity within cancer 
cells (Hessmann et al., 2017), there may not be sufficient gemcitabine within these cells to 
induce an effect, which might also explain the result here. Despite the results documented 
above, further investigation into gemcitabine metabolism using mass spectrometry across 
CAF and cancer cell types in both monoculture and coculture conditions, matched alongside 
more in-depth classification of CAF subtypes used, would likely add valuable insights into 
the specifics of the CAF-driven effects of metabolism.  These findings could independently 
form an important line research towards development of improved clinical practice and 
dosing guidelines.  
These data together served to firstly demonstrate the requirement of direct cell-cell contact 
within this model, as well as further disqualify a number of documented gemcitabine 
resistance mechanisms in PDAC as drivers of the resistance phenomenon identified.  
5.3 Gemcitabine resistance in this model is driven by cancer cells, not cancer-associated 
fibroblasts.  
Next, I focused on identifying and understanding the specific subset of fibroblast-like cell 
capable of conferring resistance to gemcitabine within our model. As MH17031 cells exhibit 
a broadly mesenchymal morphology and were isolated originally using a traditional and 
documented tumour outgrowth method of CAF isolation, they were labelled as such within 
the lab. The initial hypothesis was therefore that CAFs within the PDAC tumour were the key 
factor driving the observed effect. This hypothesis was compounded with a wide body of 
pre-clinical and clinical investigations successfully targeting this stromal component to 
ablate gemcitabine resistance (Duluc et al., 2015; Hessmann et al., 2017; K. P. Olive et al., 
2009; Shan et al., 2017).  
The ability of MH17031 cells to confer resistance to gemcitabine was contrasted against 
non-CAF cells including the pancreatic stellate cells NF18073, a mouse embryonic fibroblast 
line, as well as the canonical 3T3 fibroblast line. The fact that only MH17031 conferred 
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resistance here aligned with the hypothesis of a cancer-related fibroblast line driving the 
effect.  This effect was mirrored in the coculture of MH17031 cells with the human PDAC 
line MIA PaCa-2, supporting the likelihood of a conserved mechanism relevant in the human 
form of the disease. 
To better understand the cellular profile of the resistance-conferring MH17031 cells, levels 
of both epithelial and mesenchymal protein markers were assessed and contrasted to the 
K8484 cancer line and the PSC line NF18073. Surprisingly, the MH17031 line expressed an 
almost exclusively epithelial signature through high expression of E-Cadherin and low or 
K8484-matched expression of mesenchymal markers such as αSMA, N-Cadherin, and 
Vimentin. Further, immune-fluorescence images indicated that MH17031 cells may also be 
mutant for P53. These findings were corroborated by RNA-Seq data across each of the three 
cell lines, further adding confidence to this unexpected observation. It was postulated that 
given the mesenchymal morphology of MH17031 cells, that they may have undergone EMT, 
as epithelial cells originally. This hypothesis was tested through investigation of EMT-related 
gene signatures in the line. While MH17031 did match K8484 cells in lacking expression of 
key EMT drivers such as SNAI1 and SNAI2, it expressed higher levels of both TWIST1 and 
ZEB1, all of which were highly expressed in NF18073. Thus, MH17031 clearly expressed both 
epithelial markers (e.g. E-Cadherin) and mesenchymal markers (Twist1, Zeb1), which 
suggested a cell type of epithelial origin that had undergone partial EMT.   
Given the defined genetic manipulation within the KPC mouse model to induce tumour 
development, the specific origin of cell lines, in particular within the pancreatic epithelial 
lineage, could be assessed. To do this, PCR genotyping was used to assess Kras and Tp53 
status within the cell line, with K8484 and NF18073 cell lines as controls. Mutant Kras was 
not detected within MH17031, whereas it was within K8484 cells, which alone indicated the 
cells may not to be epithelial tumour-derived. This result was contradicted when MH17031 
cells were shown to express mutant Tp53 through a recombined LSL locus. Given cre 
recombinase expression is driven by expression of the pancreatic epithelial gene Pdx1, this 
result suggested that MH17031 may indeed be derived from an epithelial lineage. Given the 
contradictory nature of these results, additional primer pairs were used, providing the same 
paradoxical result, of genetic recombination in the Tp53 transgene but not Kras. This result 
may be explained by a number of theories. Firstly, leaky expression of cre recombinase in 
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mesenchymal cells may lead to recombination of only one of the LSL sites, and therefore 
lead to expression of either mutant Tp53 or mutant Kras. Divergence in recombination 
efficiency between LSL sites has been reported previously, which may explain this 
observation (Vooijs, Jonkers, and Berns, 2001). Also, stimuli-independent production of cre 
recombinase has been reported in another model of pancreas development, the RIP-CreER 
mouse, which while based upon basal reporter activity not relevant in the KPC mouse, 
serves to warn of potential non-specific LSL recombination is mouse models (Yanmei Liu et 
al., 2010).  
Secondly, intercellular vesicular transport of cre recombinase may also lead to variable 
recombination levels in recipient cells. Extracellular vesicular transport of protein and 
genetic information has been documented (Costa-Silva et al., 2015), and its relevance 
specifically between cancer cells for cre recombinase mRNA transfer in vivo has been 
further demonstrated (Zomer et al., 2015).  
Lastly, the sensitivity of the PCR genotyping assay may prevent accurate detection of mutant 
kras in MH17031, as the PCR product was not abundant even in K8484 cells, the defined 
epithelial line. This might be further compounded if MH17031 is a mixed population 
therefore with lower levels of mutant transcripts, although IF protein data revealed a 
relatively homogenous expression level of epithelial cell markers throughout the population.  
This result not only challenges the initial assignment within our group of MH17031 being of 
CAF origin, but also serves to potentially challenge CAF cellular identity in existing literature, 
factoring in the documented prevalence of EMT in PDAC and therefore subsets of epithelial 
cells developing mesenchymal properties. This challenge is exemplified in a recent paper by 
Hessmann et al where it appears that isolation of CAFs, verified through similar PCR 
genotyping, may have led to misinterpretation of phenotypically mesenchymal cells as 
genotypically mesenchymal.  These cells were used as validation of our CAF-driven 
resistance within our model, inducing significant resistance. This study exemplifies the 
challenge of isolating pure pancreatic CAFs. The absence of this validation technique in the 
majority of CAF-focused studies may lead to a larger number of misclassifications and 
therefore misinterpretations of phenotypic effects.  
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In order to test the original hypothesis that pancreatic CAFs do drive resistance within this 
model, a series of lines were isolated from tumours of KPC GEDA mice using the differential 
trypsinisation technique, validated for Kras and Tp53 wildtype status, and checked for 
mesenchymal morphologies and high expression of αSMA. From an initial isolation of 384 
single cell clones from this population, 2 validated CAF cell lines under the above definition 
were isolated, GDF14 and GDF17. This extremely low plating efficiency using two canonical 
techniques (differential adhesion and differential trypsinisation) further exemplifies the 
need for thorough validation of cell line origin prior to subsequent CAF analysis. Within the 
coculture model neither cell line conferred gemcitabine resistance to K8484 cells. These 
data indicate that at least within our model system, true CAFs do not confer resistance to 
gemcitabine. 
Of particular interest both for our model here described, as well as any translational value 
subsequently derived, when K8484-mVenus cells were bedded on K8484 cells at the same 
1:10 ratio used with MH17031 cells, resistance to gemcitabine was induced to an equal level 
as to that seen when in coculture with MH17031. This result, coupled with the genotyping 
above, suggested that the resistance effect observed within our coculture model is not 
necessarily a product of CAF coculture, but perhaps more a product of cancer-on-cancer 
culture, or perhaps high-density cancer growth.  
5.4 Cancer cell-driven resistance is a product of cell density-related signalling and not an 
assay artefact. 
Next, focusing on the cancer cell on cancer cell resistance result, I queried whether the 
resistance phenomenon may be simply an artefact of the coculture assay and not a 
reflection of a true and clinically relevant resistance mechanism. Noting the relatively high 
proliferation rate (doubling time of 20 to 24 hours) and therefore high cell density at assay 
completion of the K8484 and MH17031 cells, I assessed whether the initial seeding ratio/cell 
number used within the cancer cell-on-cancer cell assay modulated the degree of induced 
resistance. From a gemcitabine GI50 of 22nM when K8484 cells were seeded at 2,000 cells 
per well, this increased to 52nM, 1µM, and above the limit of quantification for each of the 
5,000, 10,000, and 20,000 cells per well initial seeding count respectively. This suggested 
that the resistance effect observed, both with cancer cell monoculture as well as in 
coculture with MH17031, may be a direct product of cell density. The observation that the 
142 
 
other fibroblastic lines tested did not drive resistance despite similar seeding densities, may 
be a product of lower proliferation rates leading to lower cell density through the assay or 
contact inhibition preventing cellular accumulation, although the use of the protein-
quantifying SRB assay indicated to an extent that cell numbers were similar between 
resistant and non-resistant coculture assays. In future experiments to better appraise the 
effect of density for non-resistance driving cells, I would employ more rigorous models of 
density assessment, to ensure it is controlled for between resistance-driving and non-
resistance-driving cells, such as normalisation of nuclear counts at completion of the assay, 
not at the start.   
Density-driven resistance phenomena have been reported previously, including in PDAC, 
adding credence that such a mechanism may contribute to the effect here observed 
(Chauffert et al., 1998; Y. Fang et al., 2007; Garrido et al., 1995). To assess whether this was 
an assay artefact or a true mechanism of gemcitabine resistance specifically, the experiment 
was replicated with the platinum-based antineoplastic oxaliplatin and the nucleoside analog 
5-FU. While cell density had a minor effect in both in increasing resistance within K8484 
cells, neither was shifted in the order of magnitude observed with gemcitabine, suggesting 
that the resistance mechanism was specific in some form to gemcitabine only.  
As cell density is typically a product of cell proliferation rate as well as non-contact-inhibited 
growth, I re-designed my gemcitabine sensitivity analysis to control for the former. To do 
this, I used the GR metric, as developed by Hafner et al 2016, to evaluate gemcitabine 
sensitivities discounting for proliferation rate differences (Hafner et al., 2016). Within this 
analysis K8484 cells in coculture with MH17031 retained a significantly increased GR50 
metric when compared to monoculture or coculture with either NF18073 or with a mouse 
embryonic fibroblast line. Cell line independent correlative analysis of gemcitabine GI50 to 
proliferation rate identified a notable and significant effect of growth rate of gemcitabine 
efficacy, but with a Spearman coefficient of < 0.7, is unlikely the sole contributor to the 
observed effect. Together these data indicated that while proliferation rate of cells is a 
known modulator of gemcitabine efficacy, it is likely not the sole contributor towards the 
effect within this model.  
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5.5 Development and validation of a high-throughput shRNA screen to interrogate 
gemcitabine resistance mechanisms. 
Developing and validating a novel coculture model of gemcitabine resistance in vitro, I 
focused on leveraging this model in a high-throughput screening fashion to identify 
candidate targets and pathways causative in this phenomenon. To achieve this, and in 
collaboration with Nicolas Erard in the group of Professor Greg Hannon, I performed a 
whole-genome shRNA depletion screen within the K8484 cells both in monoculture in 
coculture with MH17031 cells with and without gemcitabine exposure. The primary goal 
was to identify the genes that when knocked down in the coculture plus gemcitabine 
condition specifically, when compared to a timepoint zero population, sensitised the cell to 
gemcitabine. Therefore, depletion in this condition of an shRNA suggested a causative role 
of its corresponding gene in driving the resistance effect.  
Demonstrating that the resistance phenomenon was maintained when scaled into 15cm 
dishes, required to process the volume of cells cultured for the screen, an initial screen was 
undertaken using a whole-genome shRNA library, designed using the shERWOOD algorithm 
to optimise for potency and minimise off-target effects of the shRNA constructs (Knott et 
al., 2014). Differential expression was scored with two differed computational 
methodologies to increase true positives being missed and decrease false positive 
detection, due to methodology-specific artefacts or biases. 
From this initial screen, a total of 827 genes were scored as hits within the coculture plus 
gemcitabine condition exclusively by at least one of the two scoring methodologies, DESeq2 
and Median Z Scores, of which 137, or 15.8% of this total, were scored as hits by both. 
Preliminary pathway analysis using gene set enrichment analysis as well as MetaCore 
clustering and PANTHER sequence analysis revealed pathways such as MTORC1 signalling, 
DNA damage responses, and receptor-binding functional subgroups as key implicated 
pathways within this subset of genes. Positive controls for modulating gemcitabine 
sensitivity in this model as well as in vivo and in some cases in human, such as Chek1 and Atr 
(Siang-Boon Koh et al., 2015; S. Liu et al., 2017; Prevo et al., 2012), held through following 
analysis of the primary screen data. This congruency with established literature provides a 
degree of confidence in the translational predictability that might be achieved through 
screening in this format.  
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5.6 Identification of 19 high-confidence genes with potential clinical value as mediators of 
gemcitabine resistance in patients.  
siRNA-mediated RNA interference screens have been used previously to investigate 
different biological functions within pancreatic cancer (Azorsa et al., 2009; Bhattacharjee, 
Zhou, and Yen, 2014; Fredebohm, Wolf, Hoheisel, and Boettcher, 2013; Henderson et al., 
2011; Sasaki et al., 2017). While this technique holds value, the more transient nature of 
siRNA vs shRNA knockdown, as well as the lower specificity (Klinghoffer et al., 2010) renders 
shRNA screening of additional value. Advent of CRISPR screening presents another novel 
approach to genome-wide targeting studies, although evidence thus far suggests that while 
both shRNA and CRISPR screening can have common hit-calling value, true positives unique 
to each approach can still be identified (Morgens et al., 2016). 
As this was the first documented whole-genome in vitro shRNA depletion screen 
investigating gemcitabine resistance in pancreatic cancer, the output data has not been 
independently replicated.  Despite this there is some crossover with existing similar 
datasets, for example Rad17, a previously reported hit in PDAC monoculture in a smaller 
screen was also a hit in the coculture plus gemcitabine condition here (Fredebohm et al., 
2013). To remove possible false-positives due to the off-target effects often ascribed to 
shRNA targeting (Jackson and Linsley, 2010; Persengiev, Zhu, and Green, 2004), I performed 
a validation screen with an expanded average number of new shRNAs targeting each gene. 
This included a refined gene list composed of those genes scored as hits in monoculture and 
coculture conditions plus gemcitabine, additional genes within their pathways and 
networks, as well as a panel of hypothesis driven genesets, totalling 1973 genes.  
Using the same scoring methodologies, within this validation pool both Atr and Chek1 were 
again significantly depleted in the coculture plus gemcitabine condition, alongside the 
enrichment of Dck as a positive control. 444 of the 1,973 genes were depleted through the 
screen in the coculture plus gemcitabine condition only, with 82 of these called using both 
scoring tools. This provided an increasingly smaller and higher-confidence panel of genes for 
targeted interrogation as drivers of the resistance phenotype. 
While pathway and network analysis can support refining of large datasets towards more 
actionable targets, it remains less effective when used to analyse smaller datasets, given the 
lower number of datapoints through which to identify true causative correlation. My goal 
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was to continue logical refinement of a gene list to the point at which gene by gene 
qualitative investigation was more feasible. To this end, the list of 82 genes was compared 
to the genes scored as hits in the coculture plus gemcitabine condition from the initial 
screen using both scoring tools. Amongst both datasets, 19 genes remained throughout, 10 
of which were exclusive to the coculture plus gemcitabine condition in each screen. 
Amongst these 19 genes were again Atr and Chek1, as well as 7 genes with an already 
documented role in PDAC development, 3 with reported synergy with gemcitabine through 
targeting, and 6 with commercial inhibitors available for purchase, supporting further 
downstream target validation. Genes were further ranked by the significance of correlation 
of expression level to survival in pancreatic cancer patients within the PAAD TCGA dataset. 
Aside from Atr and Chek1, the only genes to significantly correlate high expression to worse 
survival were Eif3e and Hsp60. Both genes are reported in studies that through their 
inhibition the carcinogenic process of PDAC is delayed (Doldan et al., 2008; Mahajan et al., 
2011; Piselli et al., 2000). Neither have been investigated in relation to their modulation of 
gemcitabine effect in PDAC. With inhibitors targeting the activity of each available, this may 
form a valuable line of future preclinical research within the model herein described.  
A chief challenge in analysing and creating actionable readouts from screens of this size, 
addressing any phenotype, is the potential valuable data and insights that may be lost 
through high signal to noise ratios and biased ranking systems. In order or refine whole 
genome data this is typically a balance: creating as high confidence a list as possible of true 
positive datapoints, while minimising inclusion of any confounding false negatives. Within 
this project I erred on the side of optimising for detection of true positives by using stringent 
hit calling criteria, coupled with repeat rounds of independent assaying with expanded 
shRNA sets. Thresholds through which hits were called for DESeq2 and Median Z Scores, 
while benchmarked against those used and validated elsewhere, may also exclude true 
positives that for reasons independent of their functional role, were not scored as hits 
consistently throughout each the initial and validation screen. 
5.7 Summary and future outlook.  
This project serves to undertake two of the imperative and arduous first steps of the drug 
development process – development of a model through which we can identify and validate 
therapeutic targets for chemoresistance in pancreatic cancer and leveraging of this model to 
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identify a confidence-ranked list of targets with potential clinical value. This is the first 
shRNA-mediated whole genome depletion screen investigating gemcitabine resistance 
mechanisms in PDAC in vitro in the context of a coculture system. 
The model itself was built with the observation that coculture of KPC cancer cells alongside 
KPC CAFs induced a 10 to 50-fold increase in gemcitabine resistance within the cancer cells. 
Further validation within this thesis verified the resistance effect to be a product of direct 
cell-cell contact, and unlikely to be mediated via secreted factors. Investigation in the 
identity of cell lines driving the effect led to the unexpected finding that the cell line driving 
the effect, MH17031, appeared to be a cancer cell in origin, confirmed via genotype and 
protein expression. Despite this observation, and the finding that true pancreatic CAFs 
herein defined did not modulate gemcitabine resistance in this model, the effect was 
deemed to be real, driven by cell density-related signalling, and not an artefact of the assay 
structure or protocol. Importantly, trialling of drugs known from in vivo and in human 
studies to be synergistic with gemcitabine within our model, yielded confirmatory and 
congruent data on the potential predictive utility of this assay.   However, those predictions 
would require further validation in other cell line models and/or in vivo studies, prior to 
being translated into clinical studies. 
Further development of this assay could focus on further interrogation of the cellular 
features causative of resistance in the model, as well as improving isolation and culture 
protocols for proliferative human CAFs, for evaluating in the same assay. The challenges 
faced in isolating pure CAFs from KPC murine tissue highlight the absolute importance in 
genotypic verification of mutation status prior to form and function investigation into 
murine CAFs for future studies. The heterogeneity of this cellular compartment is widely 
reported in the literature, and therefore isolation techniques should be suitably contrasted 
and understood when verifying the specific subtypes being studied. 
With an assay demonstrating a targetable gemcitabine resistance mechanism generating 
data congruent with clinical studies in pancreatic cancer, the use of a whole genome shRNA 
screen for preclinical target identification was a valuable next step. The challenge faced 
within the confines of a single PhD project is deciding an analysis pipeline yielding the most 
actionable data possible for subsequent research. My approach here was to use the 
addition of a validation screen to find common high-confidence genes that when depleted 
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revert gemcitabine resistance in the coculture model specifically. This refined list consisted 
of a panel of 19 genes, for which literature on each was studied for its known roles within 
pancreatic cancer, interactions with gemcitabine, and targetability with commercially 
available inhibitors. If this project were to continue, resources would focus on further 
validation of the top-ranked hits, including individual ShRNA knockdown experiments, and 
also testing the available inhibitors in vitro, before progressing to test promising therapeutic 
approaches in vivo.  In addition, further studies would include meta-analysis of total screen 
data, not only within the coculture plus gemcitabine condition, but also in the monoculture 
plus gemcitabine condition, as well as studying the signalling changes between monoculture 
and coculture DMSO control conditions. Whilst I have taken a very targeted approach to my 
refinement of genes here, the dataset remains a resource available for further genome-wide 
analyses, and a tool to investigate other hypotheses of gemcitabine effect in pancreatic 
cancer.  
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6. Appendix 
 
6.1 Gene hits in initial shRNA screen in coculture plus gemcitabine condition only.   
The list of 763 Z score hits and 241 DESq hits (total 867 genes, with overlap) unique to the 
coculture plus gemcitabine condition, related to Figure 4.11. 
Gene 
 
DESeq2 hit 
Median Z Score 
hit 
0610007L01Rik  Yes   
2310016M24Rik  Yes   
4732415M23Rik  Yes   
4922505E12Rik  Yes   
4933400C05Rik  Yes   
4933407C03Rik  Yes   
9530053A07Rik  Yes   
Aamp  Yes   
Actb  Yes   
Amn  Yes   
Arc  Yes   
Atp6v0b  Yes   
Aurka  Yes   
Bloc1s1  Yes   
Cacna1f  Yes   
Cap1  Yes   
Cd53  Yes   
Cdca8  Yes   
Chgb  Yes   
Chordc1  Yes   
Cldn13  Yes   
Clic1  Yes   
Cnot10  Yes   
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Cog6  Yes   
Cops5  Yes   
Cul9  Yes   
Cwf19l2  Yes   
Cyb5rl  Yes   
Cyhr1  Yes   
Dhx38  Yes   
Dscc1  Yes   
Dync1i2  Yes   
E030010A14Rik  Yes   
E130203B14Rik  Yes   
E130309D02Rik  Yes   
Efna4  Yes   
Eif5a  Yes   
Elof1  Yes   
Ewsr1  Yes   
Fads6  Yes   
Ffar1  Yes   
Gbf1  Yes   
Gcet2  Yes   
Gm5567  Yes   
Gm6985  Yes   
Gosr1  Yes   
Gpr3  Yes   
H2-M10.5  Yes   
Hnrnpc  Yes   
Hsp90ab1  Yes   
Il17b  Yes   
Il5ra  Yes   
Kbtbd5  Yes   
Lin7b  Yes   
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LOC547349  Yes   
Lrrc1  Yes   
March9  Yes   
Mat2a  Yes   
Mcm2  Yes   
Mettl21a  Yes   
Mrpl36  Yes   
Mtmr11  Yes   
Nasp  Yes   
Numa1  Yes   
Orc2  Yes   
Osgep  Yes   
Pdcd2l  Yes   
Pdha2  Yes   
Polr1b  Yes   
Ppp1cb  Yes   
Psma6  Yes   
Psma7  Yes   
Psmb3  Yes   
Psmc2  Yes   
Psrc1  Yes   
Rad23a  Yes   
Refbp2  Yes   
Rhox7  Yes   
Rps18  Yes   
Rps24  Yes   
Runx1t1  Yes   
Saa1  Yes   
Sbno1  Yes   
Sephs2  Yes   
Serbp1  Yes   
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Sf3a3  Yes   
Sf3b5  Yes   
Slc25a48  Yes   
Socs1  Yes   
Spats1  Yes   
Srsf6  Yes   
Ssrp1  Yes   
Supt4h1  Yes   
Supt6h  Yes   
Svs3b  Yes   
Tesk1  Yes   
Tk1  Yes   
Tnfsf11  Yes   
Tsga10  Yes   
Usp7  Yes   
Vmn1r205  Yes   
Ywhag  Yes   
Zcrb1  Yes   
Zfp512  Yes   
0910001L09Rik  Yes Yes 
1700014N06Rik  Yes Yes 
1700061J05Rik  Yes Yes 
1700065D16Rik  Yes Yes 
2410001C21Rik  Yes Yes 
2610044O15Rik  Yes Yes 
2900092C05Rik  Yes Yes 
4930432K09Rik  Yes Yes 
4931423N10Rik  Yes Yes 
4932415M13Rik  Yes Yes 
6330408A02Rik  Yes Yes 
A530099J19Rik  Yes Yes 
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Acer3  Yes Yes 
Adamts14  Yes Yes 
Agtrap  Yes Yes 
Amz2  Yes Yes 
Anp32b  Yes Yes 
Apcdd1  Yes Yes 
Apof  Yes Yes 
Arhgap25  Yes Yes 
Arhgef5  Yes Yes 
B3galt6  Yes Yes 
Bard1  Yes Yes 
BC031353  Yes Yes 
BC056474  Yes Yes 
Caml  Yes Yes 
Ccdc126  Yes Yes 
Ccdc129  Yes Yes 
Cd200r2  Yes Yes 
Cdc23  Yes Yes 
Chek1  Yes Yes 
Clec3a  Yes Yes 
Cops4  Yes Yes 
Csdc2  Yes Yes 
Cst3  Yes Yes 
Cux1  Yes Yes 
Cyp4a29-ps  Yes Yes 
Cytl1  Yes Yes 
Cyyr1  Yes Yes 
D17Wsu104e  Yes Yes 
D6Ertd527e  Yes Yes 
Ddrgk1  Yes Yes 
Dhcr24  Yes Yes 
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Dnttip2  Yes Yes 
Dpcd  Yes Yes 
Dus2l  Yes Yes 
Dusp14  Yes Yes 
Eif2ak4  Yes Yes 
Eif2s2  Yes Yes 
Ell  Yes Yes 
Ercc2  Yes Yes 
Evx2  Yes Yes 
Fam190a  Yes Yes 
Fam82b  Yes Yes 
Fosl2  Yes Yes 
Gapvd1  Yes Yes 
Glt8d2  Yes Yes 
Gltp  Yes Yes 
Gm11937  Yes Yes 
Gm13103  Yes Yes 
Gm14496  Yes Yes 
Gm7257  Yes Yes 
Gm7534  Yes Yes 
Gmnn  Yes Yes 
Gpr114  Yes Yes 
Hoxb6  Yes Yes 
Hspd1  Yes Yes 
Ifi27l1  Yes Yes 
Igbp1  Yes Yes 
Igf2bp1  Yes Yes 
Il17d  Yes Yes 
Il20ra  Yes Yes 
Klhl21  Yes Yes 
Krtap16-8  Yes Yes 
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Krtap5-3  Yes Yes 
Lce1e  Yes Yes 
Lman1  Yes Yes 
Lrp2  Yes Yes 
Mis18bp1  Yes Yes 
Mpi  Yes Yes 
Ms4a2  Yes Yes 
Mvd  Yes Yes 
Nbr1  Yes Yes 
Ndufa3  Yes Yes 
Nfix  Yes Yes 
Nfkbib  Yes Yes 
Nptn  Yes Yes 
Nr2c1  Yes Yes 
Orai1  Yes Yes 
Orc6  Yes Yes 
Pccb  Yes Yes 
Pcyt2  Yes Yes 
Pdcd10  Yes Yes 
Pdgfa  Yes Yes 
Pick1  Yes Yes 
Ppp1r11  Yes Yes 
Pppde2  Yes Yes 
Psmb4  Yes Yes 
Ptpro  Yes Yes 
Rbmxrt  Yes Yes 
Rif1  Yes Yes 
Rnf182  Yes Yes 
Rnf217  Yes Yes 
Scap  Yes Yes 
Scml2  Yes Yes 
155 
 
Scml4  Yes Yes 
Sec14l2  Yes Yes 
Senp6  Yes Yes 
Serpina10  Yes Yes 
Sfmbt1  Yes Yes 
Sgsh  Yes Yes 
Slc25a25  Yes Yes 
Slc9a3r2  Yes Yes 
Sp5  Yes Yes 
Supt5h  Yes Yes 
Tbc1d20  Yes Yes 
Tcfap4  Yes Yes 
Tfpt  Yes Yes 
Tgm2  Yes Yes 
Top1  Yes Yes 
Tram1l1  Yes Yes 
Trappc1  Yes Yes 
Tubgcp2  Yes Yes 
Txndc8  Yes Yes 
Tymp  Yes Yes 
Tyw3  Yes Yes 
Ubc  Yes Yes 
Ubxn10  Yes Yes 
Usp15  Yes Yes 
Usp39  Yes Yes 
Vmn1r20  Yes Yes 
Vmn1r212  Yes Yes 
Vmn2r94  Yes Yes 
Wfdc10  Yes Yes 
Wnk1  Yes Yes 
Zbtb7a  Yes Yes 
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Zfp142  Yes Yes 
1110012L19Rik    Yes 
1600014C10Rik    Yes 
1700013F07Rik    Yes 
1700040I03Rik    Yes 
2010015L04Rik    Yes 
2310001A20Rik    Yes 
2310010M20Rik    Yes 
2310046A06Rik    Yes 
2310061N02Rik    Yes 
2610034B18Rik    Yes 
2810002N01Rik    Yes 
2810021J22Rik    Yes 
2810030E01Rik    Yes 
3110079O15Rik    Yes 
3830417A13Rik    Yes 
4921504E06Rik    Yes 
4930571K23Rik    Yes 
4930578N16Rik    Yes 
4930579G24Rik    Yes 
4931417G12Rik    Yes 
4933407H18Rik    Yes 
4933421E11Rik    Yes 
8430406I07Rik    Yes 
A730037C10Rik    Yes 
Aarsd1    Yes 
Aatk    Yes 
Abcc9    Yes 
Abi3bp    Yes 
Abpa    Yes 
Acsl1    Yes 
157 
 
Adal    Yes 
Adam1b    Yes 
Adam21    Yes 
Adamts6    Yes 
Aes    Yes 
Afap1l1    Yes 
Afp    Yes 
Aftph    Yes 
Ahrr    Yes 
AI413582    Yes 
AI428936    Yes 
Akap17b    Yes 
Akap6    Yes 
Akap9    Yes 
Akirin1    Yes 
Aldh1l1    Yes 
Aldh1l2    Yes 
Alg5    Yes 
Anapc5    Yes 
Ankrd58    Yes 
Anpep    Yes 
Ap1s3    Yes 
Ap2m1    Yes 
Apbb1    Yes 
Aplp1    Yes 
Aqp3    Yes 
Arap2    Yes 
Arhgap9    Yes 
Arid5b    Yes 
Arl13b    Yes 
Arrdc3    Yes 
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Atg4b    Yes 
Atg9b    Yes 
Atl1    Yes 
Atp6v1b2    Yes 
Atr    Yes 
AU040320    Yes 
B230208H17Rik    Yes 
B630019K06Rik    Yes 
Batf3    Yes 
BC016495    Yes 
BC048679    Yes 
Bdp1    Yes 
Birc3    Yes 
Bmpr2    Yes 
Brap    Yes 
Brca1    Yes 
Brf1    Yes 
Brix1    Yes 
Btg2    Yes 
Bub1b    Yes 
C1qtnf6    Yes 
C1s    Yes 
C77370    Yes 
Cabp2    Yes 
Calr    Yes 
Camk1d    Yes 
Capn1    Yes 
Car5a    Yes 
Cbl    Yes 
Ccdc11    Yes 
Ccdc88b    Yes 
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Ccdc89    Yes 
Ccdc96    Yes 
Cck    Yes 
Cct2    Yes 
Cd28    Yes 
Cd300lg    Yes 
Cdc37    Yes 
Cdhr4    Yes 
Cebpa    Yes 
Cebpd    Yes 
Cenpk    Yes 
Cep192    Yes 
Cep63    Yes 
Chaf1a    Yes 
Chaf1b    Yes 
Chd4    Yes 
Chd8    Yes 
Chmp2a    Yes 
Chn1    Yes 
Chuk    Yes 
Ciita    Yes 
Ckap5    Yes 
Cldn22    Yes 
Clgn    Yes 
Clip3    Yes 
Clns1a    Yes 
Cmpk2    Yes 
Col11a2    Yes 
Cops6    Yes 
Cops7a    Yes 
Corin    Yes 
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Coro1c    Yes 
Cpa3    Yes 
Cpeb3    Yes 
Cpn2    Yes 
Cpped1    Yes 
Cpsf4    Yes 
Cpsf7    Yes 
Creb3l4    Yes 
Crh    Yes 
Csnk2a1    Yes 
Csrnp1    Yes 
Ctsb    Yes 
Cul7    Yes 
Cyp2d11    Yes 
Cyp39a1    Yes 
Cyp3a57    Yes 
D4Ertd22e    Yes 
Dach1    Yes 
Dars    Yes 
Dazl    Yes 
Dcaf12l2    Yes 
Dclk1    Yes 
Ddb1    Yes 
Ddx49    Yes 
Ddx54    Yes 
Defb8    Yes 
Dennd4b    Yes 
Depdc7    Yes 
Dgkg    Yes 
Dhrs9    Yes 
Dhx9    Yes 
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Dlgap4    Yes 
Dmrta1    Yes 
Dmxl1    Yes 
Dnahc5    Yes 
Dnaja4    Yes 
Dnajb6    Yes 
Dnajc2    Yes 
Dnm1    Yes 
Dnm2    Yes 
Dpp9    Yes 
Dpy19l4    Yes 
Dub1a    Yes 
Duoxa1    Yes 
Dusp15    Yes 
Dut    Yes 
Duxbl    Yes 
Ear10    Yes 
Ebf4    Yes 
Ect2    Yes 
Efcab1    Yes 
Egln3    Yes 
Eif3m    Yes 
Eif4ebp1    Yes 
Eif5b    Yes 
Elf1    Yes 
Elmod3    Yes 
Endou    Yes 
Entpd1    Yes 
Eny2    Yes 
Epb4.1l2    Yes 
Epha4    Yes 
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Epx    Yes 
Espl1    Yes 
Ext2    Yes 
F2r    Yes 
F3    Yes 
Fam131b    Yes 
Fam163a    Yes 
Fam184a    Yes 
Fam46c    Yes 
Fam98c    Yes 
Fancc    Yes 
Fancm    Yes 
Fastk    Yes 
Fastkd5    Yes 
Fbn1    Yes 
Fem1a    Yes 
Fgf3    Yes 
Fkbp10    Yes 
Flywch2    Yes 
Fmn1    Yes 
Fos    Yes 
Fosb    Yes 
Foxa1    Yes 
Foxf1a    Yes 
Foxj1    Yes 
Foxp2    Yes 
Fpr1    Yes 
Frmpd4    Yes 
Fuz    Yes 
Fxc1    Yes 
G6pc3    Yes 
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Gabra6    Yes 
Gal3st2    Yes 
Gapt    Yes 
Gata5    Yes 
Gbp3    Yes 
Gcg    Yes 
Gcn1l1    Yes 
Gfra3    Yes 
Ghr    Yes 
Gli2    Yes 
Glis3    Yes 
Glt6d1    Yes 
Gm11062    Yes 
Gm11565    Yes 
Gm11568    Yes 
Gm12171    Yes 
Gm13040    Yes 
Gm13212    Yes 
Gm13271    Yes 
Gm1661    Yes 
Gm2897    Yes 
Gm4934    Yes 
Gm4987    Yes 
Gm5595    Yes 
Gm5800    Yes 
Gm628    Yes 
Gm6762    Yes 
Gm8439    Yes 
Gm9112    Yes 
Gmeb1    Yes 
Gmppa    Yes 
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Golgb1    Yes 
Gpc6    Yes 
Gpcpd1    Yes 
Gpha2    Yes 
Gpkow    Yes 
Gpr149    Yes 
Gpr172b    Yes 
Gpr44    Yes 
Gpx1    Yes 
Gramd4    Yes 
Grik2    Yes 
Grp    Yes 
Gsk3a    Yes 
Gsn    Yes 
Gtpbp10    Yes 
Gucy2e    Yes 
Gusb    Yes 
H2afx    Yes 
H3f3a    Yes 
H47    Yes 
Hamp2    Yes 
Haus2    Yes 
Hcfc1    Yes 
Hcn4    Yes 
Hdac1    Yes 
Herc6    Yes 
Hes5    Yes 
Hfe    Yes 
Hic2    Yes 
Hist1h1c    Yes 
Hist1h2bk    Yes 
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Hist1h4j    Yes 
Hist2h2bb    Yes 
Hist2h3c1    Yes 
Hn1    Yes 
Hormad2    Yes 
Hoxa11    Yes 
Hoxc5    Yes 
Hpdl    Yes 
Hrh4    Yes 
Hsd3b2    Yes 
Hsf5    Yes 
Hus1    Yes 
Huwe1    Yes 
Iars    Yes 
Id2    Yes 
Id4    Yes 
Ift20    Yes 
Il10rb    Yes 
Il1f10    Yes 
Ildr1    Yes 
Immp1l    Yes 
Imp4    Yes 
Impa2    Yes 
Inca1    Yes 
Ing4    Yes 
Iqcf3    Yes 
Irf1    Yes 
Irf8    Yes 
Isoc2a    Yes 
Isoc2b    Yes 
Kars    Yes 
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Kcnh3    Yes 
Kcnh7    Yes 
Kcnh8    Yes 
Kcnj14    Yes 
Kif2b    Yes 
Kif4    Yes 
Kifc2    Yes 
Klf15    Yes 
Klhdc7a    Yes 
Klhl17    Yes 
Klhl28    Yes 
Klk15    Yes 
Klra3    Yes 
Kpna1    Yes 
Kri1    Yes 
Krtap13    Yes 
Krtap27-1    Yes 
L1td1    Yes 
Lamb1    Yes 
Lamc1    Yes 
Lamp2    Yes 
Lce3b    Yes 
Lcmt1    Yes 
Lcmt2    Yes 
Leo1    Yes 
Lgals3bp    Yes 
Lipo1    Yes 
Lmtk3    Yes 
Lpcat2    Yes 
Lrig1    Yes 
Lrrc47    Yes 
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Lrrc50    Yes 
Lrrn3    Yes 
Ly6i    Yes 
Lypd6    Yes 
Lyrm4    Yes 
Mab21l1    Yes 
Mad1l1    Yes 
Madcam1    Yes 
Mapk14    Yes 
Mapk3    Yes 
March08    Yes 
Mbd3l1    Yes 
Mbnl3    Yes 
Mc3r    Yes 
Med1    Yes 
Mei1    Yes 
Mgp    Yes 
Mib2    Yes 
Mkl2    Yes 
Mkrn3    Yes 
Mlkl    Yes 
Mll1    Yes 
Mov10    Yes 
Mrps16    Yes 
Mxra8    Yes 
Myo5b    Yes 
Nars2    Yes 
Ncbp2    Yes 
Ncf4    Yes 
Ncl    Yes 
Ncoa6    Yes 
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Ndufv1    Yes 
Nemf    Yes 
Nfe2l1    Yes 
Nfib    Yes 
Nfkbie    Yes 
Npcd    Yes 
Nr3c2    Yes 
Nras    Yes 
Nrg2    Yes 
Nudt9    Yes 
Nup160    Yes 
Ogt    Yes 
Opn5    Yes 
Osgin2    Yes 
Otud5    Yes 
Paf1    Yes 
Parg    Yes 
Parp4    Yes 
Pbrm1    Yes 
Pcca    Yes 
Pcdh11x    Yes 
Pcgf6    Yes 
Pcid2    Yes 
Pde4d    Yes 
Pdgfd    Yes 
Pds5b    Yes 
Phc1    Yes 
Phf15    Yes 
Pid1    Yes 
Pip4k2b    Yes 
Pirt    Yes 
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Pkn1    Yes 
Pkp4    Yes 
Plcg2    Yes 
Plekhm2    Yes 
Plrg1    Yes 
Pmaip1    Yes 
Pnpla2    Yes 
Pola2    Yes 
Pot1b    Yes 
Pou4f2    Yes 
Ppdpf    Yes 
Ppm1b    Yes 
Ppm1e    Yes 
Ppp1r12b    Yes 
Ppp1r1c    Yes 
Ppp2r1a    Yes 
Ppp2r5e    Yes 
Ppp6c    Yes 
Prcc    Yes 
Prima1    Yes 
Prl8a6    Yes 
Prom2    Yes 
Prpf19    Yes 
Prpf8    Yes 
Prps1l3    Yes 
Prrx2    Yes 
Prss29    Yes 
Prss57    Yes 
Psg17    Yes 
Pskh1    Yes 
Psma1    Yes 
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Psma5    Yes 
Psma8    Yes 
Psmc4    Yes 
Psmd8    Yes 
Ptges3    Yes 
Ptprc    Yes 
Rabggta    Yes 
Rad17    Yes 
Rbfox1    Yes 
Rbl1    Yes 
Rbm25    Yes 
Rbm3    Yes 
Rcc2    Yes 
Rce1    Yes 
Rcn1    Yes 
Rgs3    Yes 
Rgs8    Yes 
Rhox9    Yes 
Riok1    Yes 
Ripply2    Yes 
Ripply3    Yes 
Rnd3    Yes 
Rnf19a    Yes 
Rogdi    Yes 
Rpgr    Yes 
Rpl11    Yes 
Rpl15    Yes 
Rpl23    Yes 
Rpl27a    Yes 
Rpl3    Yes 
Rpl37    Yes 
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Rpl7a    Yes 
Rps13    Yes 
Rps6ka2    Yes 
Rps6kc1    Yes 
Rps9    Yes 
Rtn2    Yes 
Rufy4    Yes 
Sap130    Yes 
Sap30l    Yes 
Sardh    Yes 
Scaf11    Yes 
Scarb2    Yes 
Scg5    Yes 
Scrn2    Yes 
Sdr39u1    Yes 
Sel1l3    Yes 
Sema4b    Yes 
Serinc3    Yes 
Serpina5    Yes 
Serpinh1    Yes 
Sfrs18    Yes 
Siah2    Yes 
Sirpa    Yes 
Ska1    Yes 
Slc14a1    Yes 
Slc1a2    Yes 
Slc25a13    Yes 
Slc25a39    Yes 
Slc27a2    Yes 
Slc35d3    Yes 
Slc38a2    Yes 
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Slc6a7    Yes 
Slc7a15    Yes 
Slit1    Yes 
Slitrk3    Yes 
Slmo2    Yes 
Smok2b    Yes 
Snrpd1    Yes 
Snupn    Yes 
Son    Yes 
Sord    Yes 
Sp110    Yes 
Spata2L    Yes 
Speer4a    Yes 
Speer4b    Yes 
Spink4    Yes 
Srbd1    Yes 
Srgap2    Yes 
Srp72    Yes 
Srrm2    Yes 
Ssbp2    Yes 
Ssxb9    Yes 
St18    Yes 
Stag2    Yes 
Stau2    Yes 
Stk30    Yes 
Stk36    Yes 
Stoml1    Yes 
Sult3a1    Yes 
Sumf2    Yes 
Sympk    Yes 
Tas2r102    Yes 
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Tbc1d15    Yes 
Tbc1d2b    Yes 
Tbca    Yes 
Tceb2    Yes 
Tcf20    Yes 
Tcfcp2    Yes 
Tcirg1    Yes 
Tcof1    Yes 
Tead1    Yes 
Tead2    Yes 
Thbs3    Yes 
Thoc1    Yes 
Thop1    Yes 
Thumpd1    Yes 
Tial1    Yes 
Tigd3    Yes 
Timm10    Yes 
Timm17b    Yes 
Tle6    Yes 
Tmco2    Yes 
Tmed1    Yes 
Tmeff2    Yes 
Tmem186    Yes 
Tmem50b    Yes 
Tnfrsf18    Yes 
Tnks    Yes 
Tox4    Yes 
Traf3    Yes 
Trat1    Yes 
Trem3    Yes 
Trim11    Yes 
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Trim28    Yes 
Triobp    Yes 
Trip6    Yes 
Trp73    Yes 
Tspan11    Yes 
Tspan32    Yes 
Ttc12    Yes 
Tti1    Yes 
Tuba3a    Yes 
Twist1    Yes 
Txn2    Yes 
Txnrd1    Yes 
Uba1    Yes 
Ubac1    Yes 
Ube2d3    Yes 
Ube2o    Yes 
Ube2q1    Yes 
Ube4b    Yes 
Ubxn1    Yes 
Uck1    Yes 
Ucp1    Yes 
Uqcc    Yes 
Usp19    Yes 
Usp42    Yes 
Utp23    Yes 
Vdr    Yes 
Vmn1r169    Yes 
Vmn1r198    Yes 
Vmn1r23    Yes 
Vmn2r11    Yes 
Vmn2r110    Yes 
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Vmn2r26    Yes 
Vmn2r50    Yes 
Vmn2r57    Yes 
Vmn2r77    Yes 
Vmn2r95    Yes 
Vmp1    Yes 
Wdhd1    Yes 
Wdr1    Yes 
Wdr12    Yes 
Wdr33    Yes 
Wdr75    Yes 
Wfdc11    Yes 
Wwtr1    Yes 
Xlr3a    Yes 
Xrcc6bp1    Yes 
Ybey    Yes 
Zbtb24    Yes 
Zbtb40    Yes 
Zbtb9    Yes 
Zdhhc21    Yes 
Zfp202    Yes 
Zfp276    Yes 
Zfp36l2    Yes 
Zfp574    Yes 
Zfp651    Yes 
Zfp689    Yes 
Zfp72    Yes 
Zfp82    Yes 
Zfp869    Yes 
Zfp943    Yes 
Zfr    Yes 
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Zfr2    Yes 
Zkscan5    Yes 
Zmat2    Yes 
Zmpste24    Yes 
Znrf3    Yes 
Zp3r    Yes 
Zscan21    Yes 
 
6.2 Genes depleted in select MSigDB gene sets identified using GSEA.  
Referred to in A list of 21 genes in total depleted within the gene sets referred to in Section 
4.9.1. 
Gene set 
Gene significantly 
depleted in Coculture plus 
gemcitabine 
HALLMARK_MYC_TARGETS_V2 (26 total in 
set) Mphosph10 
HALLMARK_MYC_TARGETS_V2 Map3K6 
HALLMARK_MYC_TARGETS_V2 Slc29A2 
HALLMARK_MYC_TARGETS_V2 Utp20 
HALLMARK_MYC_TARGETS_V2 Imp4 
HALLMARK_MYC_TARGETS_V2 Las1L 
HALLMARK_MYC_TARGETS_V2 Hspe1 
HALLMARK_MYC_TARGETS_V2 Tcof1 
HALLMARK_DNA_REPAIR (48 total in set) Rpa3 
HALLMARK_DNA_REPAIR Pold1 
HALLMARK_DNA_REPAIR Sf3A3 
HALLMARK_DNA_REPAIR Supt5H 
HALLMARK_DNA_REPAIR Pold3 
HALLMARK_DNA_REPAIR Nudt21 
HALLMARK_DNA_REPAIR Supt4H1 
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HALLMARK_DNA_REPAIR Thoc4 
HALLMARK_DNA_REPAIR Ncbp2 
HALLMARK_DNA_REPAIR Pola2 
HALLMARK_DNA_REPAIR Guk1 
HALLMARK_DNA_REPAIR Ddb1 
HALLMARK_DNA_REPAIR Ssrp1 
 
6.3 Genes depleted in coculture plus gemcitabine only with molecular functions around 
enzyme regulator activity. 
 Data analysed using PANTHER (Mi et al., 2017), taken from the subset of catalytically active 
genes. 
Gene 
code 
Details 
Inca1 Protein INCA1 
Pot1B Protection of telomeres 1B 
Tbc1D15 TBC1 domain family member 15 
Gapvd1 GTPase-activating protein and VPS9 domain-containing protein 1 
Triobp TRIO and F-actin-binding protein 
Myo5B Unconventional myosin-Vb 
Ppp1R12B Protein phosphatase 1 regulatory subunit 12B 
Ncf4 Neutrophil cytosol factor 4 
Tbc1D2B TBC1 domain family member 2B 
Plcg2 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 
Gmppa Mannose-1-phosphate guanyltransferase alpha 
Tbc1D20 TBC1 domain family member 20 
Trappc1 Trafficking protein particle complex subunit 1 
Ppm1B Protein phosphatase 1B 
Ppm1E Protein phosphatase 1M 
Rgs8 Regulator of G-protein signaling 8 
Ppm1E Protein phosphatase 1E 
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Ppp1R11 Protein phosphatase 1 regulatory subunit 11 
 
6.4 Genes significantly depleted in coculture plus gemcitabine grouped using MetaCore 
network clustering.  
A total of 205 genes referred to in Figure 4.13. 
Gene network Name 
Cell cycle_G2-M Ywhag 
Cell cycle_G2-M Anapc5 
Cell cycle_G2-M Aurka 
Cell cycle_G2-M Bub1b 
Cell cycle_G2-M Brca1 
Cell cycle_G2-M Cdc23 
Cell cycle_G2-M Cdc37 
Cell cycle_G2-M Herc6 
Cell cycle_G2-M Chek1 
Cell cycle_G2-M Dnm1 
Cell cycle_G2-M Dnm2 
Cell cycle_G2-M Mapk3 
Cell cycle_G2-M Hcfc1 
Cell cycle_G2-M Hus1 
Cell cycle_G2-M Hist1h1c 
Cell cycle_G2-M H3f3a 
Cell cycle_G2-M Rps6kc1 
Cell cycle_G2-M Ncl 
Cell cycle_G2-M Pdgfa 
Cell cycle_G2-M Cct2 
Cell cycle_G2-M Top1 
Cell cycle_G2-M Ubc 
Cell cycle_G2-M Uba1 
Cell cycle_G2-M Mapk14 
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Cell cycle_G2-M Trp73 
Cell cycle_G2-M Rps6ka2 
DNA damage_Checkpoint 14-3-3 
DNA damage_Checkpoint 14-3-3 gamma 
DNA damage_Checkpoint ANAPC5 
DNA damage_Checkpoint Bard1 
DNA damage_Checkpoint Brca1 
DNA damage_Checkpoint BTG2 
DNA damage_Checkpoint CDC23 
DNA damage_Checkpoint Chk1 
DNA damage_Checkpoint ERK1 (MAPK3) 
DNA damage_Checkpoint ERK1/2 
DNA damage_Checkpoint Histone H2AX 
DNA damage_Checkpoint HUS1 
DNA damage_Checkpoint I-kB 
DNA damage_Checkpoint p38 MAPK 
DNA damage_Checkpoint p38alpha (MAPK14) 
DNA damage_Checkpoint RAD17 
DNA damage_Checkpoint RIF1 
DNA damage_Checkpoint Separase 
DNA damage_Checkpoint Stromalins 1/2 
DNA damage_Checkpoint Ubiquitin 
Translation_Translation initiation 4E-BP1 
Translation_Translation initiation Casein kinase II 
Translation_Translation initiation Casein kinase II, alpha chain (CSNK2A1) 
Translation_Translation initiation Casein kinase II, alpha chains 
Translation_Translation initiation Casein kinase II, alpha' chain (CSNK2A2) 
Translation_Translation initiation DAZL 
Translation_Translation initiation eIF2S2 
Translation_Translation initiation eIF5A 
Translation_Translation initiation eIF5B (IF-2) 
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Translation_Translation initiation GCN2 
Translation_Translation initiation RP40 
Translation_Translation initiation RPL11 
Translation_Translation initiation RPL15 
Translation_Translation initiation RPL17 
Translation_Translation initiation RPL23 
Translation_Translation initiation RPL27A 
Translation_Translation initiation RPL3 
Translation_Translation initiation RPL37 
Translation_Translation initiation RPL7 
Translation_Translation initiation RPL7A 
Translation_Translation initiation RPS13 
Translation_Translation initiation RPS18 
Translation_Translation initiation RPS27A 
Translation_Translation initiation RPS9 
DNA damage_DBS repair Brca1 
DNA damage_DBS repair Casein kinase II 
DNA damage_DBS repair Casein kinase II, alpha chain (CSNK2A1) 
DNA damage_DBS repair Casein kinase II, alpha chains 
DNA damage_DBS repair Casein kinase II, alpha' chain (CSNK2A2) 
DNA damage_DBS repair ChAF1 subunit A 
DNA damage_DBS repair ChAF1 subunit B 
DNA damage_DBS repair Chk1 
DNA damage_DBS repair FANCC 
DNA damage_DBS repair FANCM 
DNA damage_DBS repair Histone H2AX 
DNA damage_DBS repair Histone H3 
DNA damage_DBS repair Histone H4 
DNA damage_DBS repair NMP200 
DNA damage_DBS repair PP2A regulatory 
DNA damage_DBS repair PP2A structural 
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DNA damage_DBS repair TOP1 
DNA damage_DBS repair Ubiquitin 
Proteolysis_Ubiquitin-proteasomal proteolysis Bard1 
Proteolysis_Ubiquitin-proteasomal proteolysis Brca1 
Proteolysis_Ubiquitin-proteasomal proteolysis Brca1/Bard1 
Proteolysis_Ubiquitin-proteasomal proteolysis c-Cbl 
Proteolysis_Ubiquitin-proteasomal proteolysis DORFIN 
Proteolysis_Ubiquitin-proteasomal proteolysis Elongin B 
Proteolysis_Ubiquitin-proteasomal proteolysis HSP90 
Proteolysis_Ubiquitin-proteasomal proteolysis PSMA1 
Proteolysis_Ubiquitin-proteasomal proteolysis PSMA5 
Proteolysis_Ubiquitin-proteasomal proteolysis PSMA6 
Proteolysis_Ubiquitin-proteasomal proteolysis PSMB3 
Proteolysis_Ubiquitin-proteasomal proteolysis PSMB4 
Proteolysis_Ubiquitin-proteasomal proteolysis PSMC2 
Proteolysis_Ubiquitin-proteasomal proteolysis PSMD8 
Proteolysis_Ubiquitin-proteasomal proteolysis SELS 
Proteolysis_Ubiquitin-proteasomal proteolysis SENP6 
Proteolysis_Ubiquitin-proteasomal proteolysis SIAH2 
Proteolysis_Ubiquitin-proteasomal proteolysis UBE1 
Proteolysis_Ubiquitin-proteasomal proteolysis UBE2D3 
Proteolysis_Ubiquitin-proteasomal proteolysis Ubiquitin 
Proteolysis_Ubiquitin-proteasomal proteolysis USP7 
Translation_Regulation of initiation 4E-BP1 
Translation_Regulation of initiation c-Cbl 
Translation_Regulation of initiation Casein kinase II 
Translation_Regulation of initiation Casein kinase II, alpha chain (CSNK2A1) 
Translation_Regulation of initiation Casein kinase II, alpha chains 
Translation_Regulation of initiation Casein kinase II, alpha' chain (CSNK2A2) 
Translation_Regulation of initiation eIF2S2 
Translation_Regulation of initiation ERK1 (MAPK3) 
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Translation_Regulation of initiation ERK1/2 
Translation_Regulation of initiation GSK3 alpha 
Translation_Regulation of initiation GSK3 alpha/beta 
Translation_Regulation of initiation IGBP1 
Translation_Regulation of initiation MLCP (cat) 
Translation_Regulation of initiation MSK1/2 (RPS6KA5/4) 
Translation_Regulation of initiation p38 MAPK 
Translation_Regulation of initiation p38alpha (MAPK14) 
Translation_Regulation of initiation PP1-cat 
Cell cycle_G1-S 14-3-3 
Cell cycle_G1-S 14-3-3 gamma 
Cell cycle_G1-S ANAPC5 
Cell cycle_G1-S Brca1 
Cell cycle_G1-S CDC23 
Cell cycle_G1-S CDC37 
Cell cycle_G1-S Ceb1 
Cell cycle_G1-S Chk1 
Cell cycle_G1-S Fe65 
Cell cycle_G1-S FosB 
Cell cycle_G1-S HUS1 
Cell cycle_G1-S I-kB 
Cell cycle_G1-S Importin (karyopherin)-alpha 
Cell cycle_G1-S JAB1 
Cell cycle_G1-S Karyopherin alpha 1 
Cell cycle_G1-S NFKBIB 
Cell cycle_G1-S NFKBIE 
Cell cycle_G1-S p107 
Cell cycle_G1-S UBE1 
Cell cycle_G1-S Ubiquitin 
Cell cycle_Mitosis 14-3-3 gamma 
Cell cycle_Mitosis ANAPC5 
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Cell cycle_Mitosis Aurora-A 
Cell cycle_Mitosis BUBR1 
Cell cycle_Mitosis CDC23 
Cell cycle_Mitosis DYI2 
Cell cycle_Mitosis Dynamin 
Cell cycle_Mitosis Dynamin-1 
Cell cycle_Mitosis Dynamin-2 
Cell cycle_Mitosis Dynein 1, cytoplasmic, intermediate chains 
Cell cycle_Mitosis Histone H1 
Cell cycle_Mitosis Histone H3 
Cell cycle_Mitosis Importin (karyopherin)-alpha 
Cell cycle_Mitosis Karyopherin alpha 1 
Cell cycle_Mitosis MAD1 (mitotic checkpoint) 
Cell cycle_Mitosis NUMA1 
Cell cycle_Mitosis Separase 
Cell cycle_Mitosis Stromalins 1/2 
Cell cycle_Mitosis TOP1 
Cell cycle_Mitosis Tubulin alpha 
Cell cycle_Mitosis Ubiquitin 
Inflammation_IFN-gamma signalling Brca1 
Inflammation_IFN-gamma signalling c-Cbl 
Inflammation_IFN-gamma signalling CIITA 
Inflammation_IFN-gamma signalling eIF2S2 
Inflammation_IFN-gamma signalling ERK1/2 
Inflammation_IFN-gamma signalling FANCC 
Inflammation_IFN-gamma signalling I-kB 
Inflammation_IFN-gamma signalling IKK-alpha 
Inflammation_IFN-gamma signalling IRF1 
Inflammation_IFN-gamma signalling NFKBIB 
Inflammation_IFN-gamma signalling NFKBIE 
Inflammation_IFN-gamma signalling p38 MAPK 
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Inflammation_IFN-gamma signalling PLC-gamma 
Inflammation_IFN-gamma signalling PLC-gamma 2 
Inflammation_IFN-gamma signalling SOCS1 
Reproduction_Feeding and Neurohormone 
signalling 14-3-3 gamma 
Reproduction_Feeding and Neurohormone 
signalling 4E-BP1 
Reproduction_Feeding and Neurohormone 
signalling Antileukoproteinase 1 
Reproduction_Feeding and Neurohormone 
signalling Brca1 
Reproduction_Feeding and Neurohormone 
signalling c-Fos 
Reproduction_Feeding and Neurohormone 
signalling Casein kinase II 
Reproduction_Feeding and Neurohormone 
signalling Casein kinase II, alpha chains 
Reproduction_Feeding and Neurohormone 
signalling Corticoliberin 
Reproduction_Feeding and Neurohormone 
signalling ERK1 (MAPK3) 
Reproduction_Feeding and Neurohormone 
signalling Galpha(i)-specific peptide GPCRs 
Reproduction_Feeding and Neurohormone 
signalling 
Galpha(q)-specific Class A Orphan/other 
GPCRs 
Reproduction_Feeding and Neurohormone 
signalling Galpha(q)-specific peptide GPCRs 
Reproduction_Feeding and Neurohormone 
signalling GHR 
Reproduction_Feeding and Neurohormone 
signalling Histone H3 
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Reproduction_Feeding and Neurohormone 
signalling IRF1 
Reproduction_Feeding and Neurohormone 
signalling LAMG1 
Reproduction_Feeding and Neurohormone 
signalling LRP2 (Megalin) 
Reproduction_Feeding and Neurohormone 
signalling PICK1 
Reproduction_Feeding and Neurohormone 
signalling PLC-gamma 
Reproduction_Feeding and Neurohormone 
signalling PLC-gamma 2 
Reproduction_Feeding and Neurohormone 
signalling PP2A regulatory 
Reproduction_Feeding and Neurohormone 
signalling PP2A structural 
Reproduction_Feeding and Neurohormone 
signalling SOCS1 
 
6.5 List of all genes depleted in both coculture plus gemcitabine and monoculture plus 
gemcitabine condition in the initial shRNA screen.  
A total of 138 genes in common.  
Gene 
Acpp 
Accn3 
Copa 
Sympk 
Cops3 
Rpl23a 
Gm5567 
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Ptgs1 
E130203B14Rik 
Supt4h1 
Ugt2b5 
6430704M03Rik 
E030010A14Rik 
Psma4 
Psma7 
Metap2 
Eif3e 
Syf2 
Sf3b5 
Tgm3 
Fam89a 
Rps27a 
Csf2ra 
Iars2 
Rhox7 
Zfp512 
Actb 
Eif3f 
Higd2a 
Cyhr1 
Slc7a14 
Cdc5l 
Ltb4r2 
1300001I01Rik 
Tubb5 
Smtnl2 
Ssb 
Mettl21a 
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Mtmr11 
Rhox1 
Svs3b 
Saa1 
Eml3 
Megf10 
Inpp5k 
Akr1b8 
Serpina1c 
Supt6h 
Rad23a 
Dynlrb1 
Il5ra 
Ddx27 
Slc16a1 
Gm9513 
Rpl26 
Hist1h2bf 
Smpd3 
2310003L22Rik 
Tktl2 
Rpl36 
Gm16387 
AW146020 
Mudeng 
Fam100b 
Nutf2 
Nudt10 
Kti12 
Fbxo38 
D10Wsu52e 
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1110014N23Rik 
Ovca2 
Rps17 
Ctr9 
Setd1a 
Col18a1 
Utp20 
Tacc3 
Wdr36 
Ccdc59 
Rpl31 
Acp5 
Rpl10a 
B430306N03Rik 
Myo16 
Rps12 
Cadm4 
Mdc1 
Gpr81 
Eftud2 
Sf3b3 
Mtss1 
Serpina3k 
Rps11 
Ubd 
Pola1 
Ptpdc1 
Fam169b 
Cdkn1c 
Anapc1 
Mepe 
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2700049A03Rik 
Dedd2 
Prl8a1 
Ceacam20 
Tmem167b 
Rpf1 
Slc36a2 
Awat1 
Ddx24 
Rps4x 
Gm14326 
Ly6g6e 
Pdzd2 
Rhot2 
Cse1l 
Gm11567 
2810408M09Rik 
BC017158 
Racgap1 
Gabrb2 
Alox12e 
Fubp1 
Tmem85 
Ltb 
Trappc9 
Spink14 
Mad2l2 
Ppp1r7 
Rps5 
Eme1 
Gm3285 
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Rpl5 
Gm16404 
Riiad1 
Acad8 
Alg6 
D11Wsu99e 
Tbrg4 
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